

REFINITIV

DELTA REPORT

10-Q

DXCM - DEXCOM INC

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

| | |
|--------------|------|
| TOTAL DELTAS | 2401 |
|--------------|------|

| | |
|---|-----|
|  CHANGES | 159 |
|---|-----|

| | |
|---|------|
|  DELETIONS | 1705 |
|---|------|

| | |
|---|-----|
|  ADDITIONS | 537 |
|---|-----|


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended **September 30, 2023** **March 31, 2024**

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File Number: 000-51222

 dexcom-logo-green-rgb (1).jpg

DEXCOM, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

33-0857544

(I.R.S. Employer Identification No.)

6340 Sequence Drive, San Diego, CA

(Address of principal executive offices)

92121

(Zip Code)

(858) 200-0200

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|-------------------|---|
| Common Stock, \$0.001 Par Value Per Share | DXCM | Nasdaq Global Select Market |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

| | | | |
|-------------------------|-------------------------------------|---------------------------|--------------------------|
| Large accelerated filer | <input checked="" type="checkbox"/> | Accelerated filer | <input type="checkbox"/> |
| Non-accelerated filer | <input type="checkbox"/> | Smaller reporting company | <input type="checkbox"/> |
| | | Emerging growth company | <input type="checkbox"/> |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of **October 19, 2023**, **April 18, 2024**, there were **386,373,935** **397,683,837** shares of the registrant's common stock outstanding.

DexCom, Inc.

Table of Contents

| | | Page |
|--------------------------------------|---|---------------------------------------|
| PART I. FINANCIAL INFORMATION | | |
| ITEM 1. | Financial Statements | |
| | Consolidated Balance Sheets (unaudited) as of September 30, 2023 March 31, 2024 and December 31, 2022 2023 | 4 |
| | Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 | 5 |
| | Consolidated Statements of Comprehensive Income (unaudited) for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 | 6 |
| | Consolidated Statements of Stockholders' Equity (unaudited) for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 | 7 |
| | Consolidated Statements of Cash Flows (unaudited) for the nine three months ended September 30, 2023 March 31, 2024 and 2022 2023 | 9 8 |
| | Notes to Consolidated Financial Statements (unaudited) | 11 9 |
| ITEM 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 29 |
| ITEM 3. | Quantitative and Qualitative Disclosures about Market Risk | 40 39 |
| ITEM 4. | Controls and Procedures | 41 39 |
| PART II. OTHER INFORMATION | | |
| ITEM 1. | Legal Proceedings | 42 41 |
| ITEM 1A. | Risk Factors | 43 42 |
| ITEM 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 37 42 |
| ITEM 3. | Defaults Upon Senior Securities | 37 42 |
| ITEM 4. | Mine Safety Disclosures | 37 42 |
| ITEM 5. | Other Information | 37 43 |
| ITEM 6. | Exhibits | 38 44 |
| | Signatures | 90 46 |

[Table of Contents](#)

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Except for historical financial information contained herein, the matters discussed in this Quarterly Report on Form 10-Q may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and subject to the safe harbor created by the [Private Securities Litigation Reform Act of 1995](#). Such statements include declarations regarding our [operations](#), [financial condition and prospects](#), and [business strategies](#), and are based on management's current intent, [belief](#), or [current beliefs](#), expectations, and [those of our management](#). [Prospective investors](#) [assumptions](#). [Investors](#) are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks, uncertainties and other factors, some of which are beyond our control; actual results could differ materially from those indicated [or implied](#) by such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, but are not limited to: (i) that the information is of a preliminary nature and may be subject to further adjustment; (ii) those risks and uncertainties identified under "Risk Factors"; [in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission, or the SEC, on February 8, 2024, together with any updates identified under "Risk Factors" in our subsequent Quarterly Reports on Form 10-Q;](#) and (iii) the other risks detailed from time-to-time in our [other](#) reports and registration statements filed with [the Securities and Exchange Commission, or the SEC](#). Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

AVAILABLE INFORMATION

Our website address is located at [dexcom.com](#) and our investor relations website is located at [investors.dexcom.com](#). We file electronically with the SEC our [annual reports](#) [Annual Reports](#) on Form 10-K, [quarterly reports](#) [Quarterly Reports](#) on Form 10-Q, [current reports](#) [Current Reports](#) on Form 8-K, and [amendments to those other reports](#) filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make available on our website, free of charge, copies of these reports and other information as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. [Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.](#)

We announce material information to the public about us, our products, and other matters through a variety of means, including filings with the SEC, press releases, public conference calls, presentations, webcasts, and our investor relations website in order to achieve broad, non-exclusionary distribution of information to the public and to comply

| | | | |
|---|---|------------|-----------|
| Deferred tax assets | Deferred tax assets | 501.3 | 341.2 |
| Other assets | Other assets | 74.4 | 47.1 |
| Total assets | Total assets | \$ 6,596.2 | \$5,391.7 |
| Liabilities and Stockholders' Equity | Liabilities and Stockholders' Equity | | |
| Current liabilities: | Current liabilities: | | |
| Current liabilities: | | | |
| Current liabilities: | | | |
| Accounts payable and accrued liabilities | | | |
| Accounts payable and accrued liabilities | | | |
| Accounts payable and accrued liabilities | Accounts payable and accrued liabilities | \$ 1,373.1 | \$ 901.8 |
| Accrued payroll and related expenses | Accrued payroll and related expenses | 151.3 | 134.3 |
| Current portion of long-term senior convertible notes | | 124.2 | 772.6 |
| Short-term operating lease liabilities | | | |
| Short-term operating lease liabilities | | | |
| Short-term operating lease liabilities | Short-term operating lease liabilities | 21.0 | 20.5 |
| Deferred revenue | Deferred revenue | 9.0 | 10.1 |
| Total current liabilities | Total current liabilities | 1,678.6 | 1,839.3 |
| Long-term senior convertible notes | Long-term senior convertible notes | 2,432.4 | 1,197.7 |
| Long-term operating lease liabilities | Long-term operating lease liabilities | 83.4 | 94.6 |
| Other long-term liabilities | Other long-term liabilities | 133.9 | 128.3 |
| Total liabilities | Total liabilities | 4,328.3 | 3,259.9 |
| Commitments and contingencies | Commitments and contingencies | | |
| Commitments and contingencies | | | |
| Stockholders' equity: | Stockholders' equity: | | |
| Preferred stock, \$0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at September 30, 2023 and December 31, 2022 | | — | — |

Common stock, \$0.001 par value, 800.0 million shares authorized; 405.5 million and 386.4 million shares issued and outstanding, respectively, at September 30, 2023; and 393.2 million and 386.3 million shares issued and outstanding, respectively, at December 31, 2022

0.4 0.4

Preferred stock, \$0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023

Preferred stock, \$0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023

Preferred stock, \$0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023

Common stock, \$0.001 par value, 800.0 million shares authorized; 408.5 million and 396.1 million shares issued and outstanding, respectively, at March 31, 2024; and 407.2 million and 385.4 million shares issued and outstanding, respectively, at December 31, 2023

| | | | |
|----------------------------|----------------------------|---------|---------|
| Additional paid-in capital | Additional paid-in capital | 3,618.0 | 2,258.1 |
|----------------------------|----------------------------|---------|---------|

| | | | |
|--------------------------------------|--------------------------------------|--------|--------|
| Accumulated other comprehensive loss | Accumulated other comprehensive loss | (35.6) | (11.6) |
|--------------------------------------|--------------------------------------|--------|--------|

| | | | |
|-------------------|-------------------|-------|-------|
| Retained earnings | Retained earnings | 765.1 | 479.9 |
|-------------------|-------------------|-------|-------|

| | | | |
|--|--|-----------|---------|
| Treasury stock, at cost; 19.1 million shares at September 30, 2023 and 6.9 million shares at December 31, 2022 | | (2,080.0) | (595.0) |
|--|--|-----------|---------|

Treasury stock, at cost; 12.4 million shares at March 31, 2024 and 21.8 million shares at December 31, 2023

| | | | |
|----------------------------|----------------------------|---------|---------|
| Total stockholders' equity | Total stockholders' equity | 2,267.9 | 2,131.8 |
|----------------------------|----------------------------|---------|---------|

| | | | |
|--|--|------------|-----------|
| Total liabilities and stockholders' equity | Total liabilities and stockholders' equity | \$ 6,596.2 | \$5,391.7 |
|--|--|------------|-----------|

See accompanying notes

[Table of Contents](#)

DexCom, Inc.

Consolidated Statements of Operations

(Unaudited)

| | | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--------------------------------------|--------------------------------------|-------------------------------------|----------|------------------------------------|------------|
| | | Three Months Ended March 31, | | Three Months Ended March 31, | |
| | | Three Months Ended March 31, | | Three Months Ended March 31, | |
| | | Three Months Ended March 31, | | Three Months Ended March 31, | |
| (In millions, except per share data) | | | | | |
| (In millions, except per share data) | | | | | |
| (In millions, except per share data) | (In millions, except per share data) | 2023 | 2022 | 2023 | 2022 |
| Revenue | Revenue | \$ 975.0 | \$ 769.6 | \$ 2,587.8 | \$ 2,094.6 |
| Revenue | | | | | |
| Revenue | | | | | |
| Cost of sales | | | | | |
| Cost of sales | | | | | |
| Cost of sales | Cost of sales | 351.7 | 275.4 | 955.5 | 752.8 |
| Gross profit | Gross profit | 623.3 | 494.2 | 1,632.3 | 1,341.8 |
| Gross profit | | | | | |
| Gross profit | | | | | |
| Operating expenses: | | | | | |
| Operating expenses: | | | | | |
| Operating expenses: | Operating expenses: | | | | |
| Research and development | Research and development | 131.4 | 110.3 | 369.7 | 367.9 |
| Research and development | | | | | |
| Research and development | | | | | |
| Amortization of intangible assets | | 1.7 | 1.8 | 5.2 | 5.7 |
| Selling, general and administrative | | | | | |
| Selling, general and administrative | | | | | |
| Selling, general and administrative | Selling, general and administrative | 284.7 | 234.6 | 876.6 | 702.4 |
| Total operating expenses | Total operating expenses | 417.8 | 346.7 | 1,251.5 | 1,076.0 |
| Total operating expenses | | | | | |
| Total operating expenses | | | | | |
| Operating income | Operating income | 205.5 | 147.5 | 380.8 | 265.8 |
| Income from equity investments | | 1.0 | — | 1.0 | 0.2 |

| | | | | | |
|---|---|----------|----------|----------|----------|
| Operating income | | | | | |
| Operating income | | | | | |
| Other income (expense), net | | | | | |
| Other income (expense), net | | | | | |
| Other income (expense), net | Other income (expense), net | 33.9 | (1.3) | 82.4 | (8.4) |
| Income before income taxes | | | | | |
| Income before income taxes | | | | | |
| Income tax expense (benefit) | | | | | |
| Income tax expense (benefit) | | | | | |
| Income tax expense (benefit) | | | | | |
| Net income | | | | | |
| Net income | | | | | |
| Net income | Net income | \$ 120.7 | \$ 101.2 | \$ 285.2 | \$ 249.4 |
| Basic net income per share | | | | | |
| Basic net income per share | | | | | |
| Basic net income per share | | | | | |
| Shares used to compute basic net income per share | | | | | |
| Shares used to compute basic net income per share | | | | | |
| Shares used to compute basic net income per share | Shares used to compute basic net income per share | 386.6 | 389.8 | 386.7 | 390.4 |
| Diluted net income per share | | | | | |
| Diluted net income per share | | | | | |
| Diluted net income per share | Diluted net income per share | \$ 0.29 | \$ 0.24 | \$ 0.69 | \$ 0.60 |
| Diluted net income per share | | | | | |
| Diluted net income per share | | | | | |
| Shares used to compute diluted net income per share | Shares used to compute diluted net income per share | 426.8 | 425.8 | 428.3 | 428.0 |
| Shares used to compute diluted net income per share | | | | | |
| Shares used to compute diluted net income per share | | | | | |

See accompanying notes

[Table of Contents](#)

| | |
|---|-------------------------------------|
| DexCom, Inc. | |
| Consolidated Statements of Comprehensive Income | |
| (Unaudited) | |
| | Three Months Ended September 30, |
| | Nine Months Ended September 30, |
| | Three Months Ended March 31, |

| | | Three Months Ended March 31, | | Three Months Ended March 31, | |
|--|--|---------------------------------|----------|---------------------------------|----------|
| (In millions) | | | | | |
| (In millions) | | | | | |
| (In millions) | (In millions) | 2023 | 2022 | 2023 | 2022 |
| Net income | Net income | \$ 120.7 | \$ 101.2 | \$ 285.2 | \$ 249.4 |
| Net income | | | | | |
| Net income | | | | | |
| Other comprehensive income (loss), net of tax: | | | | | |
| Other comprehensive income (loss), net of tax: | | | | | |
| Other comprehensive income (loss), net of tax: | Other comprehensive income (loss), net of tax: | | | | |
| Translation adjustments and other | Translation adjustments and other | (7.0) | (19.6) | (25.8) | (34.9) |
| Translation adjustments and other | | | | | |
| Translation adjustments and other | | | | | |
| Unrealized gain (loss) on marketable debt securities | Unrealized gain (loss) on marketable debt securities | 0.7 | 1.5 | 1.8 | (6.7) |
| Total other comprehensive loss, net of tax | | (6.3) | (18.1) | (24.0) | (41.6) |
| Unrealized gain (loss) on marketable debt securities | | | | | |
| Unrealized gain (loss) on marketable debt securities | | | | | |
| Total other comprehensive income (loss), net of tax | | | | | |
| Total other comprehensive income (loss), net of tax | | | | | |
| Total other comprehensive income (loss), net of tax | | | | | |
| Comprehensive income | Comprehensive income | \$ 114.4 | \$ 83.1 | \$ 261.2 | \$ 207.8 |
| Comprehensive income | | | | | |
| Comprehensive income | | | | | |

See accompanying notes

[Table of Contents](#)

DexCom, Inc.
Consolidated Statements of Stockholders' Equity
(Unaudited)

| |
|-----------------------------------|
| Three Months Ended March 31, 2024 |
| Three Months Ended March 31, 2024 |

| Three Months Ended March 31, 2024 | | | | | | | |
|---|---------------|--------------|----------------------------|--------------------------|-------------------|----------------|----------------------------|
| (In millions) | (In millions) | Common Stock | Accumulated | | | | Total Stockholders' Equity |
| | | | Additional Paid-In Capital | Other Comprehensive Loss | Retained Earnings | Treasury Stock | |
| Balance at December 31, 2023 | | | | | | | |
| Balance at December 31, 2023 | | | | | | | |
| Balance at December 31, 2023 | | | | | | | |
| Issuance of common stock under equity incentive plans | | | | | | | |
| Issuance of common stock for Employee Stock Purchase Plan | | | | | | | |
| Issuance of common stock in connection with achievement of sales-based milestone, net of issuance costs | | | | | | | |

| | Three Months Ended September 30, 2023 | | | | | | |
|---|---------------------------------------|--------|----------------------------|--------------------------|-------------------|----------------|---------------------|
| (In millions) | Common Stock | | Accumulated | | | | Total Stockholders' |
| | Shares | Amount | Additional Paid-In Capital | Other Comprehensive Loss | Retained Earnings | Treasury Stock | |
| | | | | | | | |
| | | | | | | | |
| Balance at June 30, 2023 | 386.1 | \$ 0.4 | \$2,269.0 | \$ (29.3) | \$ 644.4 | \$ (784.1) | \$ 2,100.4 |
| Issuance of common stock under equity incentive plans | 0.1 | — | — | — | — | — | — |
| Issuance of common stock for Employee Stock Purchase Plan | 0.1 | — | 14.3 | — | — | — | 14.3 |
| Exercise and settlement of warrants | | | | | | | |
| Purchases of treasury stock, including excise tax | — | — | — | — | — | 0.2 | 0.2 |
| Conversions of 2023 Notes | 10.6 | — | (0.4) | — | — | — | (0.4) |
| Benefit of note hedge upon conversions of 2023 Notes | (10.5) | — | 1,296.1 | — | — | (1,296.1) | — |
| Exercise and settlement of warrants | | | | | | | |
| Exercise and settlement of warrants | | | | | | | |
| Share-based compensation expense | | | | | | | |
| Share-based compensation expense | | | | | | | |

| | | | | | | | | |
|--------------------------------------|--------------------------------------|-------|--------|------------|-----------|----------|--------------|------------|
| Share-based compensation expense | Share-based compensation expense | — | — | 39.0 | — | — | — | 39.0 |
| Net income | Net income | — | — | — | — | 120.7 | — | 120.7 |
| Other comprehensive loss, net of tax | Other comprehensive loss, net of tax | — | — | — | (6.3) | — | — | (6.3) |
| Balance at September 30, 2023 | | | | | | | | |
| | | 386.4 | \$ 0.4 | \$ 3,618.0 | \$ (35.6) | \$ 765.1 | \$ (2,080.0) | \$ 2,267.9 |
| Balance at March 31, 2024 | | | | | | | | |

| Three Months Ended March 31, 2023 | | | | | | Three Months Ended March 31, 2023 | | | | |
|---|---------------|--|--|--|--|-----------------------------------|----------------------------|--------------------------------------|-------------------|----------------|
| | | | | | | Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Loss | Retained Earnings | Treasury Stock |
| (In millions) | (In millions) | | | | | | | | | |
| Balance at December 31, 2022 | | | | | | | | | | |
| Balance at December 31, 2022 | | | | | | | | | | |
| Balance at December 31, 2022 | | | | | | | | | | |
| Issuance of common stock under equity incentive plans | | | | | | | | | | |
| Issuance of common stock for Employee Stock Purchase Plan | | | | | | | | | | |

| Three Months Ended September 30, 2022 | | | | | | | | |
|---|----------------------------------|--------------|--------|----------------------------|--------------------------|-------------------|----------------|----------------------------|
| | | Accumulated | | | | | | |
| | | Common Stock | | Additional Paid-In Capital | Other Comprehensive Loss | Retained Earnings | Treasury Stock | Total Stockholders' Equity |
| (In millions) | | Shares | Amount | Capital | Loss | Earnings | Stock | Equity |
| Balance at June 30, 2022 | | 392.6 | \$ 0.4 | \$ 2,028.9 | \$ (23.0) | \$ 286.9 | \$ (37.3) | \$ 2,255.9 |
| Issuance of common stock for Employee Stock Purchase Plan | | 0.2 | — | 12.4 | — | — | — | 12.4 |
| Purchases of treasury stock | | (6.6) | — | — | — | — | (557.7) | (557.7) |
| Share-based compensation expense | Share-based compensation expense | — | — | 30.8 | — | — | — | 30.8 |
| Share-based compensation expense | | | | | | | | |
| Share-based compensation expense | | | | | | | | |
| Net income | Net income | — | — | — | — | 101.2 | — | 101.2 |
| Other comprehensive loss, net of tax | | — | — | — | (18.1) | — | — | (18.1) |

| | | | | | | | | |
|--|--------------|---------------|------------------|-----------|---------------|-----------------|------------------|-------------------|
| Balance at September 30, | | | | | | | | |
| 2022 | 386.2 | \$ 0.4 | \$2,072.1 | \$ | (41.1) | \$ 388.1 | \$(595.0) | \$ 1,824.5 |
| Other comprehensive income, net of tax | | | | | | | | |
| Balance at March 31, 2023 | | | | | | | | |

See accompanying notes

[Table of Contents](#)

DexCom, Inc.
Consolidated Statements of Stockholders' Equity
(Unaudited)

| | Nine Months Ended September 30, 2023 | | | | | | |
|---|--------------------------------------|--------|-----------------|--------------------|----------|----------------|----------------------|
| | Common Stock | | Additional | Accumulated Other | Retained | Treasury Stock | Total |
| (In millions) | Shares | Amount | Paid-In Capital | Comprehensive Loss | Earnings | | Stockholders' Equity |
| Balance at December 31, 2022 | 386.3 | \$ 0.4 | \$ 2,258.1 | \$ (11.6) | \$ 479.9 | \$ (595.0) | \$ 2,131.8 |
| Issuance of common stock under equity incentive plans | 1.3 | — | — | — | — | — | — |
| Issuance of common stock for Employee Stock Purchase Plan | 0.3 | — | 26.6 | — | — | — | 26.6 |
| Purchases of treasury stock, including excise tax | (1.6) | — | — | — | — | (188.9) | (188.9) |
| Conversions of 2023 Notes | 10.6 | — | (0.4) | — | — | — | (0.4) |
| Benefit of note hedge upon conversions of 2023 Notes | (10.5) | — | 1,296.1 | — | — | (1,296.1) | — |
| Purchase of capped call transactions, net of tax | — | — | (76.3) | — | — | — | (76.3) |
| Share-based compensation expense | — | — | 113.9 | — | — | — | 113.9 |
| Net income | — | — | — | — | 285.2 | — | 285.2 |
| Other comprehensive loss, net of tax | — | — | — | (24.0) | — | — | (24.0) |
| Balance at September 30, 2023 | 386.4 | \$ 0.4 | \$ 3,618.0 | \$ (35.6) | \$ 765.1 | \$ (2,080.0) | \$ 2,267.9 |

| | Nine Months Ended September 30, 2022 | | | | | | | |
|---|--------------------------------------|--------|--------------------|--------------------------------|----------|----------------|-------------------------|--|
| | Common Stock | | Additional | Accumulated Other | Retained | Treasury Stock | Total | |
| (In millions) | Shares | Amount | Paid-In Capital | Comprehensive Income (Loss) | Earnings | | Stockholders' Equity | |
| Balance at December 31, 2021 | 388.0 | \$ 0.4 | \$ 2,108.7 | \$ 0.5 | \$ 138.7 | \$ (206.2) | \$ 2,042.1 | |
| Issuance of common stock under equity incentive plans | 1.5 | — | — | — | — | — | — | |
| Issuance of common stock for Employee Stock Purchase Plan | 0.3 | — | 22.5 | — | — | — | 22.5 | |
| Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs | 2.9 | — | (189.3) | — | — | 189.2 | (0.1) | |
| Purchases of treasury stock | (6.6) | — | — | — | — | (557.7) | (557.7) | |

| | | | | | | | |
|--|--------------|---------------|-------------------|------------------|-----------------|-------------------|-------------------|
| Conversions of 2023 Notes | 0.4 | — | 4.2 | — | — | 13.2 | 17.4 |
| Benefit of note hedge upon conversions of 2023 Notes | (0.3) | — | 33.5 | — | — | (33.5) | — |
| Share-based compensation expense | — | — | 92.5 | — | — | — | 92.5 |
| Net income | — | — | — | — | 249.4 | — | 249.4 |
| Other comprehensive loss, net of tax | — | — | — | (41.6) | — | — | (41.6) |
| Balance at September 30, 2022 | 386.2 | \$ 0.4 | \$ 2,072.1 | \$ (41.1) | \$ 388.1 | \$ (595.0) | \$ 1,824.5 |

See accompanying notes

[Table of Contents](#)

DexCom, Inc. Consolidated Statements of Cash Flows (Unaudited)

| (In millions) | Nine Months Ended September 30, | |
|---|------------------------------------|----------------|
| | 2023 | 2022 |
| Operating activities | | |
| Net income | \$ 285.2 | \$ 249.4 |
| Adjustments to reconcile net income to cash provided by operating activities: | | |
| Depreciation and amortization | 133.5 | 119.6 |
| Share-based compensation | 113.9 | 92.5 |
| Non-cash interest expense | 5.8 | 4.7 |
| Realized (gain) loss on equity investment | (1.0) | (0.2) |
| Deferred income taxes | (136.5) | (53.6) |
| Other non-cash income and expenses | (47.3) | 31.9 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable, net | (72.9) | (51.6) |
| Inventory | (193.6) | 43.6 |
| Prepaid and other assets | 13.2 | (81.2) |
| Operating lease right-of-use assets and liabilities, net | (4.4) | (6.1) |
| Accounts payable and accrued liabilities | 496.5 | 171.3 |
| Accrued payroll and related expenses | 16.6 | (14.0) |
| Deferred revenue and other liabilities | 5.9 | 30.7 |
| Net cash provided by operating activities | 614.9 | 537.0 |
| Investing activities | | |
| Purchases of marketable securities | (2,947.9) | (1,397.7) |
| Proceeds from sale and maturity of marketable securities | 2,228.4 | 1,387.8 |
| Purchases of property and equipment | (184.1) | (301.3) |
| Acquisitions, net of cash acquired | — | (3.9) |
| Other investing activities | (18.5) | (12.3) |
| Net cash used in investing activities | (922.1) | (327.4) |
| Financing activities | | |
| Net proceeds from issuance of common stock | 26.6 | 22.5 |
| Purchases of treasury stock | (188.7) | (557.7) |
| Proceeds from issuance of senior convertible notes, net of issuance costs | 1,230.6 | — |
| Purchases of capped call transactions | (101.3) | — |
| Payments for conversions of senior convertible notes | (650.5) | — |

| | | |
|--|-----------------|-----------------|
| Other financing activities | (3.4) | (16.3) |
| Net cash provided by (used in) financing activities | 313.3 | (551.5) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (4.6) | (12.6) |
| Increase (decrease) in cash, cash equivalents and restricted cash | 1.5 | (354.5) |
| Cash, cash equivalents and restricted cash, beginning of period | 643.3 | 1,053.6 |
| Cash, cash equivalents and restricted cash, end of period | \$ 644.8 | \$ 699.1 |
| Reconciliation of cash, cash equivalents and restricted cash, end of period: | | |
| Cash and cash equivalents | \$ 643.7 | \$ 698.1 |
| Restricted cash | 1.1 | 1.0 |
| Total cash, cash equivalents and restricted cash | \$ 644.8 | \$ 699.1 |
| Supplemental disclosure of non-cash investing and financing transactions: | | |
| Shares issued for conversions of 2023 Notes | \$ 1,316.4 | \$ 35.9 |
| Shares received under note hedge upon conversion of 2023 Notes | \$ (1,296.1) | \$ (33.5) |
| Acquisition of property and equipment included in accounts payable and accrued liabilities | \$ 47.0 | \$ 60.3 |
| Right-of-use assets obtained in exchange for operating lease liabilities | \$ 6.0 | \$ (0.7) |
| Right-of-use assets obtained in exchange for finance lease liabilities | \$ 1.8 | \$ 15.8 |

[Table of Contents](#)

| (In millions) | Three Months Ended March 31, | |
|---|---------------------------------|----------------|
| | 2024 | 2023 |
| Operating activities | | |
| Net income | \$ 146.4 | \$ 48.6 |
| Adjustments to reconcile net income to cash provided by operating activities: | | |
| Depreciation and amortization | 52.5 | 41.6 |
| Share-based compensation | 39.0 | 35.2 |
| Non-cash interest expense | 1.9 | 1.5 |
| Deferred income taxes | (41.8) | (9.3) |
| Other non-cash income and expenses | (7.8) | (13.7) |
| Changes in operating assets and liabilities: | | |
| Accounts receivable, net | (5.8) | 76.6 |
| Inventory | (36.7) | (59.6) |
| Prepaid and other assets | 11.4 | (13.4) |
| Operating lease right-of-use assets and liabilities, net | (2.0) | (0.7) |
| Accounts payable and accrued liabilities | 109.6 | 86.7 |
| Accrued payroll and related expenses | (60.7) | (39.3) |
| Deferred revenue and other liabilities | 3.2 | 1.2 |
| Net cash provided by operating activities | 209.2 | 155.4 |
| Investing activities | | |
| Purchases of marketable securities | (992.4) | (809.6) |
| Proceeds from sale and maturity of marketable securities | 1,121.8 | 697.6 |
| Purchases of property and equipment | (56.9) | (74.7) |
| Other investing activities | 2.3 | — |
| Net cash provided by (used in) investing activities | 74.8 | (186.7) |
| Financing activities | | |
| Net proceeds from issuance of common stock | 13.4 | 12.3 |
| Other financing activities | (8.7) | (1.1) |
| Net cash provided by financing activities | 4.7 | 11.2 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (3.8) | 1.1 |

| | | |
|--|-----------------|-----------------|
| Increase (decrease) in cash, cash equivalents and restricted cash | 284.9 | (19.0) |
| Cash, cash equivalents and restricted cash, beginning of period | 567.5 | 643.3 |
| Cash, cash equivalents and restricted cash, end of period | \$ 852.4 | \$ 624.3 |
| Reconciliation of cash, cash equivalents and restricted cash, end of period: | | |
| Cash and cash equivalents | \$ 851.2 | \$ 623.2 |
| Restricted cash | 1.2 | 1.1 |
| Total cash, cash equivalents and restricted cash | \$ 852.4 | \$ 624.3 |
| Supplemental disclosure of non-cash investing and financing transactions: | | |
| Acquisition of property and equipment included in accounts payable and accrued liabilities | \$ 40.7 | \$ 55.8 |
| Right-of-use assets obtained in exchange for operating lease liabilities | \$ 1.1 | \$ 1.9 |
| Right-of-use assets obtained in exchange for finance lease liabilities | \$ 7.4 | \$ 1.0 |

See accompanying notes

[Table of Contents](#)

DexCom, Inc. Notes to Consolidated Financial Statements (Unaudited)

1. Organization and Significant Accounting Policies

Organization and Business

DexCom, Inc. is We are a medical device company that develops primarily focused on the design, development and markets commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “Dexcom” refer to DexCom, Inc. and its subsidiaries.

Basis of Presentation and Principles of Consolidation

We have prepared the accompanying unaudited consolidated financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Securities and Exchange Commission, or SEC, Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.

Operating results for the three and nine months ended September 30, 2023 March 31, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023 December 31, 2024.

These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto for the fiscal year ended December 31, 2022 December 31, 2023 included in the Annual Report on Form 10-K that we filed with the SEC on February 9, 2023 February 8, 2024.

These consolidated financial statements include the accounts of DexCom, Inc. and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

We have reclassified certain amounts previously reported in our financial statements to conform to the current presentation.

On June 10, 2022, the Company effected a four-for-one forward stock split of its common stock to shareholders of record as of May 19, 2022. The par value of the common stock remains \$0.001 per share. Accordingly, an amount equal to the par value of the increased shares resulting from the stock split was reclassified from “Additional paid-in capital” to “Common stock.” All share and per share information has been retroactively adjusted to reflect the stock split for all periods presented.

We determine the functional currencies of our international subsidiaries by reviewing the environment where each subsidiary primarily generates and expends cash. For international subsidiaries whose functional currencies are the local currencies, we translate the financial statements into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. We include translation-related adjustments in comprehensive income and in accumulated other comprehensive loss in the equity section of our consolidated balance sheets. We record gains and losses resulting from transactions with customers and vendors that are denominated in currencies other than the functional currency and from certain intercompany transactions in other income (expense), net in our consolidated statements of operations.

Seasonality

We expect that the revenue we generate from the sales of our products will fluctuate from quarter to quarter. We typically experience seasonality, with lower sales in the first quarter of each year compared to the immediately preceding fourth quarter. This seasonal sales pattern relates to U.S. annual insurance deductible resets and unfunded

[flexible spending accounts.](#)

Significant Accounting Policies

There were no material changes to our significant accounting policies as described in Note 1 "[Organization and Significant Accounting Policies](#)" to the financial statements in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended [December 31, 2022](#) [December 31, 2023](#) during the [nine](#) three months ended [September 30, 2023](#) [March 31, 2024](#).

[Table of Contents](#)

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in our consolidated financial statements and the disclosures made in the accompanying notes. Areas requiring significant estimates include rebates, excess or obsolete inventories and the valuation of inventory, accruals for litigation contingencies, and the amount of our worldwide tax provision and the realizability of deferred tax assets. Despite our intention to establish accurate estimates and use reasonable assumptions, actual results may differ from our estimates.

[Table of Contents](#)

Concentration of Credit Risk

Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, short-term marketable securities, and accounts receivable. We limit our exposure to credit risk by placing our cash and investments with a few major financial institutions. We have also established guidelines regarding diversification of our investments and their maturities that are designed to maintain principal and maximize liquidity. We review these guidelines periodically and modify them to take advantage of trends in yields and interest rates and changes in our operations and financial position.

Contract Balances

Contract balances represent amounts presented in our consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable and deferred revenue. Payment terms vary by contract type and type of customer and generally range from 30 to 90 days.

Accounts receivable as of [September 30, 2023](#) [March 31, 2024](#) included unbilled accounts receivable of [\\$8.8 million](#) [\\$10.1 million](#). We expect to invoice and collect all unbilled accounts receivable within twelve months.

We record deferred revenue when we have entered into a contract with a customer and cash payments are received or due prior to transfer of control or satisfaction of the related performance obligation.

Our performance obligations are generally satisfied within twelve months of the initial contract date. The deferred revenue balances related to performance obligations that will be satisfied after twelve months [was \\$21.3 million](#) [were \\$7.4 million](#) as of [September 30, 2023](#) [March 31, 2024](#) and [\\$19.0 million as of December 31, 2022](#) [December 31, 2023](#). These balances are included in other long-term liabilities in our consolidated balance sheets. Revenue recognized in the period from performance obligations satisfied in previous periods was not material for the periods presented.

Net Income Per Share

Basic net income per share attributable to common stockholders is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares outstanding during the period and, when dilutive, potential common share equivalents.

Potentially dilutive common shares consist of shares issuable from restricted stock units, or RSUs, performance stock units, or PSUs, warrants, [and](#) our senior convertible [notes, notes, and collaborative sales-based milestones](#). Potentially dilutive common shares issuable upon vesting of RSUs, PSUs, and exercise of warrants are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our senior convertible notes are determined using the if-converted method. In periods of net losses, we exclude all potentially dilutive common shares from the computation of the diluted net loss per share for those periods as the effect would be anti-dilutive.

[Table of Contents](#)

The following table sets forth the computation of basic and diluted net income per share for the periods shown:

| | | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|--|-------------------------------------|----------|------------------------------------|----------|
| | | Three Months Ended March 31, | | Three Months Ended March 31, | |
| | | Three Months Ended March 31, | | Three Months Ended March 31, | |
| | | Three Months Ended March 31, | | Three Months Ended March 31, | |
| (In millions, except per share data) | | | | | |
| (In millions, except per share data) | | | | | |
| (In millions, except per share data) | | | | | |
| | | 2023 | 2022 | 2023 | 2022 |
| Net income | Net income | \$ 120.7 | \$ 101.2 | \$ 285.2 | \$ 249.4 |
| Net income | | | | | |
| Net income | | | | | |
| Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes | Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes | 3.0 | 2.8 | 9.6 | 8.3 |
| Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes | | | | | |
| Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes | | | | | |
| Net income - diluted | | | | | |
| Net income - diluted | | | | | |
| Net income - diluted | Net income - diluted | \$ 123.7 | \$ 104.0 | \$ 294.8 | \$ 257.7 |
| Net income per common share | Net income per common share | | | | |
| Net income per common share | | | | | |
| Net income per common share | | | | | |
| Basic | Basic | \$ 0.31 | \$ 0.26 | \$ 0.74 | \$ 0.64 |
| Basic | | | | | |
| Basic | | | | | |
| Diluted | | | | | |
| Diluted | | | | | |
| Diluted | Diluted | \$ 0.29 | \$ 0.24 | \$ 0.69 | \$ 0.60 |
| Basic weighted average shares outstanding | Basic weighted average shares outstanding | 386.6 | 389.8 | 386.7 | 390.4 |
| Dilutive potential common stock outstanding: | | | | | |
| Restricted stock units and performance stock units | | 1.0 | 0.5 | 1.1 | 0.9 |
| Basic weighted average shares outstanding | | | | | |
| Basic weighted average shares outstanding | | | | | |
| Dilutive potential securities: | | | | | |
| Dilutive potential securities: | | | | | |
| Dilutive potential securities: | | | | | |
| Collaborative sales-based milestones | | | | | |
| Collaborative sales-based milestones | | | | | |

| | | | | | |
|---|---|-------|-------|-------|-------|
| Collaborative sales-based milestones | | | | | |
| RSUs and PSUs | | | | | |
| RSUs and PSUs | | | | | |
| RSUs and PSUs | | | | | |
| Senior convertible notes | | | | | |
| Senior convertible notes | | | | | |
| Senior convertible notes | | | | | |
| Warrants | Warrants | 11.6 | 8.6 | 11.8 | 9.8 |
| Senior convertible notes | | 27.6 | 26.9 | 28.7 | 26.9 |
| Warrants | | | | | |
| Warrants | | | | | |
| Diluted weighted average shares outstanding | Diluted weighted average shares outstanding | 426.8 | 425.8 | 428.3 | 428.0 |
| Diluted weighted average shares outstanding | | | | | |
| Diluted weighted average shares outstanding | | | | | |

Outstanding anti-dilutive securities not included in the calculations of diluted net income per share attributable to common stockholders calculations were as follows:

| (In millions) | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|-------------------------------------|------|------------------------------------|------|
| | 2023 | 2022 | 2023 | 2022 |
| Restricted stock units and performance stock units | — | 1.3 | — | 0.5 |

Recent Accounting Guidance

Recently Adopted Accounting Pronouncements

In October 2021, the FASB issued ASU No. 2021-08, *Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers*. This guidance is intended improve the accounting for acquired revenue contracts with customers in a business combination. The new guidance requires that the acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective for public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The amendments should be applied prospectively to business combinations occurring on or after the adoption date. We adopted ASU 2021-08 in the first quarter of 2023 and there was no impact to our consolidated financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

We do not expect any recently issued accounting pronouncements will have a material effect on our consolidated financial statements.

| (In millions) | Three Months Ended March 31, | |
|--------------------------|---------------------------------|------|
| | 2024 | 2023 |
| RSUs and PSUs | 0.4 | 0.1 |
| Senior convertible notes | — | 8.0 |
| Total | 0.4 | 8.1 |

[Table of Contents](#)

Recent Accounting Guidance

Recently Issued Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*. The ASU expands public entities' segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the chief operating decision maker, or CODM, and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S.

GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. We are currently evaluating the impact of this standard on our disclosures.

In December 2023, the FASB issued ASU 2023-09, *Improvements to Income Tax Disclosures*. The ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity's exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. The ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The ASU should be applied on a prospective basis although retrospective application is permitted. We are currently evaluating the impact of this standard on our disclosures.

On March 6, 2024, the SEC adopted SEC Release Nos. 33-11275; 34-99678, *The Enhancement and Standardization of Climate-Related Disclosures for Investor*, to require the disclosure of certain climate-related information in registration statements and annual reports, including Scope 1 and 2 emissions and information about climate-related risks that have materially impacted, or are reasonably likely to have a material impact on, a company's business strategy, results of operations, or financial condition. In addition, under the final rules, certain disclosures related to severe weather events and other natural conditions will be required in audited financial statements. The disclosure requirements will begin phasing in for our reports and registration statements including financial information in the fiscal year ending December 31, 2025. On April 4, 2024, the SEC issued an order staying the final rules until the completion of judicial review. We are currently evaluating the impact of this final rule on our disclosures.

[Table of Contents](#)

2. Development and Other Agreements

Collaboration with Verily Life Sciences

On November 20, 2018, we entered into an Amended and Restated Collaboration and License Agreement with Verily Life Sciences LLC (an Alphabet Company) and Verily Ireland Limited (collectively, "Verily"), which we refer to as the Restated Collaboration Agreement. This replaced our original Collaboration and License Agreement with Verily dated August 10, 2015, as amended in October 2016, including the royalty obligations provisions under that original agreement. Pursuant to the Restated Collaboration Agreement, we and Verily have agreed to continue to jointly develop a certain next-generation CGM product, and potentially one or more additional CGM products, for which we will have exclusive commercialization rights.

The Restated Collaboration Agreement also provides us with an exclusive license to use intellectual property of Verily resulting from the collaboration, and certain Verily patents, in the development, manufacture and commercialization of blood-based or interstitial glucose monitoring products more generally (subject to certain exclusions, which are outside of the CGM field as it is commonly understood). It also provides us with non-exclusive license rights under Verily's other intellectual property rights to develop, manufacture and commercialize those kinds of glucose monitoring products and certain CGM-product companion software functionalities. The In connection with the Restated Collaboration Agreement, requires us to use commercially reasonable efforts to develop, launch we developed, launched and commercialize commercialized a CGM product in connection with the CGM product(s) that are the subject of the collaboration according to certain timing and other objectives, and provides for one executive sponsor from each of Dexcom and Verily to meet periodically and make decisions related to the collaboration (within a limited scope of authority) by consensus. collaboration.

In consideration of Verily's performance of its obligations under the joint development plan of the Restated Collaboration Agreement, the licenses granted to us and the amendment of the original agreement, we made upfront, incentive, and the product regulatory approval payments, and will make potential payments for contingent sales-based milestones upon the achievement of certain revenue targets.

We account for the contingent milestones payable in shares of our common stock as equity instruments within the scope of ASC Topic 718. The product regulatory approval and sales-based milestones are accounted for as performance-based awards that vest when the performance conditions have been achieved and are recognized when the achievement of the respective contingent milestone is deemed probable. The value of the contingent milestones is based on our closing stock price on December 28, 2018, which was \$29.57 per share.

Upfront and Incentive payments

In the fourth quarter of 2018, we made an initial payment for an upfront fee of \$250.0 million through the issuance of 7,363,772 7.4 million shares of our common stock. We recorded a \$217.7 million charge in our consolidated statements of operations during 2018 relating to the issuance of this common stock because this milestone payment did not meet the capitalization criteria. The value of the charge was based on our closing stock price of \$29.57 per share on December 28, 2018, the date on which we obtained the necessary regulatory approvals and represents the date the performance-based awards were issued. In 2019, we made a cash incentive payment of \$3.2 million due to the completion of certain development obligations and we recorded these payments as research and development expense in our consolidated statements of operations.

Contingent milestones

In the fourth quarter of 2021, we determined the achievement of the regulatory approval milestone to be probable and recorded an \$87.1 million research and development charge in our consolidated statements of operations. This charge is associated with IPR&D in-process research and development obtained in an asset acquisition prior to regulatory approval and therefore does not have an alternative future use.

In the first quarter of 2022, we received regulatory approval and issued 2,945,508 2.9 million shares of our common stock in connection with our achievement of the related milestone.

In the fourth quarter of 2022, we received FDA approval from the Food and Drug Administration and determined the achievement of the sales-based milestones to be probable. As such, we capitalized the full value of the sales-based milestones, \$152.4 million, as an intangible asset. The sales-based milestones are contingent upon the achievement of certain revenue targets. The value of the sales-based milestones is based on: 1) 5,154,640 5.2 million shares of our common stock, as agreed upon in November 2018 and 2)

our closing stock price on December 28, 2018 of \$29.57 per share. December 28, 2018 is the date on which we obtained the necessary regulatory approvals and represents the date the ~~performance-~~ ~~based~~ ~~performance-based~~ awards were issued. The intangible asset will be amortized using the straight-line method over its estimated useful

[Table of Contents](#)

life of 64 months through March 2028. The related amortization expense is recognized in ~~Cost~~ ~~cost~~ of ~~Sales~~ ~~sales~~ in our consolidated statements of operations.

[Table of Contents](#)

In the fourth quarter of 2023, we issued 3.7 million shares of our common stock in connection with our achievement of the first sales-based milestone.

In the first quarter of 2024, we issued 1.5 million shares of our common stock in connection with our achievement of the second sales-based milestone.

All milestones ~~may be~~ ~~were~~ paid in cash or shares of our common stock, at our election. ~~If we elect to make these milestone payments in cash, any such cash payment would be equal to the number of shares that would otherwise be issued for the given milestone payment multiplied by the value of our stock on the date the relevant milestone is achieved, and adjusted to give effect to any stock splits, dividends, or similar events. We intend to pay the sales-based contingent milestones in shares of our common stock.~~

The Restated Collaboration Agreement will continue until December 31, 2028, unless terminated by either party upon uncured material breach of the Restated Collaboration Agreement by the other party. Upon achievement of the first sales-based milestone event and payment of the corresponding milestone fee by us, the term of the Restated Collaboration Agreement will be extended until December 31, 2033, unless terminated by either party upon uncured material breach of the Restated Collaboration Agreement by the other party.

[Table of Contents](#)

3. Fair Value Measurements

Assets and Liabilities Measured at Fair Value on a Recurring Basis

We estimate the fair value of our Level 1 financial instruments, which are in active markets, using unadjusted quoted market prices for identical instruments.

We obtain the fair values for our Level 2 financial instruments, which are not in active markets, from a primary professional pricing source that uses quoted market prices for identical or comparable instruments, rather than direct observations of quoted prices in active markets. Fair values obtained from this professional pricing source can also be based on pricing models whereby all significant observable inputs, including maturity dates, issue dates, settlement dates, benchmark yields, reported trades, broker-dealer quotes, issue spreads, benchmark securities, bids, offers or other market related data, are observable or can be derived from, or corroborated by, observable market data for substantially the full term of the asset. We validate the quoted market prices provided by our primary pricing service by comparing the fair values of our Level 2 marketable securities portfolio balance provided by our primary pricing service against the fair values provided by our investment managers.

The following table summarizes financial assets that we measured at fair value on a recurring basis as of ~~September 30, 2023~~ ~~March 31, 2024~~, classified in accordance with the fair value hierarchy:

| Fair Value Measurements Using | | | | | | | | | |
|---|---|---------|---------|-----|----------|-------------------------------|---------|---------|---------|
| Fair Value Measurements Using | | | | | | Fair Value Measurements Using | | | |
| (In millions) | (In millions) | Level | | | | (In millions) | Level 1 | Level 2 | Level 3 |
| | | Level 1 | Level 2 | 3 | Total | | | | |
| Cash equivalents | Cash equivalents | \$360.9 | \$ 29.9 | \$— | \$ 390.8 | | | | |
| Debt securities, available-for-sale: | Debt securities, available-for-sale: | | | | | | | | |
| Debt securities, available-for-sale: | | | | | | | | | |
| Debt securities, available-for-sale: | | | | | | | | | |
| U.S. government agencies ⁽¹⁾ | | | | | | | | | |
| U.S. government agencies ⁽¹⁾ | | | | | | | | | |
| U.S. government agencies ⁽¹⁾ | U.S. government agencies ⁽¹⁾ | — | 1,819.0 | — | 1,819.0 | | | | |

| | | | | | |
|--|--|---------|-----------|-----|-----------|
| Commercial paper | Commercial paper | — | 387.3 | — | 387.3 |
| Corporate debt | Corporate debt | — | 390.3 | — | 390.3 |
| Total debt securities, available-for-sale | Total debt securities, available-for-sale | — | 2,596.6 | — | 2,596.6 |
| Total debt securities, available-for-sale | | | | | |
| Total debt securities, available-for-sale | | | | | |
| Other assets ⁽²⁾ | | | | | |
| Other assets ⁽²⁾ | | | | | |
| Other assets ⁽²⁾ | Other assets ⁽²⁾ | 13.7 | — | — | 13.7 |
| Total assets measured at fair value on a recurring basis | Total assets measured at fair value on a recurring basis | \$374.6 | \$2,626.5 | \$— | \$3,001.1 |
| Total assets measured at fair value on a recurring basis | | | | | |
| Total assets measured at fair value on a recurring basis | | | | | |

⁽¹⁾ Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.

⁽²⁾ Includes assets which are held pursuant to a deferred compensation plan for senior management, which consist mainly of mutual funds.

Table of Contents

The following table summarizes financial assets that we measured at fair value on a recurring basis as of **December 31, 2022** **December 31, 2023**, classified in accordance with the fair value hierarchy:

| Fair Value Measurements Using | | | | | | Fair Value Measurements Using | | | | |
|---|---|---------|---------|-----|----------|-------------------------------|---------|---------|---------|-------|
| Fair Value Measurements Using | | | | | | Fair Value Measurements Using | | | | |
| (In millions) | (In millions) | Level | | | | (In millions) | Level 1 | Level 2 | Level 3 | Total |
| | | Level 1 | Level 2 | 3 | Total | | | | | |
| Cash equivalents | Cash equivalents | \$375.9 | \$ 44.8 | \$— | \$ 420.7 | | | | | |
| Debt securities, available-for-sale: | Debt securities, available-for-sale: | | | | | | | | | |
| Debt securities, available-for-sale: | | | | | | | | | | |
| Debt securities, available-for-sale: | | | | | | | | | | |
| U.S. government agencies ⁽¹⁾ | | | | | | | | | | |
| U.S. government agencies ⁽¹⁾ | | | | | | | | | | |
| U.S. government agencies ⁽¹⁾ | U.S. government agencies ⁽¹⁾ | — | 1,530.7 | — | 1,530.7 | | | | | |
| Commercial paper | Commercial paper | — | 119.4 | — | 119.4 | | | | | |
| Corporate debt | Corporate debt | — | 163.8 | — | 163.8 | | | | | |

| | | | | | |
|--|--|---------|-----------|-----|-----------|
| Total debt securities, available-for-sale | Total debt securities, available-for-sale | — | 1,813.9 | — | 1,813.9 |
| Total debt securities, available-for-sale | | | | | |
| Total debt securities, available-for-sale | | | | | |
| Other assets ⁽²⁾ | | | | | |
| Other assets ⁽²⁾ | | | | | |
| Other assets ⁽²⁾ | Other assets ⁽²⁾ | 10.2 | — | — | 10.2 |
| Total assets measured at fair value on a recurring basis | Total assets measured at fair value on a recurring basis | \$386.1 | \$1,858.7 | \$— | \$2,244.8 |
| Total assets measured at fair value on a recurring basis | | | | | |
| Total assets measured at fair value on a recurring basis | | | | | |

(1) Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.

(2) Includes assets which are held pursuant to a deferred compensation plan for senior management, which consist mainly of mutual funds.

There were no transfers into or out of Level 3 securities during the three and nine months ended September 30, 2023 March 31, 2024 and September 30, 2022. March 31, 2023.

Fair Value of Senior Convertible Notes

The fair value, based on trading prices (Level 1 inputs), of our senior convertible notes were as follows as of the dates indicated:

| Fair Value Measurements Using Level 1 | | | Fair Value Measurements Using Level 1 | |
|--|---------------------------------------|-------------------|---------------------------------------|-------------------|
| (In millions) | | (In millions) | March 31, 2024 | December 31, 2023 |
| | Fair Value Measurements Using Level 1 | | | |
| | September 30, 2023 | December 31, 2022 | | |
| Senior Convertible Notes due 2025 | | | | |
| Senior Convertible Notes due 2023 | \$ 281.3 | \$2,136.2 | | |
| Senior Convertible Notes due 2025 | | | | |
| Senior Convertible Notes due 2025 | 1,140.5 | 1,314.9 | | |
| Senior Convertible Notes due 2028 | 1,109.4 | — | | |
| Total fair value of outstanding senior convertible notes | \$2,531.2 | \$3,451.1 | | |

For See Note 5 "Debt—Senior Convertible Notes" to the consolidated financial statements in Part I, Item I of this Quarterly Report on Form 10-Q for more information on regarding the carrying values of our senior convertible notes, see Senior Convertible Notes in Note 5 "Debt" to the consolidated financial statements. notes.

Foreign Currency and Derivative Financial Instruments

We enter into foreign currency forward contracts to hedge monetary assets and liabilities denominated in foreign currencies. Our foreign currency forward contracts are not designated as hedging instruments. Therefore, changes in the fair values of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The duration of these contracts is generally one month. The derivative gains and losses are included in other income (expense), net in our consolidated statements of operations.

As of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, the notional amounts of outstanding foreign currency forward contracts were **\$89.0 million** **\$80.0 million** and **\$62.0 million** **\$71.0 million**, respectively. The resulting impact on our consolidated financial statements from currency hedging activities was not significant for the three **and nine** months ended **September 30, 2023** **March 31, 2024** and **September 30, 2022** **March 31, 2023**.

Our foreign currency exposures vary but are primarily concentrated in the Australian Dollar, the British Pound, the Canadian Dollar, the Euro, and the Malaysian Ringgit. We monitor the costs and the impact of foreign currency risks upon our financial results as part of our risk management program. We do not use derivative financial instruments for speculation or trading purposes or for activities other than risk management. We do not require and are not required to pledge collateral for these financial instruments and we do not carry any master netting arrangements to mitigate the credit risk.

[Table of Contents](#)

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

In accordance with authoritative guidance, we measure certain non-financial assets and liabilities at fair value on a non-recurring basis. These measurements are usually performed using the discounted cash flow method or cost method and Level 3 inputs. These include items such as non-financial assets and liabilities initially measured at fair value in a business combination and non-financial long-lived assets measured at fair value for an impairment assessment. In general, non-financial assets, including goodwill, intangible assets, and property and equipment, are measured at fair value when there are indicators of impairment and are recorded at fair value only when an impairment is recognized.

We hold certain other investments that we do not measure at fair value on a recurring basis. The carrying values of these investments are **\$38.5** **\$39.8** million as of **September 30, 2023** **March 31, 2024** and **\$19.0 million** **\$38.5 million** as of **December 31, 2022** **December 31, 2023**. We include them in other assets in our consolidated balance sheets. It is impracticable for us to estimate the fair value of these investments on a recurring basis due to the fact that these entities are privately held and limited information is available. We monitor the information that becomes available from time to time and adjust the carrying values of these investments if there are identified events or changes in circumstances that have a significant effect on the fair values.

There were no significant impairment losses during the three **and nine** months ended **September 30, 2023** **March 31, 2024** and **September 30, 2022** **March 31, 2023**.

[Table of Contents](#)

4. Balance Sheet Details and Other Financial Information

Short-Term Marketable Securities

Short-term marketable securities, consisting of available-for-sale debt securities, were as follows as of the dates indicated:

| | | September 30, 2023 | | | | | | | | |
|---|---|--------------------|------------------|------------------|------------------|----------------|-----------|------------------|------------------|------------------|
| | | March 31, 2024 | | | | March 31, 2024 | | | | |
| | | Amortized | Gross Unrealized | Gross Unrealized | Estimated Market | | Amortized | Gross Unrealized | Gross Unrealized | Estimated Market |
| (In millions) | (In millions) | Cost | Gains | Losses | Value | (In millions) | Cost | Gains | Losses | Value |
| Debt securities, available-for-sale: | Debt securities, available-for-sale: | | | | | | | | | |
| U.S. government agencies ⁽¹⁾ | U.S. government agencies ⁽¹⁾ | | | | | | | | | |
| U.S. government agencies ⁽¹⁾ | U.S. government agencies ⁽¹⁾ | \$1,820.5 | \$ 0.5 | \$ (2.0) | \$1,819.0 | | | | | |
| Commercial paper | Commercial paper | 387.5 | — | (0.2) | 387.3 | | | | | |
| Corporate debt | Corporate debt | 391.2 | — | (0.9) | 390.3 | | | | | |

| | | | | | |
|---|---|-----------|--------|----------|-----------|
| Total debt securities, available-for-sale | Total debt securities, available-for-sale | \$2,599.2 | \$ 0.5 | \$ (3.1) | \$2,596.6 |
|---|---|-----------|--------|----------|-----------|

| |
|---|
| Total debt securities, available-for-sale |
| Total debt securities, available-for-sale |

| (In millions) | December 31, 2022 | | | |
|---|-------------------|------------------|-------------------|--------------|
| | Amortized | Gross | Gross | Estimated |
| | Cost | Unrealized Gains | Unrealized Losses | Market Value |
| Debt securities, available-for-sale: | | | | |
| U.S. government agencies ⁽¹⁾ | \$ 1,535.1 | \$ 0.2 | \$ (4.6) | \$ 1,530.7 |
| Commercial paper | 119.6 | — | (0.2) | 119.4 |
| Corporate debt | 164.3 | — | (0.5) | 163.8 |
| Total debt securities, available-for-sale | \$ 1,819.0 | \$ 0.2 | \$ (5.3) | \$ 1,813.9 |

⁽¹⁾ Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.

| (In millions) | December 31, 2023 | | | |
|---|-------------------|------------------|-------------------|--------------|
| | Amortized | Gross | Gross | Estimated |
| | Cost | Unrealized Gains | Unrealized Losses | Market Value |
| Debt securities, available-for-sale: | | | | |
| U.S. government agencies ⁽¹⁾ | \$ 1,611.8 | \$ 1.2 | \$ (0.5) | \$ 1,612.5 |
| Commercial paper | 184.8 | — | (0.1) | 184.7 |
| Corporate debt | 360.8 | 0.1 | (0.3) | 360.6 |
| Total debt securities, available-for-sale | \$ 2,157.4 | \$ 1.3 | \$ (0.9) | \$ 2,157.8 |

⁽¹⁾ Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.

As of **September 30, 2023** March 31, 2024, the estimated market value of our short-term debt securities with contractual maturities up to 12 months and up to 18 months was \$1.77 billion and \$275.6 million, respectively. As of December 31, 2023, the estimated market value of our short-term debt securities with contractual maturities up to 12 months was \$2.60 billion. As of December 31, 2022, the estimated market value of our short-term debt securities with contractual maturities up to 12 months was \$1.81 \$2.16 billion. Gross realized gains and losses on sales of our short-term debt securities for the three and nine months ended **September 30, 2023** March 31, 2024 and **September 30, 2022** March 31, 2023 were not significant.

We periodically review our portfolio of debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For debt securities where the fair value of the investment is less than the amortized cost basis, we have assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst

Table of Contents

reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities at **September 30, 2023** March 31, 2024 were primarily due to increases in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, we have not recorded an allowance for credit losses. We do not intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.

Inventory

| (In millions) | September 30, 2023 | December 31, 2022 |
|-----------------|--------------------|-------------------|
| Raw materials | \$ 277.5 | \$ 159.0 |
| Work-in-process | 27.5 | 17.2 |
| Finished goods | 193.6 | 130.5 |
| Total inventory | \$ 498.6 | \$ 306.7 |

Prepaid and Other Current Assets

| (In millions) | September 30, 2023 | December 31, 2022 |
|--|--------------------|-------------------|
| Prepaid expenses | \$ 55.2 | \$ 48.9 |
| Prepaid inventory | 61.5 | 67.8 |
| Deferred compensation plan assets | 13.7 | 10.2 |
| Income tax receivables | 2.8 | 38.9 |
| Other current assets | 40.6 | 26.8 |
| Total prepaid and other current assets | \$ 173.8 | \$ 192.6 |

Property and Equipment

| (In millions) | September 30, 2023 | December 31, 2022 |
|--|--------------------|-------------------|
| Land and land improvements | \$ 31.8 | \$ 26.9 |
| Building | 163.2 | 54.3 |
| Furniture and fixtures | 35.9 | 32.6 |
| Computer software and hardware | 62.1 | 48.8 |
| Machinery and equipment | 632.5 | 449.2 |
| Leasehold improvements | 276.6 | 264.4 |
| Construction in progress | 343.1 | 542.6 |
| Total cost | 1,545.2 | 1,418.8 |
| Less accumulated depreciation and amortization | (466.3) | (363.2) |
| Total property and equipment, net | \$ 1,078.9 | \$ 1,055.6 |

Other Assets

| (In millions) | September 30, 2023 | December 31, 2022 |
|-----------------------|--------------------|-------------------|
| Long-term investments | \$ 38.5 | \$ 19.0 |
| Long-term deposits | 13.6 | 16.2 |
| Other assets | 22.3 | 11.9 |
| Total other assets | \$ 74.4 | \$ 47.1 |

| (In millions) | March 31, 2024 | December 31, 2023 |
|-----------------|----------------|-------------------|
| Raw materials | \$ 301.2 | \$ 319.5 |
| Work-in-process | 49.8 | 30.0 |
| Finished goods | 238.1 | 210.1 |
| Total inventory | \$ 589.1 | \$ 559.6 |

Table of Contents

Prepaid and Other Current Assets

| (In millions) | March 31, 2024 | December 31, 2023 |
|-----------------------------------|----------------|-------------------|
| Prepaid expenses | \$ 59.4 | \$ 58.7 |
| Prepaid inventory | 31.7 | 31.5 |
| Deferred compensation plan assets | 18.3 | 15.2 |
| Income tax receivables | 6.2 | 13.6 |

| | | |
|--|----------|----------|
| Other current assets | 40.4 | 49.3 |
| Total prepaid and other current assets | \$ 156.0 | \$ 168.3 |

Property and Equipment

| | | |
|---|----------------|-------------------|
| (In millions) | March 31, 2024 | December 31, 2023 |
| Land and land improvements | \$ 43.2 | \$ 34.5 |
| Building | 216.1 | 190.5 |
| Furniture and fixtures | 36.9 | 36.9 |
| Computer software and hardware | 67.5 | 65.8 |
| Machinery and equipment | 735.1 | 683.3 |
| Leasehold improvements | 283.9 | 283.4 |
| Construction in progress | 274.9 | 328.1 |
| Total cost | 1,657.6 | 1,622.5 |
| Less: accumulated depreciation and amortization | (549.0) | (509.4) |
| Total property and equipment, net | \$ 1,108.6 | \$ 1,113.1 |

Other Assets

| | | |
|-----------------------|----------------|-------------------|
| (In millions) | March 31, 2024 | December 31, 2023 |
| Long-term investments | \$ 39.8 | \$ 38.5 |
| Long-term deposits | 14.4 | 14.4 |
| Other assets | 23.5 | 22.1 |
| Total other assets | \$ 77.7 | \$ 75.0 |

Accounts Payable and Accrued Liabilities

| | | |
|--|--------------------|-------------------|
| (In millions) | September 30, 2023 | December 31, 2022 |
| Accounts payable trade | \$ 242.4 | \$ 237.9 |
| Accrued tax, audit, and legal fees | 218.8 | 44.8 |
| Accrued rebates | 837.4 | 556.4 |
| Accrued warranty | 13.3 | 12.8 |
| Deferred compensation plan liabilities | 13.7 | 10.2 |
| Other accrued liabilities | 47.5 | 39.7 |
| Total accounts payable and accrued liabilities | \$ 1,373.1 | \$ 901.8 |

Accrued Payroll and Related Expenses

| | | |
|--|--------------------|-------------------|
| (In millions) | September 30, 2023 | December 31, 2022 |
| Accrued wages, bonus and taxes | \$ 129.1 | \$ 96.8 |
| Other accrued employee benefits | 22.2 | 37.5 |
| Total accrued payroll and related expenses | \$ 151.3 | \$ 134.3 |

Other Long-Term Liabilities

| | | |
|-----------------------------|--------------------|-------------------|
| (In millions) | September 30, 2023 | December 31, 2022 |
| Finance lease obligations | \$ 57.9 | \$ 59.6 |
| Deferred revenue, long-term | 21.3 | 19.0 |

| | | | | |
|-----------------------------------|----|-------|----|-------|
| Deferred tax liabilities | | 4.6 | | 4.9 |
| Other tax liabilities | | 37.0 | | 32.7 |
| Other liabilities | | 13.1 | | 12.1 |
| Total other long-term liabilities | \$ | 133.9 | \$ | 128.3 |

Other Income (Expense), Net

| (In millions) | Three Months Ended | | Nine Months Ended | |
|-----------------------------------|--------------------|----------|-------------------|----------|
| | September 30, | | September 30, | |
| | 2023 | 2022 | 2023 | 2022 |
| Interest and dividend income | \$ 41.5 | \$ 5.7 | \$ 101.2 | \$ 10.4 |
| Interest expense | (4.9) | (4.6) | (15.4) | (13.9) |
| Other expense, net | (2.7) | (2.4) | (3.4) | (4.9) |
| Total other income (expense), net | \$ 33.9 | \$ (1.3) | \$ 82.4 | \$ (8.4) |

| (In millions) | March 31, 2024 | December 31, 2023 |
|--|----------------|-------------------|
| Accounts payable trade | \$ 269.7 | \$ 276.4 |
| Accrued tax, audit, and legal fees | 43.0 | 42.6 |
| Accrued rebates | 1,050.1 | 950.7 |
| Accrued warranty | 7.2 | 12.6 |
| Income tax payable | 11.9 | 7.5 |
| Deferred compensation plan liabilities | 18.3 | 15.2 |
| Other accrued liabilities | 46.4 | 40.5 |
| Total accounts payable and accrued liabilities | \$ 1,446.6 | \$ 1,345.5 |

Table of Contents

Accrued Payroll and Related Expenses

| (In millions) | March 31, 2024 | December 31, 2023 |
|--|----------------|-------------------|
| Accrued wages, bonus and taxes | \$ 81.3 | \$ 139.8 |
| Other accrued employee benefits | 29.2 | 31.2 |
| Total accrued payroll and related expenses | \$ 110.5 | \$ 171.0 |

Other Long-Term Liabilities

| (In millions) | March 31, 2024 | December 31, 2023 |
|-----------------------------------|----------------|-------------------|
| Finance lease obligations | \$ 57.6 | \$ 58.6 |
| Deferred revenue, long-term | 7.4 | 7.4 |
| Asset retirement obligation | 15.9 | 15.7 |
| Other tax liabilities | 43.7 | 38.7 |
| Other liabilities | 4.8 | 5.2 |
| Total other long-term liabilities | \$ 129.4 | \$ 125.6 |

Other Income (Expense), Net

| | Three Months Ended | |
|-----------------------------------|--------------------|---------|
| | March 31, | |
| (In millions) | 2024 | 2023 |
| Interest and dividend income | \$ 36.3 | \$ 22.3 |
| Interest expense | (4.6) | (4.6) |
| Other expense, net | (0.3) | (0.4) |
| Total other income (expense), net | \$ 31.4 | \$ 17.3 |

5. Debt

The carrying amounts of our senior convertible notes were as follows as of the dates indicated:

For our senior convertible notes for which the if-converted value exceeded the principal amount, the amount in excess of principal was as follows as of the dates indicated:

| (In millions) | | March 31, 2024 | | December 31, 2023 | |
|---|---|----------------|-----------|-------------------|------|
| Senior Convertible Notes due 2025 | | | | | |
| Senior Convertible Notes due 2025 | | | | | |
| Senior Convertible Notes due 2025 | Senior Convertible Notes due 2025 | — | 33.6 | 105.4 | 56.1 |
| Senior Convertible Notes due 2028 | Senior Convertible Notes due 2028 | — | — | | 56.1 |
| Total by which the notes' if-converted value exceeds their principal amount | Total by which the notes' if-converted value exceeds their principal amount | \$ 158.1 | \$1,395.1 | | |

The following table summarizes the components of interest expense and the effective interest rates for each of our senior convertible notes for the periods shown:

| (In millions) | Three Months Ended | | Nine Months Ended | |
|--|--------------------|--------|-------------------|---------|
| | September 30, | | September 30, | |
| | 2023 | 2022 | 2023 | 2022 |
| Cash interest expense: | | | | |
| Contractual coupon interest ⁽¹⁾ | \$ 1.8 | \$ 2.3 | \$ 7.0 | \$ 6.7 |
| Non-cash interest expense: | | | | |
| Amortization of debt issuance costs | 2.0 | 1.4 | 5.5 | 4.3 |
| Total interest expense recognized on senior notes | \$ 3.8 | \$ 3.7 | \$ 12.5 | \$ 11.0 |
| Effective interest rate: | | | | |
| Senior Convertible Notes due 2023 | 1.1 % | 1.1 % | 1.1 % | 1.1 % |
| Senior Convertible Notes due 2025 | 0.5 % | 0.5 % | 0.5 % | 0.5 % |
| Senior Convertible Notes due 2028 | 0.7 % | * | 0.7 % | * |
| ⁽¹⁾ Interest on the 2023 Notes began accruing upon issuance and is payable semi-annually on June 1 and December 1 of each year. Interest on the 2025 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year. Interest on the 2028 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year. | | | | |
| * Not applicable as no notes were outstanding at this date. | | | | |

0.75% Senior Convertible Notes due 2023

In November 2018, we completed an offering of \$850.0 million aggregate principal amount of unsecured senior convertible notes with a stated interest rate of 0.75% and a maturity date of December 1, 2023 (the "2023 Notes"). The net proceeds from the offering, after deducting initial purchasers' discounts and costs directly related to the offering, were approximately \$836.6 million. The initial conversion rate of the 2023 Notes is 24.3476 shares per \$1,000 principal amount of notes, which is equivalent to a conversion price of approximately \$41.07 per share, subject to adjustments. We entered into transactions for a convertible note hedge (the "2023 Note Hedge") and

| (In millions) | Three Months Ended | |
|---|--------------------|--------|
| | March 31, | |
| | 2024 | 2023 |
| Cash interest expense: | | |
| Contractual coupon interest ⁽¹⁾ | \$ 1.9 | \$ 2.2 |
| Non-cash interest expense: | | |
| Amortization of debt issuance costs | 1.8 | 1.5 |
| Total interest expense recognized on senior notes | \$ 3.7 | \$ 3.7 |

Effective interest rate:

| | | |
|--|-------|-------|
| Senior Convertible Notes due 2023 ⁽²⁾ | * | 1.1 % |
| Senior Convertible Notes due 2025 | 0.5 % | 0.5 % |
| Senior Convertible Notes due 2028 | 0.7 % | * |

⁽¹⁾ Interest on our unsecured senior convertible notes due 2023, or the 2023 Notes, began accruing upon issuance and was payable semi-annually on June 1 and December 1 of each year until the 2023 Notes matured on December 1, 2023. Interest on our unsecured senior convertible notes due 2025, or the 2025 Notes, began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year. Interest on our unsecured senior convertible notes due 2028, or the 2028 Notes, began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year.

⁽²⁾ The effective interest rate presented represents the rate applicable for the period outstanding. The 2023 Notes matured on December 1, 2023 and are no longer outstanding.

* Not applicable as no notes were outstanding at this date.

[Table of Contents](#)

[warrants \(the "2023 Warrants"\) concurrently with Convertible Debt Summary](#)

The following table summarizes the issuance of key details for the 2023 Notes. The 2023 Notes, may be settled in cash, stock, or a combination thereof, solely at our discretion. 2025 Notes, and 2028 Notes:

| Senior Convertible Notes | Offering Completion Date | Maturity Date | Stated Interest Rate | Aggregate Principal Amount Issued | Net Proceeds ⁽¹⁾ | Initial Conversion Rate ⁽²⁾ (per \$1,000 principal amount) | Conversion Price (per share) | Settlement Methods ⁽³⁾ |
|---------------------------|--------------------------|-------------------|----------------------|-----------------------------------|-----------------------------|--|---------------------------------|-----------------------------------|
| 2023 Notes ⁽⁴⁾ | November 2018 | December 1, 2023 | 0.75% | \$850.0 million | \$836.6 million | 24.3476 shares | \$41.07 | Cash and/or shares |
| 2025 Notes | May 2020 | November 15, 2025 | 0.25% | \$1.21 billion | \$1.19 billion | 6.6620 shares | \$150.11 | Cash and/or shares |
| 2028 Notes | May 2023 | May 15, 2028 | 0.375% | \$1.25 billion | \$1.23 billion | 6.1571 shares | \$162.41 | Cash and/or shares |

⁽¹⁾ Net proceeds is calculated by deducting the initial purchasers' discounts and estimated costs directly related to the offering from the aggregate principal amount of the applicable series of notes.

⁽²⁾ Subject to adjustments as defined in the applicable indentures.

⁽³⁾ The 2025 Notes and 2028 Notes may be settled in cash, stock, or a combination thereof, solely at our discretion. The 2023 Notes, while outstanding, could be settled in cash, stock, or a combination thereof, solely at our discretion.

⁽⁴⁾ The 2023 Notes matured on December 1, 2023 and are no longer outstanding.

We use the if-converted method for assumed conversion of the 2023 Notes our senior convertible notes to compute the weighted average shares of common stock outstanding for diluted earnings per share.

No principal payments are due on the 2023 Notes senior convertible notes prior to maturity. Other than restrictions relating to certain fundamental changes and consolidations, mergers or asset sales and customary anti-dilution adjustments, the indenture relating to the 2023 Notes includes our senior convertible notes include customary terms and covenants, including certain events of default after which the 2023 Notes senior convertible notes may be due and payable immediately.

For the twelve months ended December 31, 2022, holders of \$17.5 million in aggregate principal amount of the 2023 Notes elected conversion at their option. We settled these conversions using treasury stock. We issued 425,552 shares to settle the converted 2023 Notes. We received 287,492 shares of common stock from the exercise of a portion of the 2023 Note Hedge that we purchased concurrently with the issuance of the 2023 Notes, as described below.

For the three and nine months ended September 30, 2023, we settled \$650.5 million in aggregate principal amount of the 2023 Notes through a combination of \$650.5 million in cash for the principal amount and 10,599,907 shares of common stock for the amount in excess of the principal amount. We received 10,585,850 shares of common stock from the exercise of a portion of the 2023 Note Hedge that we purchased concurrently with the issuance of the 2023 Notes, as described below.

The remaining outstanding principal of \$124.3 million as of September 30, 2023 and any amount in excess of the principal amount will settle on or before the maturity date of December 1, 2023.

[Conversion Rights at the Option of the Holders](#)

Holders of the 2023 Notes have the right to require us to repurchase for cash all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the notes). We will also be required to increase the conversion rate for holders who convert their 2023 Notes in connection with certain fundamental changes occurring prior to the maturity date or following the delivery by Dexcom of a notice of redemption.

Holders of the 2023 Notes had the ability to convert all or a portion of their notes at their option prior to 5:00 p.m., New York City time, on the business day immediately preceding September 1, 2023, in multiples of \$1,000 principal amount, only under the following circumstances:

- (1) during any calendar quarter commencing after March 31, 2019 (and only during such calendar quarter), if the last reported sale price of Dexcom's common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar

quarter is greater than or equal to 130% of the applicable conversion price of the 2023 Notes on each such trading day;

- (2) during the five business day period after any five consecutive trading day period in which the trading price per \$1,000 principal amount of the 2023 Notes for each day of that five-day consecutive trading day period was less than 98% of the product of the last reported sale price of Dexcom's common stock and the applicable conversion rate of the 2023 Notes on such trading day;
- (3) if we call any or all of the 2023 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or
- (4) upon the occurrence of specified corporate transactions.

Circumstance (1) listed above occurred during the quarters ended December 31, 2022, March 31, 2023, and June 30, 2023. As a result, the 2023 Notes were convertible at the option of the holder from January 1, 2023 through August 31, 2023.

On or after September 1, 2023, until 5:00 p.m., New York City time, on the second scheduled trading day immediately preceding the maturity date, holders of the 2023 Notes may convert all or a portion of their notes regardless of the foregoing circumstances. See above for a description of conversion activity related to the 2023 Notes.

Conversion Rights at Our Option

Dexcom did not have a right to redeem the 2023 Notes prior to December 1, 2021. On or after December 1, 2021 and prior to September 1, 2023, Dexcom was permitted to redeem for cash all or part of the 2023 Notes, at its option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in

Table of Contents

effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Dexcom provides notice of redemption. The redemption price was equal to 100% of the principal amount of the 2023 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date.

2023 Note Hedge

In connection with the offering of the 2023 Notes, in November 2018 we entered into convertible note hedge transactions, or the 2023 Note Hedge, with two of the initial purchasers of the 2023 Notes, (the "2023 Counterparties") which we refer to as the 2023 Counterparties, entitling us to purchase up to 20.7 million shares of our common stock at an initial price of \$41.07 per share, each of which is subject to adjustment. The cost of the 2023 Note Hedge was \$218.9 million and we accounted for it as an equity instrument by recognizing \$218.9 million in additional paid-in capital during 2018, stock. The 2023 Note Hedge will expire expired on December 1, 2023. The 2023 Note Hedge is expected to reduce the potential equity dilution upon any conversion of the 2023 Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted 2023 Notes if the daily volume-weighted average price per share of our common stock exceeds the strike price of the 2023 Note Hedge. The strike price of the 2023 Note Hedge initially corresponds to the conversion price of the 2023 Notes and is subject to certain adjustments under the terms of the 2023 Note Hedge. An assumed exercise of the 2023 Note Hedge by us is considered anti-dilutive since the effect of the inclusion would always be anti-dilutive with respect to the calculation of diluted earnings per share. See above below for a description of conversion activity related to the 2023 Notes and shares received as the result of exercising a the remaining portion of the 2023 Note Hedge. Hedge in 2023.

2023 Warrants

In November 2018, we also sold warrants, or the 2023 Warrants, to the 2023 Counterparties to acquire up to 20.7 million shares of our common stock. The 2023 Warrants require net share settlement and a pro rated pro-rated number of warrants will expire on each of the 60 scheduled trading days starting on March 1, 2024. We received \$183.8 million in cash proceeds from the sale of the 2023 Warrants, which we recorded in additional paid-in capital during 2018. The 2023 Warrants could have a dilutive effect on our earnings per share to the extent that the price of our common stock during a given measurement period exceeds the strike price of the 2023 Warrants. The strike price of the 2023 Warrants is was initially \$49.60 per share, and is subject to certain adjustments under the terms of the warrant agreements. We use the treasury share method for assumed conversion of the 2023 Warrants when computing the weighted average common shares outstanding for diluted earnings per share.

0.25% Senior Convertible Notes due 2025

In May 2020, On February 13, 2024, we completed an offering of \$1.21 billion aggregate principal amount of unsecured senior convertible notes entered into a warrant termination agreement with a stated interest rate of 0.25% and a maturity date of November 15, 2025 (the "2025 Notes"). The net proceeds from the offering, after deducting initial purchasers' discounts and estimated costs directly related to the offering, were approximately \$1.19 billion. The initial conversion rate one of the 2025 Notes is 6.6620 shares per \$1,000 principal amount 2023 Counterparties to terminate outstanding warrants to purchase an aggregate of notes, which is equivalent to a conversion price of approximately \$150.11 per share, subject to adjustments. The 2025 Notes may be settled in cash, stock, or a combination thereof, solely at our discretion. We use the if-converted method for assumed conversion of the 2025 Notes to compute the weighted average 10.3 million shares of common stock outstanding for diluted earnings per share.

No principal payments are due on stock. In consideration of the 2025 Notes prior to maturity. Other than restrictions relating to certain fundamental changes and consolidations, mergers or asset sales and customary anti-dilution adjustments, the indenture relating termination of these warrants, we delivered 6.0 million shares of our common stock to the 2025 Notes includes customary terms and covenants, including certain events holder.

During the first quarter of default after which the 2025 Notes may be due and payable immediately.

Conversion Rights at the Option of the Holders

In the event of a fundamental change (as defined in the indenture related to the 2025 Notes), holders of the 2025 Notes have the right to require us to repurchase for cash all or 2024, a portion of their notes at a price equal the 2023 Warrants was exercised and we issued 1.9 million shares of our common stock in addition to 100% of the principal amount of the 2025 Notes, plus any accrued and unpaid interest. Holders of the 2025 Notes who convert their notes aforementioned 6.0 million shares issued in connection with a make-whole fundamental change (as defined in the indenture) or following the delivery by Dexcom of a notice of redemption are, under certain circumstances, entitled to an increase in the conversion rate.

Prior to 5:00 p.m., New York City time, on the business day immediately preceding August 15, 2025, holders of the 2025 Notes may convert all or a portion of their notes, in multiples of \$1,000 principal amount, only under the following circumstances:

- (1) during any calendar quarter commencing after September 30, 2020 (and only during such calendar quarter), if the last reported sale price of Dexcom's common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the applicable conversion price of the Notes on each such trading day;

[Table of Contents](#)

- (2) during the five business day period after any five consecutive trading day period in which the trading price per \$1,000 principal amount of the Notes for each day of that five day consecutive trading day period was less than 98% of the product of the last reported sale price of Dexcom's common stock and the applicable conversion rate of the Notes on such trading day;
- (3) if we call any or all of the Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or
- (4) upon the occurrence of specified corporate transactions.

On or after August 15, 2025, until 5:00 p.m., New York City time, on the business day immediately preceding the maturity date, holders of the 2025 Notes may convert all or a portion of their notes regardless of the foregoing circumstances.

[Conversion Rights at Our Option](#)

Dexcom was not permitted to redeem the 2025 Notes prior to May 20, 2023. On or after May 20, 2023 and prior to August 15, 2025, Dexcom may redeem for cash all or part of the 2025 Notes, at its option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Dexcom provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the 2025 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date.

[0.375% Senior Convertible Notes due 2028](#)

In May 2023, we completed an offering of \$1.25 billion aggregate principal amount of unsecured senior convertible notes with a stated interest rate of 0.375% and a maturity date of May 15, 2028 (the "2028 Notes"). The net proceeds from the offering, after deducting initial purchasers' discounts and estimated costs directly related to the offering, were approximately \$1.23 billion. The initial conversion rate of the 2028 Notes is 6.1571 shares per \$1,000 principal amount of notes, which is equivalent to a conversion price of approximately \$162.41 per share, subject to adjustments. The 2028 Notes may be settled in cash, stock, or a combination thereof, solely at our discretion. We use the if-converted method for assumed conversion of the 2028 Notes to compute the weighted average shares of common stock outstanding for diluted earnings per share.

No principal payments are due on the 2028 Notes prior to maturity. Other than restrictions relating to certain fundamental changes and consolidations, mergers or asset sales and customary anti-dilution adjustments, the indenture relating to the 2028 Notes includes customary terms and covenants, including certain events of default after which the 2028 Notes may be due and payable immediately.

[Conversion Rights at the Option of the Holders](#)

In the event of a fundamental change (as defined in the indenture related to the 2028 Notes), holders of the 2028 Notes have the right to require us to repurchase for cash all or a portion of their notes at a price equal to 100% of the principal amount of the 2028 Notes, plus any accrued and unpaid interest. Holders of the 2028 Notes who convert their notes in connection with a make-whole fundamental change (as defined in the indenture) or following the delivery by Dexcom of a notice of redemption are, under certain circumstances, entitled to an increase in the conversion rate.

Prior to 5:00 p.m., New York City time, on the business day immediately preceding February 15, 2028, holders of the 2028 Notes may convert all or a portion of their notes, in multiples of \$1,000 principal amount, only under the following circumstances:

- (1) during any calendar quarter commencing after September 30, 2023 (and only during such calendar quarter), if the last reported sale price of Dexcom's common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the applicable conversion price of the Notes on each such trading day;
- (2) during the five business day period after any five consecutive trading day period in which the trading price per \$1,000 principal amount of the Notes for each day of that five day consecutive trading day period was less than 98% of the product of the last reported sale price of Dexcom's common stock and the applicable conversion rate of the Notes on such trading day;

[Table of Contents](#)

- (3) if we call any or all of the Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or
- (4) upon the occurrence of specified corporate transactions.

On or after February 15, 2028, until 5:00 p.m., New York City time, on the second scheduled trading day immediately preceding the maturity date, holders of the 2028 Notes may convert all or a portion of their notes regardless of the foregoing circumstances.

[Conversion Rights at Our Option](#)

Dexcom may not redeem the 2028 Notes prior to May 20, 2026. On or after May 20, 2026 and prior to February 15, 2028, Dexcom may redeem for cash all or part of the 2028 Notes, at its option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Dexcom provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the 2028 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date.

2028 Capped Call Transactions

In May 2023, in connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions, (the "2028 or the 2028 Capped Calls") Calls, with certain financial institutions. The 2028 Capped Calls will cover, subject to anti-dilution adjustments substantially similar to those applicable to the 2028 Notes, the number of shares of our common stock that will initially underlie underlying the 2028 Notes. The 2028 Capped Calls are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes and/or offset any cash payments that we are required to make in excess of the principal amount of converted 2028 Notes, as the case may be, with such reduction and/or offset subject to a cap. The 2028 Capped Calls have an initial cap price of \$212.62 per share, subject to adjustments, which represents a premium of 80% over the closing price of our common stock of \$118.12 per share on the Nasdaq Global Select Market on May 2, 2023. The cost to purchase the 2028 Capped Calls of \$101.3 million was recorded as a reduction to additional paid-in capital in our consolidated balance sheets as the 2028 Capped Calls met the criteria for classification in stockholders' equity.

Conversion Activity for Senior Convertible Notes

The 2023 Notes matured on December 1, 2023 and all outstanding principal was settled. There was no conversion activity for the 2025 Notes or 2028 Notes for the three months ended March 31, 2024. See the following table for the details of conversion activity for the 2023 Notes for the fiscal year ended December 31, 2023:

| Fiscal Period | Converted Notes | Aggregate Principal Amount | Shares Issued for Settlement | Shares Received from Exercise of 2023 Note |
|-----------------------|-----------------|----------------------------|------------------------------|--|
| | | Converted | | Hedge |
| 1/1/2023 - 12/31/2023 | 2023 Notes | \$774.8 million | 12.2 million | 12.2 million |

Table of Contents

Conversion Rights for Senior Convertible Notes

Holders of our outstanding senior convertible notes have the right to require us to repurchase for cash all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the applicable indenture relating to the notes). We are also required to increase the conversion rate for holders who convert their notes in connection with certain fundamental changes occurring prior to the maturity date or following the delivery by Dexcom of a notice of redemption.

The following table outlines the conversion options related for each of our senior convertible notes:

Summary of Conversions Rights at the Option of the Holders for the 2025 Notes and 2028 Notes, which we refer to collectively as the Notes

| | |
|---|---|
| Conversion Rights at the Option of the Holders | Holders of the Notes have the ability to convert all or a portion of their notes in multiples of \$1,000 principal amount, at their option prior to 5:00 p.m., New York City time, on the business day immediately preceding August 15, 2025 and February 15, 2028 for the 2025 Notes and 2028 Notes, respectively, only under the following circumstances: |
| Circumstance 1⁽¹⁾ | During any calendar quarter commencing after the applicable period (and only during such calendar quarter), if the last reported sale price of Dexcom's common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the applicable conversion price for the Notes on each applicable trading day |
| Circumstance 2 | During the five business day period after any five consecutive trading day period in which the trading price per \$1,000 principal amount of the Notes for each trading day of that five consecutive trading day period was less than 98% of the product of the last reported sale price of Dexcom's common stock and the applicable conversion rate of the Notes on each such trading day |
| Circumstance 3 | If we call any or all of the Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date (only with respect to the notes called or deemed called for redemption) |
| Circumstance 4 | Upon the occurrence of specified corporate events |
| Circumstance 5⁽²⁾ | Holders of the Notes may convert all or a portion of their Notes regardless of the foregoing circumstances prior to the close of business on the business day immediately preceding the maturity date for the 2025 Notes and prior to the close of business on the second scheduled trading day immediately preceding the maturity date for the 2028 Notes |

⁽¹⁾ Circumstance 1 is available after the calendar quarter ended September 30, 2020 and September 30, 2023 for the 2025 Notes and 2028 Notes, respectively.

⁽²⁾ Circumstance 5 is available on or after August 15, 2025 and February 15, 2028 for the 2025 Notes and 2028 Notes, respectively.

Summary of Conversion Right at the Option of the Company for the 2025 Notes and 2028 Notes

| | |
|---|---|
| Conversion Right at Our Option⁽¹⁾ | Dexcom may redeem for cash all or part of the Notes, at its option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Dexcom provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date |
|---|---|

⁽¹⁾ Dexcom does not have the right to redeem the Notes prior to May 20, 2023 and May 20, 2026 for the 2025 Notes and 2028 Notes, respectively. Dexcom has the right to redeem the notes on or after May 20, 2023 and prior to August 15, 2025 for the 2025 Notes, and on or after May 20, 2026 and prior to February 15, 2028 for the 2028 Notes.

Table of Contents

Revolving Credit Agreement

Terms of the Revolving Credit Agreement

In June 2023, we entered into the First Amendment to the Second Amended and Restated Credit Agreement, (the "Amended as amended, or the Amended Credit Agreement"), Agreement, which we had previously entered into in October 2021. The Amended Credit Agreement is a five-year revolving credit facility, or the Credit Facility, that provides for an available principal amount of \$200.0 million which can be increased up to \$500.0 million at our option subject to customary conditions and approval of our lenders (the "Credit Facility"). lenders. The Amended Credit Agreement will mature on October 13, 2026. Borrowings under the Amended Credit Agreement are available for general corporate purposes, including working capital and capital expenditures.

Information related to availability and outstanding borrowings on our Amended Credit Agreement is as follows as of the date indicated:

| | September 30, 2023 | March 31, 2024 |
|--------------------------------|--------------------|----------------|
| (In millions) | | |
| Available principal amount | | 200.0 |
| Letters of credit sub-facility | | 25.0 |
| Outstanding borrowings | | — |
| Outstanding letters of credit | | 7.3 |
| Total available balance | \$ | 192.7 |

Revolving loans under the Amended Credit Agreement bear interest at our choice of one of three base rates plus a range of applicable rates that are based on our leverage ratio. The first base rate is minimum and maximum range of applicable rates per annum with respect to any ABR Loan, Term Benchmark Revolving Loan, or RFR Revolving Loan, each as defined in the Alternate Base Rate ("ABR") and loans comprising each ABR borrowing shall bear interest at Amended Credit Agreement under the ABR plus the applicable rate between 0.375% to 1.000%. The ABR is the highest of (a) the prime rate last quoted by The Wall Street Journal, (b) the Federal Reserve Bank of New York rate plus one half of 1% captions "ABR Spread", "Term Benchmark/CDOR Spread", and (c) "RFR Spread", or "Unused Commitment Fee Rate", respectively, are outlined in the Adjusted Term Secured Overnight Financing Rate ("Term SOFR") for a one month interest period plus 1%. The second base rate is the Term Benchmark rate and loans comprising each Term Benchmark borrowing shall bear interest at the Adjusted Term following table:

Table of Contents

SOFR, the Adjusted Euro Interbank Offered Rate, the Adjusted Stockholm Interbank Offered Rate, the Adjusted Canadian Dollar Offered Rate, Adjusted Australian Dollar Rate, the Adjusted Bank Bill Benchmark Rate or the Adjusted Tokyo Interbank Offered Rate, as applicable based on the currency denomination borrowed, plus the applicable rate between 1.375% to 2.000%. The third base rate is the Adjusted Daily Simple Repo Funds Rate ("RFR") and loans comprising each Daily Simple RFR Loan shall bear interest at a rate per annum equal to the applicable Daily Simple RFR for Sterling or Dollars (as applicable) plus the applicable rate between 0.0326% to 0.100% depending on the loan denomination. We will also pay a commitment fee of between 0.175% and 0.250%, payable quarterly in arrears, on the average daily unused amount of the revolving facility based on our leverage ratio.

| Range | ABR Spread | Term Benchmark/CDOR Spread and RFR Spread | Unused Commitment Fee Rate |
|---------|------------|---|----------------------------|
| Minimum | 0.375% | 1.375% | 0.175% |
| Maximum | 1.000% | 2.000% | 0.250% |

Our obligations under the Amended Credit Agreement are guaranteed by our existing and future wholly-owned domestic subsidiaries, and are secured by a first-priority security interest in substantially all of the assets of Dexcom and the guarantors, including all or a portion of the equity interests of our domestic subsidiaries and first-tier foreign subsidiaries but excluding real property and intellectual property (which is subject to a negative pledge). The Amended Credit Agreement contains covenants that limit certain indebtedness, liens, investments, transactions with affiliates, dividends and other restricted payments, subordinated indebtedness and amendments to subordinated indebtedness documents, and sale and leaseback transactions of Dexcom or any of its domestic subsidiaries. The Amended Credit Agreement also requires us to maintain a maximum leverage ratio and a minimum fixed charge coverage ratio. We were in compliance with these covenants as of September 30, 2023 March 31, 2024.

As of September 30, 2023 March 31, 2024, we also have a no other material guarantee facility related to our international operations which is collateralized by a \$5.3 million term deposit that is included in non-current "Other assets" on our consolidated balance sheets. facilities or lines of credit.

[Table of Contents](#)

6. Contingencies

Litigation

We are subject to various claims, complaints and legal actions that arise from time to time in the normal course of business, including commercial insurance, product liability, intellectual property and employment related matters. In addition, from time to time we may bring claims or initiate lawsuits against various third parties with respect to matters arising out of the ordinary course of our business, including commercial and employment related matters.

Between June 2021 through the nine three months ended September 30, 2023 March 31, 2024, we and certain Abbott Diabetes Care, Inc. ("Abbott") entities have served patent infringement complaints against each other in multiple jurisdictions including in the United States (United States District Court ("U.S.D.C."), District of Delaware), the United Kingdom (Business and Property Courts of England and Wales), France (United Patent Court ("UPC") in Paris), Spain (Commercial Courts of Barcelona) and Germany (National Courts ("N.C.") of Munich, Mannheim, Dusseldorf and Hamburg and the UPC in Munich), primarily involving claims of patent infringement, invalidity and other patent related actions. In June and July of 2021, we initiated patent infringement litigation against Abbott in the United States (U.S.D.C., Western District of Texas) and Germany (N.C. in Mannheim) and filed additional patent infringement actions in May 2023 in Germany (N.C. in Munich) over certain of Abbott's continuous glucose monitoring products. In July and August 2023, we initiated products of each company.

Abbott's patent infringement litigation in France and Germany in the UPC and in Spain (Commercial Courts of Barcelona).

Between July 2021 through the nine months ended September 30, 2023 trial, "D1", Abbott initiated patent infringement litigation against Dexcom in multiple jurisdictions, including the United States (U.S.D.C., Delaware), the United Kingdom (Business and Property Courts of England and Wales), and in Germany (N.C. in Mannheim, Dusseldorf and Hamburg) over certain of Dexcom's continuous glucose monitoring products. In response to the lawsuits initiated by Abbott in the United Kingdom, Dexcom also filed patent infringement counterclaims in that jurisdiction. Three trials on liability have already been conducted in the United Kingdom. On October 18, judgment was handed down in favor of Dexcom in one of these trials. The parties are awaiting rulings on the remaining two. Dexcom and Abbott seek injunctive relief and monetary damages as a result of their respective claims.

In December 2021, Abbott filed a breach of contract lawsuit against Dexcom commenced in the U.S.D.C., District of Delaware alleging that Dexcom breached the parties' Settlement and License Agreement dated July 2, 2014 ("SLA"). The U.S.D.C., District of Delaware consolidated Abbott's breach of contract lawsuit with Dexcom's patent infringement lawsuit which had been transferred from the U.S.D.C., Western District of Texas. Dexcom asserted counterclaims that Abbott also breached the SLA. A jury trial on Abbott's breach of contract claims commenced on July 10, 2023. On July 14, 2023, the jury verdict determined that Abbott was not licensed to thirteen claims of certain Dexcom patents and that Abbott was licensed to five claims. Dexcom's patent infringement claims in Delaware are stayed until November 10, 2023, at which point the U.S. Patent and Trademark Office will have issued

[Table of Contents](#)

its final written decisions on certain patents involved in the lawsuit. We will continue to enforce the remaining claims of the patents asserted in Delaware.

Abbott's patent infringement action against Dexcom is currently scheduled for trial in the U.S.D.C., District of Delaware on March 11, 2024. March 2024. In the lead up to trial, the U.S.D.C., District of Delaware invalidated one of Abbott's patents on factory calibration and Abbott dropped four other patents from the litigation.

The claims litigated were isolated to the inserter mechanism and the wearable seal and mount of Dexcom's G6. On March 22, 2024, a jury returned a mixed verdict. The jury found that Dexcom infringes one patent, that Dexcom did not infringe a second patent, and that Dexcom also did not infringe a third patent, which the jury also found invalid. The jury found that any infringement was not willful. It could not reach unanimity as to a fourth patent. No determination of damages was made or awarded by the jury. Dexcom will challenge the sole finding of infringement and continue to defend itself vigorously. Commencing We analyzed the potential for a loss from this litigation in December 2023, Abbott has several patent infringement hearings against Dexcom accordance with ASC 450, Contingencies. We believe it is not probable that we will have an unfavorable outcome and incur a material loss contingency due to our beliefs about our position in the National Court in Hamburg and Munich wherein Abbott is seeking case. In addition, the jury did not award damages and injunctive relief. In March and April for the one patent they believe we infringed nor can we reasonably estimate the amount of 2024, Dexcom has several patent infringement hearings in Munich against Abbott, wherein Dexcom is seeking damages and injunctive relief. loss we would incur if we do not prevail. As a result, we have not recorded an accrual for a contingent liability.

Due to uncertainty surrounding the other patent litigation procedures initiated by Dexcom and Abbott throughout multiple jurisdictions, we are unable to reasonably estimate the ultimate outcome of any of the litigation matters at this time. We intend to protect our intellectual property and defend against Abbott's claims vigorously in all of these actions.

We do not believe we are party to any other currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial condition, or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial condition, or results of operations.

7. Income Taxes

We estimate our annual effective tax rate to be 24.7% 23.8% for the full year 2023, 2024, which differs from the U.S. federal statutory rate due to state and foreign income taxes and nondeductible executive compensation, increases to unrecognized tax benefits, and impact of foreign operations, partially offset by federal tax credits generated. Our actual negative effective tax rate of 38.6% 10.5% for the nine three months ended September 30, 2023 March 31, 2024 was primarily due to income tax expense from normal, recurring operations, increased by discrete foreign taxes related to an intra-entity transfer of certain intellectual property, and decrease in the state tax rate applied to beginning of year deferred tax assets, partially offset by tax benefits recognized for share-based compensation for employees, net of disallowed executive compensation, compensation, and the Verily milestone payment.

The Organization for Economic Co-operation and Development has a framework to implement a global minimum corporate tax of 15% for companies with global revenues and profits above certain thresholds (referred to as Pillar 2), with certain aspects of Pillar 2 effective January 1, 2024 and other aspects effective January 1, 2025. While it is uncertain whether the United States will enact legislation to adopt Pillar 2, certain countries in which we operate have adopted legislation, and other countries in which we operate are in the process of introducing legislation to implement Pillar 2. We have assessed the impact of Pillar 2 and the impact is immaterial.

In August 2023, we completed January 2024, the California Franchise Tax Board commenced an intra-entity asset transfer of certain intellectual property between two audit of our wholly owned foreign subsidiaries California income tax returns for the 2020 and 2021 years primarily related to align our structure with the expansion of international business operations, research and development tax credit carryforwards. We recorded do not expect any significant adjustments as a \$186.6 million deferred tax asset, which represents the difference between the basis result of the intellectual property for financial statement and tax purposes, applying the appropriate enacted statutory tax rate. Based on available evidence, management believes it is not more-likely-than-not that the additional foreign deferred tax asset will be realizable, and is therefore, fully offset by a valuation allowance, audit.

The transfer resulted in \$65.2 million of net tax expense, which increased our actual effective tax rate for the nine months ended September 30, 2023.

[Table of Contents](#)

8. Stockholders' Equity

Share-Based Compensation

Our share-based compensation expense is associated with RSUs, PSUs, and our Employee Stock Purchase Plan, or ESPP. The following table summarizes our share-based compensation expense included in our consolidated statements of operations for the periods shown:

| | | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|--|-------------------------------------|---------|------------------------------------|---------|
| | | Three Months Ended March 31, | | Three Months Ended March 31, | |
| | | Three Months Ended March 31, | | Three Months Ended March 31, | |
| (In millions) | | | | | |
| (In millions) | | | | | |
| (In millions) | (In millions) | 2023 | 2022 | 2023 | 2022 |
| Cost of sales | Cost of sales | \$ 3.9 | \$ 3.0 | \$ 11.1 | \$ 8.1 |
| Cost of sales | | | | | |
| Cost of sales | | | | | |
| Research and development | | | | | |
| Research and development | | | | | |
| Research and development | Research and development | 11.4 | 10.8 | 34.3 | 32.0 |
| Selling, general and administrative | Selling, general and administrative | 23.7 | 17.0 | 68.5 | 52.4 |
| Selling, general and administrative | | | | | |
| Selling, general and administrative | | | | | |
| Total share-based compensation expense | Total share-based compensation expense | \$ 39.0 | \$ 30.8 | \$ 113.9 | \$ 92.5 |
| Total share-based compensation expense | | | | | |
| Total share-based compensation expense | | | | | |

At September 30, 2023 As of March 31, 2024, unrecognized estimated compensation costs related to RSUs and PSUs and ESPP totaled \$238.4 million \$362.5 million and are expected to be recognized through 2027.

Equity Award Activity

The total vest date fair value over a weighted-average period of RSUs and PSUs that vested during the nine months ended September 30, 2023 was \$138.5 million and \$9.9 million, respectively, approximately 2.2 years.

Share Repurchase Program and Treasury Shares

On July 26, 2022, a duly authorized committeeIn the first quarter of our Board of Directors authorized and approved a share repurchase program of up to 2024, we issued 7.9 million treasury shares to \$700.0 million of our outstanding common stock, with a repurchase period that ended on June 30, 2023 (the “2022 Share Repurchase Program”). Shares of common stock repurchased under the 2022 Share Repurchase Program became treasury shares.

We repurchased approximately \$557.7 million of our outstanding common stock throughout the duration of the 2022 Share Repurchase Program. The 2022 Share Repurchase Program and the remaining authorization of approximately \$142.3 million expired on June 30, 2023. There were no share repurchases under the 2022 Share Repurchase Program in 2023.

In May 2023, we used settle a portion of the proceeds 2023 Warrants. See Note 5 “Debt—Senior Convertible Notes” to the consolidated financial statements for more information.

In the first quarter of 2024, we issued 1.5 million treasury shares in connection with our achievement of the 2028 Notes to repurchase 1.6 million shares of our common stock for \$188.7 million, excluding excise tax due second sales-based milestone under the Inflation Reduction Act of 2022, Restated Collaboration Agreement. See Note 2 “Development and Other Agreements—Collaboration with Verily Life Sciences” to the consolidated financial statements for an average per share price of \$118.12, via privately negotiated transactions, independent of the 2022 Share Repurchase Program.

more information.

Repurchased shares of our common stock are held as treasury shares until they are reissued or retired. We have not yet determined the ultimate disposition of repurchased shares and consequently we continue to hold them as treasury shares rather than retiring them. Authorization of future stock repurchase programs is subject to the final determination of our Board of Directors.

9. Business Segment and Geographic Information

Reportable Segments

An operating segment is identified as a component of a business that has discrete financial information available and for which the chief operating decision maker CODM must decide the level of resource allocation. In addition, the guidance for segment reporting indicates certain quantitative materiality thresholds. None of the components of our business meet the definition of an operating segment.

We currently consider our operations to be, and manage our business globally within, one reportable segment, which is consistent with how our President and Chief Executive Officer, who is our chief operating decision maker, CODM, reviews our business, makes investment and resource allocation decisions, and assesses operating performance.

Disaggregation of Revenue

We disaggregate revenue by geographic region and by major sales channel. We have determined that disaggregating revenue into these categories achieves the ASC Topic 606 disclosure objectives of depicting how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

Revenue by geographic region

During the three and nine months ended September 30, 2023 March 31, 2024 and September 30, 2022 March 31, 2023, no individual country outside the United States generated revenue that represented more than 10% of our total revenue. The following table sets forth revenue by our two primary geographical markets, the United States and International, based on the geographic location to which we deliver the components, for the periods shown:

| Three Months Ended September 30, 2023 | | Three Months Ended September 30, 2022 | |
|--|--|--|--|
| Three Months Ended March 31, 2024 | | Three Months Ended March 31, 2024 | |
| | | Three Months Ended March 31, 2023 | |

| (In millions) | (In millions) | Amount | % of Total | Amount | % of Total | (In millions) | Amount | % of Total | Amount | % of Total |
|---------------|---------------|--------------------------------------|------------|--------------------------------------|------------|---------------|----------|------------|----------|------------|
| United States | United States | \$ 713.6 | 73 % | \$ 573.4 | 75 % | United States | \$ 653.2 | 71 % | \$ 526.0 | 71 % |
| International | International | 261.4 | 27 % | 196.2 | 25 % | International | 267.8 | 29 % | 215.5 | 29 % |
| Total revenue | Total revenue | \$ 975.0 | 100 % | \$ 769.6 | 100 % | Total revenue | \$ 921.0 | 100 % | \$ 741.5 | 100 % |
| | | Nine Months Ended September 30, 2023 | | Nine Months Ended September 30, 2022 | | | | | | |
| (In millions) | | Amount | % of Total | Amount | % of Total | | | | | |
| United States | | \$1,856.2 | 72 % | \$1,535.6 | 73 % | | | | | |
| International | | 731.6 | 28 % | 559.0 | 27 % | | | | | |
| Total revenue | | \$2,587.8 | 100 % | \$2,094.6 | 100 % | | | | | |

Revenue by customer sales channel

We sell our CGM systems through a direct sales organization and through distribution arrangements that allow distributors to sell our products. The following table sets forth revenue by major sales channel for the periods shown:

| (In millions) | Three Months Ended September 30, 2023 | | Three Months Ended September 30, 2022 | |
|---------------|---------------------------------------|------------|---------------------------------------|------------|
| | Amount | % of Total | Amount | % of Total |
| Distributor | \$ 839.7 | 86 % | \$ 656.2 | 85 % |
| Direct | 135.3 | 14 % | 113.4 | 15 % |
| Total revenue | \$ 975.0 | 100 % | \$ 769.6 | 100 % |
| | Nine Months Ended September 30, 2023 | | Nine Months Ended September 30, 2022 | |
| (In millions) | Amount | % of Total | Amount | % of Total |
| Distributor | \$ 2,197.4 | 85 % | \$ 1,768.4 | 84 % |
| Direct | 390.4 | 15 % | 326.2 | 16 % |
| Total revenue | \$ 2,587.8 | 100 % | \$ 2,094.6 | 100 % |

10. Subsequent Events

On October 24, 2023, our Board of Directors authorized and approved a share repurchase program of up to \$500.0 million of our outstanding common stock, with a repurchase period ending no later than October 31, 2024 (the "2023 Share Repurchase Program").

Repurchases of our common stock under the 2023 Share Repurchase Program may be made from time to time, on the open market, in privately negotiated transactions or by other methods, at our discretion, and in accordance with the limitations set forth in Rule 10b-18 promulgated under the Securities Exchange Act of 1934, as amended, and other applicable federal and state laws and regulations. The timing of any repurchases will depend on market conditions and will be made at our discretion.

The 2023 Share Repurchase Program does not obligate us to repurchase any dollar amount or number of shares, and the program may be extended, modified, suspended, or discontinued at any time.

| (In millions) | Three Months Ended March 31, 2024 | | Three Months Ended March 31, 2023 | |
|---------------|-----------------------------------|------------|-----------------------------------|------------|
| | Amount | % of Total | Amount | % of Total |
| Distributor | \$ 778.8 | 85 % | \$ 618.9 | 83 % |
| Direct | 142.2 | 15 % | 122.6 | 17 % |
| Total revenue | \$ 921.0 | 100 % | \$ 741.5 | 100 % |

Table of Contents

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q, including the following Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements that are not purely historical regarding Dexcom's or its management's intentions, beliefs, expectations and strategies for the future. These forward-looking statements fall within the meaning of the federal securities laws that relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "expect," "plan," "anticipate," "believe," "estimate," "intend," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements are made as of the date of this Quarterly Report on Form 10-Q, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward looking statements. The risks and uncertainties that could cause actual results to differ materially are more fully described under "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on February 8, 2024, together with any updates identified under "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on February 8, 2024, together with any updates identified under "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q, elsewhere in this Quarterly Report on Form 10-Q, and in our other reports filed with the SEC. We assume no obligation to update any of the forward-looking statements after the date of this report or to conform these forward-looking statements to actual results. You should read the following discussion and analysis together with our consolidated financial statements and related notes in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Overview

Who We Are

We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world.

We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation **systems, system,** the Dexcom G6® integrated Continuous Glucose Monitoring System, or G6, in 2018, and **more recently received marketing clearance from the FDA on** we launched the Dexcom G7®, or G7, in **December 2022, 2023.** In March 2024, we received marketing clearance from the FDA on Stelo, our new 15-day sensor designed for people with **Type 2 diabetes who do not use insulin, as the first glucose biosensor that does not require a prescription.**

Unless the context requires otherwise, the terms "we," "us," "our," the "company," or "Dexcom" refer to DexCom, Inc. and its subsidiaries.

Global Presence

We have built a direct sales organization in North America and certain international markets to call on health care professionals, such as endocrinologists, physicians and diabetes educators, who can educate and influence patient adoption of continuous glucose monitoring. To complement our direct sales efforts, we have entered into distribution arrangements in North America and several international markets that allow distributors to sell our products.

Future Developments

Product Development: We plan to develop future generations of technologies that are focused on improved performance and convenience and that will enable intelligent insulin administration. Over the longer term, we plan to continue to develop and improve networked platforms with open architecture, connectivity and transmitters capable of communicating with other devices. We also intend to expand our efforts to accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights that can inform patient behavior.

Partnerships: We also continue to pursue and support development partnerships with insulin pump companies and companies or institutions developing insulin delivery systems, including automated insulin delivery systems.

New Opportunities: We are also exploring how to extend our offerings to other opportunities, including for people with Type 2 diabetes that are non-insulin using, people with pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting. Eventually, we may apply our technological expertise to products beyond glucose monitoring.

Table of Contents

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with **U.S.** GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as the reported revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that the estimates, assumptions and judgments involved in the accounting policies described in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended **December 31, 2022 December 31, 2023,** have the greatest potential impact

on our financial statements, so we consider them to be our critical accounting policies and estimates. There were no material changes to our critical accounting estimates during the **nine** **three** months ended **September 30, 2023** **March 31, 2024**.

[Table of Contents](#)

Overview of Financial Results

The most important financial indicators that we use to assess our business are revenue, gross profit, operating income, net income, and operating cash flow.

Key Highlights for the Three Months Ended **September 30, 2023** **March 31, 2024** include the following:

| Revenue | Gross Profit | Operating Income | Net Income | Operating Cash Flow |
|---|---|--|--|---|
| \$975.0 921.0 million | \$623.3 561.9 million | \$205.5 101.1 million | \$120.7 146.4 million | \$269.2 209.2 million |
| up 27% 24% from the same period 2022 2023 | up 26% 21% from the same period 2022 2023 | up 39% 114% from the same period 2022 2023 | up 19% 201% from the same period 2022 2023 | down 8% up 35% from the same period 2022 2023 |

We ended the **third** **first** quarter of **2023** **2024** with cash, cash equivalents and short-term marketable securities totaling **\$3.24 billion** **\$2.90 billion**.

Business Trends

Looking ahead we expect our business could be affected by the following:

- Increase in the worldwide incidence of people diagnosed with diabetes and costs related to the management and treatment of diabetes.
- Changes in medical reimbursement policies and programs.
- Growing demand for digital health technologies by both healthcare providers and consumers to reduce costs.
- An expected interest in empowering consumers to make better-informed decisions about their own health and new potential options for facilitating prevention, early diagnosis of life-threatening diseases, and management of chronic conditions outside of traditional health care settings.
- Growing research and interest in the use of CGM technology outside of the ambulatory care setting, including use by hospital systems.
- Continued product innovation and competition from other CGM device makers.
- Our ability to scale efficiently with our Malaysia manufacturing facility.

[Table of Contents](#)

Results of Operations



Financial Overview

| Three Months Ended September 30, 2023 Compared to Three Months Ended September 30, 2022 | | | | | | |
|---|----------------------------------|------------------|----------|------------------|-------------|----------|
| (In millions, except per share amounts) | Three Months Ended September 30, | | | | 2023 - 2022 | |
| | 2023 | % of Revenue (1) | 2022 | % of Revenue (1) | \$ Change | % Change |
| Revenue | \$ 975.0 | 100 % | \$ 769.6 | 100 % | \$ 205.4 | 27 % |
| Cost of sales | 351.7 | 36 % | 275.4 | 36 % | 76.3 | 28 % |
| Gross profit | 623.3 | 63.9 % | 494.2 | 64.2 % | 129.1 | 26 % |
| Operating expenses: | | | | | | |
| Research and development | 131.4 | 13 % | 110.3 | 14 % | 21.1 | 19 % |
| Amortization of intangible assets | 1.7 | — % | 1.8 | — % | (0.1) | (6)% |
| Selling, general and administrative | 284.7 | 29 % | 234.6 | 30 % | 50.1 | 21 % |
| Total operating expenses | 417.8 | 43 % | 346.7 | 45 % | 71.1 | 21 % |
| Operating income | 205.5 | 21 % | 147.5 | 19 % | 58.0 | 39 % |
| Income from equity investments | 1.0 | — % | — | — % | 1.0 | ** |
| Other income (expense), net | 33.9 | 3 % | (1.3) | — % | 35.2 | ** |

| | | | | | | |
|------------------------------|----------|------|----------|------|---------|------|
| Income before income taxes | 240.4 | 25 % | 146.2 | 19 % | 94.2 | 64 % |
| Income tax expense | 119.7 | 12 % | 45.0 | 6 % | 74.7 | ** |
| Net income | \$ 120.7 | 12 % | \$ 101.2 | 13 % | \$ 19.5 | 19 % |
| Basic net income per share | \$ 0.31 | ** | \$ 0.26 | ** | \$ 0.05 | 19 % |
| Diluted net income per share | \$ 0.29 | ** | \$ 0.24 | ** | \$ 0.05 | 21 % |

(1) The sum of the individual percentages may not equal the total due to rounding.

** Not meaningful

Table of Contents

Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023

| (In millions, except per share amounts) | Three Months Ended March 31, | | | | 2024 - 2023 | |
|---|------------------------------|------------------|----------|------------------|-------------|----------|
| | 2024 | % of Revenue (1) | 2023 | % of Revenue (1) | \$ Change | % Change |
| Revenue | \$ 921.0 | 100 % | \$ 741.5 | 100 % | \$ 179.5 | 24 % |
| Cost of sales | 359.1 | 39 % | 278.9 | 38 % | 80.2 | 29 % |
| Gross profit | 561.9 | 61.0 % | 462.6 | 62.4 % | 99.3 | 21 % |
| Operating expenses: | | | | | | |
| Research and development | 141.5 | 15 % | 119.0 | 16 % | 22.5 | 19 % |
| Selling, general and administrative | 319.3 | 35 % | 296.4 | 40 % | 22.9 | 8 % |
| Total operating expenses | 460.8 | 50 % | 415.4 | 56 % | 45.4 | 11 % |
| Operating income | 101.1 | 11 % | 47.2 | 6 % | 53.9 | 114 % |
| Other income (expense), net | 31.4 | 3 % | 17.3 | 2 % | 14.1 | 82 % |
| Income before income taxes | 132.5 | 14 % | 64.5 | 9 % | 68.0 | ** |
| Income tax expense (benefit) | (13.9) | (2)% | 15.9 | 2 % | (29.8) | ** |
| Net income | \$ 146.4 | 16 % | \$ 48.6 | 7 % | \$ 97.8 | 201 % |
| Basic net income per share | \$ 0.38 | ** | \$ 0.13 | ** | \$ 0.25 | ** |
| Diluted net income per share | \$ 0.36 | ** | \$ 0.12 | ** | \$ 0.24 | ** |

(1) The sum of the individual percentages may not equal the total due to rounding.

** Not meaningful

Revenue

We generate our revenue from the sale of disposable sensors and our reusable transmitter and receiver, collectively referred to as Reusable Hardware. We expect that the revenue we generate from the sales of our products will fluctuate from quarter to quarter. We typically experience seasonality, with lower sales in the first quarter of each year compared to the immediately preceding fourth quarter. This seasonal sales pattern relates to U.S. annual insurance deductible resets and unfunded flexible spending accounts.

Cost of sales

Cost of sales includes direct labor and materials costs related to each product sold or produced, including assembly, test labor and scrap, as well as factory overhead supporting our manufacturing operations. Factory overhead includes facilities, material procurement and control, manufacturing engineering, quality assurance, supervision and management. These costs are primarily salary, fringe benefits, share-based compensation, facility expense, supplies and purchased services. All of our manufacturing costs are included in cost of sales. In addition, amortization of certain licensing related intangibles are also included in cost of sales.

Research and development

Our research and development expenses primarily consist of engineering and research expenses related to our continuous glucose monitoring sensing technology, clinical trials, regulatory expenses, quality assurance programs, materials and products for clinical trials. Research and development expenses are primarily related to employee compensation, including salary, fringe benefits, share-based compensation, and temporary employee expenses. We also incur significant expenses to operate our clinical trials including budgeted clinical site compensation and reimbursement, study monitoring and oversight expenses, clinical trial product and associated travel expenses. Our research and development expenses also include fees for design services, contractors and development materials, business process outsourcers.

Amortization of intangible assets

Our amortization expense primarily relates to acquired technology and intellectual property and other acquired intangible assets.

Table of Contents

Selling, general and administrative

Our selling, general and administrative expenses primarily consist of salary, fringe benefits and share-based employee compensation for our executive, financial, sales, marketing, information technology and administrative functions. Other significant expenses include commissions, marketing and advertising, IT software license costs, insurance, professional fees for our outside legal counsel and independent auditors, litigation expenses, patent application expenses and consulting expenses.

Income from equity investments

Income from equity investments is comprised of realized gains from the sale of an equity investment.

Other income (expense), net

Other income (expense), net consists primarily of interest and dividend income on our cash, cash equivalents and short-term marketable securities portfolio, foreign currency transaction gains and losses due to the effects of foreign currency fluctuations, and interest expense related to our senior convertible notes.

Table of Contents

Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023



| (In millions) | Three Months Ended March 31, | | | | 2024 - 2023 | |
|---------------|------------------------------|------------|----------|------------|--------------------|-----|
| | 2024 | | 2023 | | Change in Revenues | |
| | Revenue | % of Total | Revenue | % of Total | \$ | % |
| | | | | | | |
| United States | \$ 653.2 | 71% | \$ 526.0 | 71% | \$ 127.2 | 24% |
| International | 267.8 | 29% | 215.5 | 29% | 52.3 | 24% |
| Total Revenue | \$ 921.0 | 100% | \$ 741.5 | 100% | \$ 179.5 | 24% |

Three Months Ended September 30, 2023 March 31, 2024 Compared to
Three Months Ended September 30, 2022 March 31, 2023

| | |
|------------------------------|--|
| Revenue | <p>The revenue increase was primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer base. We added approximately 600,000 users to our worldwide customer base and the shift to G7, partially offset by mix shift and price associated with the evolution of our channel and product strategy in 2023.</p> <p>Disposable sensor and other revenue comprised approximately 90% 93% of total revenue and Reusable Hardware revenue comprised approximately 10% 7% of total revenue for the three months ended September 30, 2023 March 31, 2024. Disposable sensor and other revenue comprised approximately 87% 88% of total revenue and Reusable Hardware revenue comprised approximately 13% 12% of total revenue for the three months ended September 30, 2022 March 31, 2023.</p> |
| Cost of sales & Gross profit | <p>Cost of sales and gross profit increased primarily due to an increase in sales volume, volume driven by the addition of approximately 600,000 users to our worldwide customer base in 2023.</p> <p>The decrease in gross profit margin percentage in the third first quarter of 2024 compared to the first quarter of 2023 compared to the third quarter of 2022 was primarily driven by the amortization of an intangible asset and price, product and channel mix changes.</p> |

Table of Contents

**Three Months Ended March 31, 2024 Compared to
Three Months Ended March 31, 2023**

| | |
|--|--|
| Research and development expense | <p>Research and development expense increased primarily due to \$13.6 million \$6.8 million in compensation-related costs most notably due to higher headcount, headcount, \$5.0 million in supplies and other support costs, and \$3.2 million in clinical trials costs.</p> <p>We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy.</p> |
| Selling, general and administrative expense | <p>Selling, general and administrative expense increased primarily due to \$32.2 million \$16.0 million in compensation-related costs most notably due to higher headcount, \$5.9 million of travel related expenses, and \$12.6 million in legal expense primarily \$2.5 million related to a patent infringement lawsuit.</p> <p>the divestiture of certain non-CGM assets, partially offset by \$9.6 million in lower advertising and marketing costs.</p> |
| Other income (expense), net | <p>Other income (expense), net, increased primarily due to \$35.8 \$14.0 million in interest and dividend income on our cash, cash equivalents, and marketable securities portfolio. The increase in interest income was related to a significant increase change in market interest rates, as well as an increase in the average invested balances compared to the same period in 2022, 2023.</p> |
| Income tax expense (benefit) | <p>Our estimated annual effective tax rate from normal, recurring operations decreased from 28.5% to 24.7% during the three months ended September 30, 2023 primarily due to decrease in state and foreign taxes, increase in federal tax credits generated, partially offset by an increase to unrecognized tax benefits and an increase in disallowed executive compensation. There are discrete taxes related to the intra-entity transfer of certain intellectual property and decrease in the state tax rate applied to beginning of year deferred tax assets.</p> <p>The income tax expense benefit recorded for the three months ended September 30, 2022 March 31, 2024 was primarily attributable to income tax expense from normal, recurring operations.</p> |

[Table of Contents](#)



Nine Months Ended September 30, 2023 Compared to Nine Months Ended September 30, 2022

| (In millions, except per share amounts) | Nine Months Ended September 30, | | | | 2023 - 2022 | |
|---|---------------------------------|-----------------------------|------------|-----------------------------|-------------|----------|
| | 2023 | % of Revenue ⁽¹⁾ | 2022 | % of Revenue ⁽¹⁾ | \$ Change | % Change |
| Revenue | \$ 2,587.8 | 100 % | \$ 2,094.6 | 100 % | \$ 493.2 | 24 % |
| Cost of sales | 955.5 | 37 % | 752.8 | 36 % | 202.7 | 27 % |
| Gross profit | 1,632.3 | 63.1 % | 1,341.8 | 64.1 % | 290.5 | 22 % |
| Operating expenses: | | | | | | |
| Research and development | 369.7 | 14 % | 367.9 | 18 % | 1.8 | — % |
| Amortization of intangible assets | 5.2 | — % | 5.7 | — % | (0.5) | (9)% |
| Selling, general and administrative | 876.6 | 34 % | 702.4 | 34 % | 174.2 | 25 % |
| Total operating expenses | 1,251.5 | 48 % | 1,076.0 | 51 % | 175.5 | 16 % |
| Operating income | 380.8 | 15 % | 265.8 | 13 % | 115.0 | 43 % |
| Income from equity investments | 1.0 | — % | 0.2 | — % | 0.8 | ** |
| Other income (expense), net | 82.4 | 3 % | (8.4) | — % | 90.8 | ** |
| Income before income taxes | 464.2 | 18 % | 257.6 | 12 % | 206.6 | 80 % |
| Income tax expense | 179.0 | 7 % | 8.2 | — % | 170.8 | ** |
| Net income | \$ 285.2 | 11 % | \$ 249.4 | 12 % | \$ 35.8 | 14 % |
| Basic net income per share | \$ 0.74 | ** | \$ 0.64 | ** | \$ 0.10 | 16 % |
| Diluted net income per share | \$ 0.69 | ** | \$ 0.60 | ** | \$ 0.09 | 15 % |

⁽¹⁾ The sum of the individual percentages may not equal the total due to rounding.
 ** Not meaningful

| Nine Months Ended September 30, 2023 Compared to Nine Months Ended September 30, 2022 | |
|--|---|
| Revenue | <p>The revenue increase was primarily driven by operations increased sales volume at an estimated annual effective tax rate of our disposable sensors due to the continued growth of our worldwide customer base and the shift to G7, partially 23.8%, offset by mix shift and price associated with the evolution of our channel and product strategy.</p> <p>Disposable sensor and other revenue comprised approximately 89% of total revenue and Reusable Hardware revenue comprised approximately 11% of total revenue for the nine months ended September 30, 2023. Disposable sensor and other revenue comprised approximately 86% of total revenue and Reusable Hardware revenue comprised approximately 14% of total revenue for the nine months ended September 30, 2022.</p> |
| Cost of sales & Gross profit | <p>Cost of sales and gross profit increased primarily due to an increase in sales volume.</p> <p>The decrease in gross profit margin percentage in 2023 compared to 2022 was primarily driven by the amortization of an intangible asset and price, product, and channel mix changes.</p> |
| Research and development expense | <p>Research and development expense increased primarily due to \$26.8 million in compensation-related costs most notably due to higher headcount and various increases to individually insignificant items, partially offset by \$16.4 million of lower third party and consulting fees primarily related to software development for new products and significant enhancements and \$11.5 million in lower costs related to set-up and validation costs for new CGM equipment.</p> <p>We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy.</p> |
| Selling, general and administrative expense | <p>Selling, general and administrative expense increased primarily due to \$73.9 million in compensation-related costs most notably due to higher headcount, \$43.0 million in legal expense primarily related to a patent infringement lawsuit, and \$30.7 million in advertising and marketing costs associated with global product launches.</p> |
| Other income (expense), net | <p>Other income (expense), net, increased primarily due to \$90.8 million in interest and dividend income on our cash, cash equivalents, and marketable securities portfolio. The increase in interest income was related to a significant increase in market interest rates, as well as an increase in the average invested balances compared to the same period in 2022.</p> |
| Income tax expense | <p>The income tax expense recorded for the nine months ended September 30, 2023 is primarily attributable to state and foreign income taxes, nondeductible executive compensation, increases to unrecognized tax benefits, and impact of foreign operations, partially offset by federal tax credits generated. There are discrete taxes related to the intra-entity asset transfer of certain intellectual property, and decrease in the state tax rate applied to beginning of year deferred tax assets, partially offset by excess tax benefits recognized for share-based compensation for employees, net of disallowed executive compensation.</p> <p>compensation and the Verily milestone payment.</p> <p>The income tax expense recorded for the nine three months ended September 30, 2022 is March 31, 2023 was primarily attributable to income tax expense from normal, recurring operations, partially offset by discrete excess tax benefits recognized for share-based compensation for employees, (net net of disallowed executive compensation) compensation. The decrease in our effective tax rate for the three months ended March 31, 2024 compared to the same period in 2023 is primarily attributable to impacts of the prior year tax restructuring and the Verily milestone payment, and generation of research and development tax credits. payment.</p> |

Liquidity and Capital Resources

Overview, Capital Resources, and Capital Requirements

Our principal sources of liquidity are our existing cash, cash equivalents and marketable securities, cash generated from operations, proceeds from our senior convertible notes issuances, and access to our Credit Facility. Our primary uses of cash have been for research and development programs, selling and marketing activities, capital expenditures, acquisitions of businesses, and debt service costs.

We expect that cash provided by our operations may fluctuate in future periods as a result of a number of factors, including fluctuations in our operating results, working capital requirements and capital deployment decisions. We have historically invested our cash primarily in U.S. dollar-denominated, investment grade, highly liquid obligations of U.S. government agencies, commercial paper, corporate debt, and money market funds. Certain of these investments are subject to general credit, liquidity and other market risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets.

Our future capital requirements will depend on many factors, including but not limited to:

| | | |
|---|---|--|
| The evolution of the international expansion of our business and the revenue generated by sales of our approved products and other any future products; | Our ability to efficiently scale our operations to meet demand for our current and any future products; | The success of our research and development efforts; |
| The expenses we incur in manufacturing, developing, selling and marketing our products; | The costs, timing and risks of delays of additional regulatory approvals; | The costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; |
| The quality levels of our products and services; | The emergence of competing or complementary technological developments; | The terms and timing of any collaborative, licensing and other arrangements that we may establish; and |
| The third-party reimbursement of our products for our customers; | The rate of progress and cost of our clinical trials and other development activities; | The acquisition of businesses, products and technologies and our ability to integrate and manage any acquired businesses, products and technologies. |

We expect that existing cash and short-term investments and cash flows from our future operations will generally be sufficient to fund our ongoing core business. As current borrowing sources become due, we may be required to access the capital markets for additional funding. As we assess inorganic growth strategies, we may need to supplement our internally generated cash flow with outside sources. In the event that we are required to access the debt market, we believe that we will be able to secure reasonable borrowing rates. As part of our liquidity strategy, we will continue to monitor our current level of earnings and cash flow generation as well as our ability to access the market in light of those earning levels.

A substantial portion of our operations are located in the United States, and the majority of our sales since inception have been made in U.S. dollars. We will be exposed to additional foreign currency exchange risk related to our international operations as we expand our manufacturing internationally and as our business continues to increase in international markets. See "Foreign "Foreign Currency Exchange Risk" Risk" in Part II, Item 7A of our Annual Report on Form 10-K for the fiscal year endedDecember 31, 2023,for more information.

Table of Contents

Main Sources of Liquidity

Cash, cash equivalents and short-term marketable securities

Our cash, cash equivalents and short-term marketable securities totaled \$3.24 billion \$2.90 billion as of September 30, 2023 March 31, 2024. None of those funds were restricted and \$3.07 billion \$2.67 billion (approximately 95% 92%) of those funds were located in the United States.

Cash flow from Operations

For the nine three months ended September 30, 2023 March 31, 2024, we had positive cash flows of \$614.9 million \$209.2 million from operating activities. We anticipate that we will continue to generate positive cash flows from operations for the foreseeable future.

Senior Convertible Notes

We received net proceeds of \$836.6 million in November 2018 from the 2023 Notes offering, net proceeds of \$1.19 billion in May 2020 from the 2025 Notes offering, and net proceeds of \$1.23 billion in May 2023 from the 2028 Notes offering. We used \$100.0 million of the net proceeds from the offering of the 2023 Notes to repurchase a portion of our common stock in 2018. We used \$282.6 million of the net proceeds from the offering of the 2025 Notes to repurchase a portion of our senior convertible notes due in 2022. We used \$289.9 million of the net proceeds from the offering of the 2028 Notes to purchase capped call transactions and repurchase shares of our common stock in May 2023. We intend to use the remainder of the net proceeds from the 2023 2025 Notes 2025 Notes, offering and 2028 Notes offerings offering for general corporate purposes and capital expenditures, including working capital needs. We may also use the net proceeds to expand our current business through in-licensing or acquisitions of, or investments in, other businesses, products or technologies; however, we do not have any significant commitments with respect to any such acquisitions or investments at this time.

In connection with the 2023 Notes and 2028 Notes offerings, offering, we purchased the 2023 Note Hedge and 2028 Capped Calls, respectively. Calls. See Note 5 "Debt" "Debt" to the consolidated financial statements in Part I, Item 1 of this Quarterly Report for conversion activity related to the 2023 Notes and shares received as the result of exercising a portion of the 2023 Note Hedge as well as on Form 10-Q for more information about our senior convertible notes the 2023 Note Hedge, the 2023 Warrants, and the 2028 Capped Calls.

Revolving Credit Agreement

As of **September 30, 2023** **March 31, 2024**, we had no outstanding borrowings, **\$7.3 million** **\$7.6 million** in outstanding letters of credit, and a total available balance of **\$192.7 million** **\$192.4 million** under the Amended Credit Agreement. We monitor counterparty risk associated with the institutional lenders that are providing the Credit Facility. We currently believe that the Credit Facility will be available to us should we choose to borrow under it. Revolving loans will be available for general corporate purposes, including working capital and capital expenditures. See Note 5 "**Debt**" "**Debt**" to the consolidated financial statements in Part I, Item 1 of this Quarterly Report **on Form 10-Q** for more **details information** on the Revolving Credit Agreement.

Short-term Liquidity Requirements

Our short-term liquidity requirements primarily consist of regular operating costs, interest payments related to our senior convertible notes, capital expenditures for the development of our manufacturing facilities and office spaces, and short-term material cash requirements as described below. As of **September 30, 2023** **March 31, 2024**, we had a working capital ratio of **2.80** **2.90** and a quick ratio of **2.40**, **2.43**, which indicates that our current assets are more than enough to cover our short-term liabilities. We expect to have significant capital expenditures for the next year to **scale-up capacity in Mesa, Arizona** and drive our strategic **initiative initiatives** of building out our manufacturing facilities and/or equipment in Malaysia and **Ireland and the capacity scale-up in Mesa, Arizona. Ireland.**

We believe that our cash, cash equivalents, and marketable securities balances, projected cash contributions from our commercial operations, and borrowings under our Credit Facility will be sufficient to meet our anticipated seasonal working capital needs, all capital expenditure requirements, material cash requirements as described below, and other liquidity requirements associated with our operations for at least the next 12 months. We may use cash **to repurchase Dexcom shares or for other** strategic initiatives that strengthen our foundation for long-term growth.

The outstanding principal related to our 2023 Notes of \$124.3 million as of September 30, 2023 and any amount in excess of the principal amount will primarily settle through a combination of cash and stock on or before the maturity date of December 1, 2023.

Table of Contents

Long-term Liquidity Requirements

Our long-term liquidity requirements primarily consist of interest and principal payments related to our senior convertible notes, capital expenditures for the development of our manufacturing facilities and office spaces, and long-term material cash requirements as described below. As of **September 30, 2023** **March 31, 2024**, we had a debt-to-assets ratio of **0.39**, **0.38**, which indicates that our total assets are more than enough to cover our short-term and long-term debts. As demand grows for our products, we will continue to expand global operations to meet demand through investments in manufacturing and operations. We expect to meet our long-term liquidity requirements from our main sources of liquidity as described above to support our future operations, capital expenditures, acquisitions, and other liquidity requirements associated with our operations beyond the next 12 months.

Table of Contents

As of **September 30, 2023** **March 31, 2024**, we have outstanding senior convertible notes that will mature in November 2025 and May 2028. However, the outstanding principal of our senior convertible notes could be converted into cash and/or shares of our common stock prior to maturity once certain conditions are met. See Note 5 "**Debt**" "**Debt—Senior Convertible Notes**" to the consolidated financial statements in Part I, Item 1 of this Quarterly Report **on Form 10-Q** for information on conversion rights prior to maturity.

Material Cash Requirements

From time to time in the ordinary course of business, we enter into a variety of purchase arrangements including but not limited to, purchase arrangements related to capital expenditures, components used in manufacturing, **for the United States and Malaysia**, and research and development activities. See "**Contractual Obligations**" "**Contractual Obligations**" below in Part I, Item 2 of this Quarterly Report for more information.

We issued senior convertible notes in November 2018, May 2020, Our obligations under the 2025 Notes and May 2023. These obligations 2028 Notes include both principal and interest for these notes. Although these notes the 2025 Notes and 2028 Notes mature in December 2023, November 2025 and May 2028, respectively, they may be converted into cash and/or shares of our common stock prior to maturity if certain conditions are met. Any conversion prior to maturity can may result in repayment of the principal amounts due under the Notes sooner than the scheduled repayment.

As of September 30, 2023, market conditions warrant, we had may, from time to time, repurchase our outstanding letters of credit of \$7.3 million for which we cannot forecast with certainty debt securities in the amount open market, in privately negotiated transactions, by exchange transaction or otherwise. Such repurchases, if any, will depend on prevailing market conditions, our liquidity and timing of repayments. other factors and may be commenced or suspended at any time. The amounts involved and total consideration paid may be material.

See Note 5 "**Debt**" "**Debt—Senior Convertible Notes**" to the consolidated financial statements in Part I, Item 1 of this Quarterly Report **on Form 10-Q** for **further discussion of more information about the terms of the Credit Agreement, our senior convertible notes, notes, and the 2028 Capped Calls.**

We are party to various leasing arrangements, primarily for office, manufacturing and warehouse space that expire at various times through December 2030, excluding any renewal options. We also have land leases in Penang, Malaysia **that expire in 2082 and Athenry, Ireland that expire in 2023 for the build-out of our international manufacturing facility lease that expire through 2082. facilities.** We anticipate incurring significant expenditures related to **the build-out of the our Malaysia manufacturing facility and equipment over the next year and the build-out of the Ireland manufacturing facility and equipment over the next five years.** See Note 6 "**Leases**" "**Leases and Other Commitments**" "**Commitments—Leases**" to the consolidated financial statements in Part II, Item 8 of our Annual Report for **the fiscal year ended December 31, 2023** for more information about our leases.

See Note 5 “Debt” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report for more information about the terms of the Credit Agreement, our senior convertible notes, the 2023 Note Hedge, the 2023 Warrants, and the 2028 Capped Calls.

[Table of Contents](#)

Cash Flows

The following table sets forth a summary of our cash flows for the periods indicated. See the consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for complete consolidated statements of cash flows for these periods.



As of September 30, 2023 March 31, 2024, we had \$3.24 billion \$2.90 billion in cash, cash equivalents and short-term marketable securities, which is an increase of \$784.1 million \$172.9 million compared to \$2.46 billion \$2.72 billion as of December 31, 2022 December 31, 2023.

The primary cash flows during the nine three months ended September 30, 2023 March 31, 2024 and September 30, 2022 March 31, 2023 are described below. See the consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for complete consolidated statements of cash flows for these periods.

[Table of Contents](#)

Nine Three Months Ended

| | | September 30, 2023 | March 31, 2024 | September 30, 2022 | March 31, 2023 |
|----------------------------|---|---|----------------|--|---|
| Operating Cash Flows | | + \$285.2 146.4 million of net income, \$68.4 million \$43.8 million of net non-cash adjustments, and a net increase of \$261.3 million \$19.0 million in changes of working capital balances | | + \$249.4 48.6 million of net income, and \$194.9 million \$55.3 million of net non-cash adjustments, and a net increase of \$92.7 million \$51.5 million in changes of working capital balances | |
| | | Net non-cash adjustments were primarily related to depreciation and amortization, share-based compensation, and depreciation and amortization. deferred income taxes. | | Net non-cash adjustments were primarily related to share-based compensation and depreciation and amortization. amortization and share-based compensation. | |
| Investing Cash Flows | | + \$129.4 million in net proceeds from marketable securities | | - \$719.5 million in net purchases of marketable securities | |
| | | - \$184.1 million in capital expenditures | | - \$12.5 million in purchases of equity investments | |
| | - 19.5 million in purchases of equity investments | - \$9.9 112.0 million in net purchases of marketable securities | | | - \$301.3 million in capital expenditures |
| | - | | | - \$3.9 74.7 million in acquisitions, net of cash acquired capital expenditures | |
| | | \$56.9 million in capital expenditures | | | |
| Financing Cash Flows | | + \$1.23 billion 13.4 million in proceeds from issuance of senior convertible notes, net of issuance costs common stock under our employee stock plans | | + \$22.5 12.3 million in proceeds from issuance of common stock under our employee stock plans | |
| | - \$650.5 million in payments for conversions of senior convertible notes | - \$14.6 million in payments for financing leases | | | |
| | - \$188.7 million in purchases of treasury stock | | | | |
| | - \$101.3 million in purchases of capped call transactions | | | | |

Contractual Obligations

We presented our contractual obligations as of [December 31, 2022](#) [December 31, 2023](#) in Note 6 "[Leases](#)" "[Leases and Other Commitments](#)" "[Commitments](#)" in our Annual Report on Form 10-K for the fiscal year ended [December 31, 2022](#) [December 31, 2023](#). There were no significant material changes to our lease obligations during the nine months ended September 30, 2023. As of September 30, 2023, we had approximately \$420.3 million of open purchase orders and/or contractual obligations in outside the ordinary course of business during the majority of which are due within one year, three months ended March 31, 2024. See Note 5 "[Debt](#)" "[Debt—Senior Convertible Notes](#)" to the consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for [conversion activity related to more information on](#) our senior convertible notes.

Recent Accounting Guidance

For a description See Note 1 "[Organization and Significant Accounting Policies](#)" to the consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information regarding recently issued accounting pronouncements and the potential impact on our consolidated financial statements, if any, see Note 1 "[Organization and Significant Accounting Policies](#)" to the consolidated financial statements in Part I, Item 1 of this Quarterly Report. any.

ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There were no material changes to our quantitative and qualitative disclosures about market risk during the [nine three](#) months ended [September 30, 2023](#) [March 31, 2024](#). See Part II, Item 7A "[Quantitative and Qualitative Disclosures about Market Risk](#)" of our Annual Report on Form 10-K for the fiscal year ended [December 31, 2022](#) [December 31, 2023](#), for a detailed discussion of our market risks.

[Table of Contents](#)

ITEM 4 - CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Regulations under the Exchange Act require public companies to maintain "disclosure controls and procedures," which are as defined to mean a company's in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Disclosure controls and procedures include, without limitation, controls and other procedures that are designed to ensure that information required to be disclosed in the reports that it files we file or submits submit under the Securities Exchange Act is accumulated and timely communicated to management, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. Our management, including with the participation of our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report of the effectiveness of our disclosure controls and procedures. Quarterly Report on Form 10-Q. Based on their evaluation as of [September 30, 2023](#) [March 31, 2024](#), our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of such date for this purpose. date.

[Table of Contents](#)

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our last the most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitation on Effectiveness of Controls

It should be noted that any system of controls, including ours, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. The design of any control system is based, in part, upon the benefits of the control system relative to its costs. Control systems can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. In addition, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of these and other inherent limitations of control systems, we cannot guarantee that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

[Table of Contents](#)

PART II. OTHER INFORMATION

ITEM 1 - LEGAL PROCEEDINGS

We are subject to various claims, complaints and legal actions that arise from time to time in the normal course of business, including commercial insurance, product liability, intellectual property and employment related matters. In addition, from time to time we may bring claims or initiate lawsuits against various third parties with respect to matters

arising out of the ordinary course of our business, including commercial and employment related matters.

Between June 2021, through the nine months ended September 30, 2023, we and certain Abbott Diabetes Care, Inc. ("Abbott") entities have served patent infringement complaints against each other in multiple jurisdictions including in the United States (United States District Court ("U.S.D.C."), District against certain continuous glucose monitoring products of Delaware), the United Kingdom (Business and Property Courts of England and Wales), France (United Patent Court ("UPC") in Paris), Spain (Commercial Courts of Barcelona) and Germany (National Courts ("N.C.") of Munich, Mannheim, Dusseldorf and Hamburg and the UPC in Munich), primarily involving claims of patent infringement, invalidity and other patent related actions. each company.

In June and July of 2021, we initiated patent infringement litigation against Abbott in the United States (U.S.D.C., Western District of Texas) and Germany (N.C. (National Court ("N.C.") in Mannheim) and . In May 2023, we filed additional patent infringement actions in May 2023 in Germany (N.C. in Munich) over certain of Abbott's continuous glucose monitoring products. In July and August 2023, we initiated patent infringement litigation in France and Germany in the UPC United Patent Court ("UPC") (Paris & Munich) and in Spain (Commercial Courts of Barcelona). In October and November 2023, we initiated patent infringement litigation in Germany (N.C. in Munich) and in the UPC (Paris & Munich). In January 2024, we initiated patent infringement litigation in Germany (N.C. in Hamburg).

Between In July 2021, through one day after we initiated litigation in the nine months ended September 30, 2023 U.S.D.C., Western District of Texas, Abbott initiated patent infringement litigation against Dexcom in multiple jurisdictions, including the United States (U.S.D.C., Delaware), Delaware ("D1"). Shortly thereafter, Abbott filed additional patent infringement litigation actions in the United Kingdom (Business and Property Courts of England and Wales) and in Germany (N.C. in Mannheim Dusseldorf and Hamburg) over certain of Dexcom's continuous glucose monitoring products. Dusseldorf.

In response to the lawsuits initiated by Abbott in the United Kingdom, Dexcom also filed patent infringement counterclaims in that jurisdiction, the Business and Property Courts of England and Wales. Three trials on liability have already been conducted in the United Kingdom. On October 18, October 18, 2023, judgment was handed down in favor of Dexcom in one of these trials. On January 15, 2024, judgment was handed down invalidating both Abbott and Dexcom's patents in another one of these trials. The parties are awaiting rulings on the remaining two trial. Dexcom and Abbott seek sought injunctive relief and monetary damages as a result of their respective claims.

In December 2021, Abbott filed a breach of contract lawsuit against Dexcom in the U.S.D.C. United States (U.S.D.C., District of Delaware Delaware) alleging that Dexcom breached the parties' Settlement and License Agreement dated July 2, 2014 ("SLA"). The U.S.D.C., District of Delaware consolidated Abbott's breach of contract lawsuit with Dexcom's patent infringement lawsuit which had been transferred from the U.S.D.C., Western District of Texas, Texas ("D3"). Dexcom asserted counterclaims that Abbott also breached the SLA. A jury trial on Abbott's breach of contract claims commenced on July 10, 2023. On July 14, 2023, the jury verdict determined that Abbott was not licensed to thirteen claims of certain Dexcom patents and that Abbott was licensed to five claims. In April 2022, Abbott initiated the inter partes review ("IPR") process on the asserted claims of Dexcom's patent infringement claims patents in Delaware are stayed until November 10, 2023, at which point the D3. The U.S. Patent and Trademark Office will have (the "PTO") denied institution of one of Dexcom's patents and instituted IPR on the other four. Ultimately, in November 2023, the PTO issued its final written decisions on Final Written Decision, upholding claims of two Dexcom patents to be patentable, which cover factory calibration and certain patents involved in the lawsuit, alarms and alerts, and two to be unpatentable, which cover certain sensor code and sensor configurations. We will continue to enforce the remaining claims of the patents asserted in Delaware. Delaware with trial set for February 2025.

In February 2023, Abbott filed patent infringement litigation against us in Germany (N.C. in Hamburg and Munich). In March 2023, Abbott filed a patent infringement litigation in the United States (U.S.D.C., Delaware ("D4")) and we filed counterclaims for patent infringement in that action in June 2023. In June 2023, Abbott filed patent infringement litigation actions in the United Kingdom (Business and Property Courts of England and Wales). In response to the lawsuits initiated by Abbott in the United Kingdom, Dexcom also filed patent infringement counterclaims in that jurisdiction.

Abbott's patent infringement action trial, "D1" against Dexcom is currently scheduled for trial commenced in the U.S.D.C., District of Delaware on March 11, 2024. In March 2024. In the lead up to trial, the U.S.D.C., District of Delaware invalidated one of Abbott's patents on factory calibration and Abbott dropped four other patents from the litigation. The claims litigated were isolated to the inserter mechanism and the wearable seal and mount of Dexcom's G6. On March 22, 2024, a jury returned a mixed verdict. The jury found that Dexcom infringes one patent, that Dexcom did not infringe a second patent, and that Dexcom also did not infringe a third patent, which the jury also found invalid. The jury found that any infringement was not willful. It could not reach unanimity as to a fourth patent. No determination of damages was made or awarded. Dexcom will challenge the sole finding of infringement and continue to defend itself vigorously.

Table of Contents

Commencing in December 2023, January 2024, Abbott has several patent infringement hearings against Dexcom in the National Court Germany (N.C. in Hamburg and Munich Munich) wherein Abbott is seeking damages and injunctive relief. On January 31, 2024, the Court in Munich in two such hearings provided Dexcom additional time to brief certain issues Abbott raised late in the proceedings, thus postponing a decision in both proceedings until May 2024. In March and April of 2024, Dexcom has several patent infringement hearings in the N.C. in Mannheim and Munich against Abbott, wherein Dexcom is seeking damages and injunctive relief. Dexcom has hearings in May and June 2024 in its first two proceedings in the UPC and in July 2024 in the N.C. in Munich.

Due to uncertainty surrounding patent litigation procedures initiated by Dexcom and Abbott throughout multiple jurisdictions, we are unable to reasonably estimate the ultimate outcome of any of the litigation matters at this time. We intend to protect our intellectual property and defend against Abbott's claims vigorously in all of these actions.

We do not believe we are party to any other currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial condition, or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial condition, or results of operations.

Table of Contents

ITEM 1A - RISK FACTORS

There were no material changes to the risk factors previously disclosed and included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Our short and long-term success is subject to numerous risks and uncertainties, many of which involve factors that are difficult to predict or beyond our control. Before making a decision to invest in, hold or sell our common stock, stockholders and potential stockholders should carefully consider the risks and uncertainties described below, in addition to the other information contained Part I, Item 1A, "Risk Factors" in or incorporated by reference into this Quarterly Report on Form 10-Q, as well as 10-K for the other information we file with the SEC. If any of the following risks are realized, fiscal year ended December 31, 2023, which could materially and adversely affect our business, financial condition, results of operations and prospects could be materially and adversely affected. prospects. In that case, the value of our common stock could decline and stockholders may lose all or part of their investment.

Furthermore, additional risks and uncertainties of which we are currently unaware, or which we currently consider to be immaterial, could have a material adverse effect on our business, financial condition, or results of operations, operations or prospects. Refer to our disclaimer regarding forward-looking statements at the beginning of Management's Discussion and Analysis of Financial Condition and Results of Operations in Part I, Item 21 of this Quarterly Report.

Summary of Risk Factors

The below summary of risk factors provides an overview of many of the risks we are exposed to in the normal course of our business activities. As a result, the below summary risks do not contain all of the information that may be important to you, and you should read the summary risks together with the more detailed discussion of risks set forth following this section under the heading "Risk Factors," as well as elsewhere in this Quarterly Report on Form 10-Q. Additional risks, beyond those summarized below or discussed elsewhere in this Quarterly Report on Form 10-Q, may apply to our activities or operations as currently conducted or as we may conduct them in the future or in the markets in which we operate or may in the future operate. Consistent with the foregoing, we are exposed to a variety of risks, including risks associated with the following:

- If we experience decreasing prices for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.
- We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in future revenue.
- Although many third-party payors have adopted some form of coverage policy for continuous glucose monitoring devices, our products do not always have such coverage, including simple broad-based contractual coverage with third-party payors, and we frequently experience administrative challenges in obtaining coverage or reimbursement for our products. If we are unable to obtain adequately broad coverage or reimbursement for our products or any future products from third-party payors, our revenue may be negatively impacted.
- The research and development efforts we undertake independently, and in some instances in connection with our collaborations with third parties, may not result in the development of commercially viable products, the generation of significant future revenues or adequate profitability.
- Our products may not achieve or maintain market acceptance.
- If our manufacturing capabilities are insufficient to produce an adequate supply of product at appropriate quality levels, our growth could be limited and our business could be harmed.
- Manufacturing difficulties and/or any disruption at our facilities may adversely affect our manufacturing operations and related product sales, and increase our expenses.
- We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our business.
- If we are unable to establish and maintain adequate sales, marketing and distribution capabilities or enter into and maintain arrangements with third parties to sell, market and distribute our products, we may have difficulty achieving market awareness and selling our products in the future.
- We operate in a highly competitive market and face competition from large, well-established companies with significant resources, and, as a result, we may not be able to compete effectively.
- We are subject to risks associated with public health issues, including pandemics, which could have a material adverse effect on our business, financial condition and results of operations.
- We are subject to a variety of risks due to our international operations that could adversely affect our business, our operations or profitability and operating results.
- We have incurred significant losses in the past and may incur losses in the future.

Table of Contents

- We are subject to complex and evolving U.S. and foreign laws and regulations and other requirements regarding privacy, data protection, security, and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.
- Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations.
- We conduct business in a heavily regulated industry and if we fail to comply with applicable laws and government regulations, we could become subject to penalties, be excluded from participation in government programs, and/or be required to make significant changes to our operations.
- Managed care trends and consolidation in the health care industry could have an adverse effect on our revenues and results of operations.

- Health care policy changes, including U.S. health care reform legislation, may have a material adverse effect on our business.
- If we are unable to successfully complete the pre-clinical studies or clinical trials necessary to support additional PMA, de novo, or 510(k) applications or supplements, we may be unable to commercialize our CGM systems under development, which could impair our business, financial condition and operating results.
- We are subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from shipping affected products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages and injunctive relief. We may also be subject to other claims or suits.
- Our inability to adequately protect our intellectual property could allow our competitors and others to produce products based on our technology, which could substantially impair our ability to compete.
- We face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things.
- We could become the subject of governmental investigations, claims and litigation.
- Our stock price is highly volatile and investing in our stock involves a high degree of risk, which could result in substantial losses for investors.
- We have indebtedness in the form of convertible senior notes, which could adversely affect our financial health and our ability to respond to changes in our business.
- Environmental, social and governance, or ESG, regulations, policies and provisions could expose us to numerous risks.

Risks Related to Our Business and Operations

Risks Related to Pricing and Reimbursement

If we experience decreasing prices for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.

We have experienced, and anticipate that we will continue to experience, decreasing prices for our products due to pricing pressure from managed care organizations and other third-party payors, increased market power of our payors, and increased competition among suppliers, including manufacturing services providers, as the medical device industry consolidates. If the prices for our products and services decrease and we are unable to reduce our expenses, including the cost of sourcing materials, logistics and the cost to manufacture our products, our business, results of operations, financial condition and cash flows will be adversely affected.

We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in future revenue.

In the United States and other countries, government and private sector access to health care products continues to be a subject of focus, and efforts to reduce health care costs are being made by third-party payors.

Table of Contents

Most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of our products. We expect that the continuing cost reduction and containment measures may reduce the cost or utilization of health care products and could lead to patients being unable to obtain approval for coverage or payment from these third-party payors or to costs being shifted to patients for our products. Additionally, as a result of the economic slowdown, some customers have lost access and others may lose access to their private health insurance plan if they lose their job, and an impact to job status may extend for a prolonged period of time, beyond possible coverage periods through COBRA, or where the cost to maintain coverage may not be affordable to our customer. As most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of our products, our customers may lose coverage or reimbursement for our products, which may harm our business and results of operations.

We have experienced, and anticipate that we will continue to experience, downward pressure on product pricing. To the extent these cost containment efforts are not offset by greater patient access to our products, our future revenue may be reduced and our business may be harmed.

Although many third-party payors have adopted some form of coverage policy for continuous glucose monitoring devices, our products do not always have such coverage, including simple broad-based contractual coverage with third-party payors, and we frequently experience administrative challenges in obtaining coverage or reimbursement for our products. If we are unable to obtain adequately broad coverage or reimbursement for our products or any future products from third-party payors, our revenue may be negatively impacted.

As a medical device company, reimbursement from government and/or commercial third-party healthcare payors, including Medicare and Medicaid, is an important element of our success. The Centers for Medicare & Medicaid Services, or CMS, provides coverage for "Therapeutic Continuous Glucose Monitors" as durable medical equipment eligible for coverage under Medicare Part B. Coverage criteria for therapeutic CGMs is determined by CMS under national coverage determinations as well as by local Medicare Administrative Contractors under local coverage determinations. Therefore, Medicare reimbursement for our CGM devices is subject to various coverage conditions and often requires a patient-specific coverage analysis. Medicare does not cover any items or services that are not "reasonable and necessary." Medicare covers the CGM system, which includes supplies necessary for the use of the device, under the Durable Medical Equipment, or DME, benefit category. In order to be covered under this benefit, one component of the CGM system must meet the criteria for a durable medical device. To date, the receiver satisfied this criteria. To the extent that a receiver is not used by a Medicare beneficiary or CMS otherwise determines that the items and supplies ordered are not medically necessary, Medicare may not cover that CGM system or any associated supplies.

A number of regulatory and commercial hurdles remain relating to wide-scale sales where a government or commercial third-party payor provides reimbursement, including sales to Medicare beneficiaries. If we are unable to successfully address these hurdles, reimbursement of our products may be limited to a smaller subset of people with diabetes covered by Medicare or to those people with diabetes covered by other third-party payors that have adopted policies for CGM devices allowing for coverage of these devices if certain conditions are met. Adverse coverage or reimbursement decisions relating to our products, or rescission or limitation of favorable determinations, by CMS, its

Medicare Administrative Contractors, other state, federal or international payors, and/or third-party commercial payors could significantly reduce reimbursement, which could have an impact on the acceptance of, and demand for, our products and the prices that our customers are willing to pay for them.

As of September 30, 2023, the eight largest private third-party payors, in terms of the number of covered lives, have issued coverage policies for the category of CGM devices. In addition, we have negotiated contracted rates with all of those third-party payors for the purchase of our current CGM systems by their members. Nevertheless, coverage and reimbursement-related barriers remain. Among other things, people with diabetes without insurance that covers our products bear the entire financial cost of using our products. In addition, in the United States, people with diabetes using existing single-point finger stick devices are generally reimbursed all or part of the product cost by Medicare or other third-party payors, which may be perceived as more advantageous for consumers. Further, while many third-party payors have adopted some form of coverage policy on CGM devices, in a sizeable percentage of cases, under durable medical equipment benefits, those coverage policies frequently are restrictive and require significant medical documentation and other requirements in order for policy holders to obtain reimbursement, and as a result, we have difficulty improving the efficiency of our customer service group. Moreover, it is not uncommon for governmental, including federal and/or state, agencies and their contractors to conduct periodic routine billing and compliance reviews that may entail extensive documentation requests, cooperation with which may require significant time and resources, and may result in identification of overpayments that may need to be refunded. The commercial success of our products in both domestic and international markets will substantially

[Table of Contents](#)

depend on whether timely and comprehensive third-party reimbursement is widely available for individuals that use them.

CMS has adopted coverage guidelines for CGMs, which could have a favorable impact on us. Previously, Medicare coverage for CGM was only available to Medicare patients who take at least three doses of insulin a day, limiting CGM reimbursement for Medicare beneficiaries with intensive Type 1 and 2 diabetes. The Local Coverage Determination, or LCD, that CMS released in April 2023 extends Medicare CGM coverage to patients who use insulin at least once per day. Further, the LCD also allows coverage for patients not taking insulin if the patient has a history of problematic hypoglycemia.

Nevertheless, third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new and existing medical devices, and, as a result, they may be restrictive, or they may not cover or provide adequate payment for our products. In order to obtain additional reimbursement arrangements, including under pharmacy benefits, we may have to agree to a net sales price lower than the net sales price we might charge in other sales channels. Our revenue may be limited by the continuing efforts of government and third-party payors to contain or reduce the costs of healthcare through various increasingly sophisticated means, such as leveraging increased competition, increasing eligibility requirements such as second opinions and other documentation, purchasing in a bundle, or redesigning benefits. In December 2021, CMS published a final rule expanding the classification of DME under Medicare Parts B & C to include adjunctive CGMs (i.e., CGMs that do not replace standard blood glucose monitors for treatment decisions) and related supplies. This final rule expands coverage of CGMs to include a large competitor's competing device, which may negatively impact our sales. We are unable to predict what effect the current or any future healthcare reform will have on our business, or the effect these matters will have on our customers. Our dependence on the commercial success of our current CGM systems makes us particularly susceptible to any cost containment or reduction efforts. Accordingly, unless government and other third-party payors provide adequate coverage and reimbursement for our current CGM systems, people without coverage who have diabetes may not use our products. Furthermore, payors are increasingly basing reimbursement rates on factors such as prior approvals and the effectiveness of the product, clinical outcomes associated with the product, and any factors that negatively impact the effectiveness or clinical outcomes (or cause a perception of any such negative impact), such as the results of a clinical trial, a product defect, or a product recall, which could negatively impact the reimbursement rate. Also, the trends toward managed healthcare in the United States and legislative efforts intended to reduce the cost of government insurance programs could significantly influence the purchase of healthcare services and products and may result in lower prices for our products or the exclusion of our products from reimbursement programs.

In some foreign markets, pricing and profitability of medical devices are subject to government control. We are susceptible to changes in government-mandated coverage requirements and other controls which could impact access to and affordability of our products. In the United States, we expect that there will continue to be federal and state proposals for similar controls.

[Risks Related to Product Development](#)

The research and development efforts we undertake independently, and in some instances in connection with our collaborations with third parties, may not result in the development of commercially viable products, the generation of significant future revenues or adequate profitability.

In order to address the anticipated needs of our customers, pursue new markets for our existing products, and remain competitive, we focus our research and development efforts and strategic third-party collaboration activities on the enhancement of our current CGM products, the development of next-generation products and the development of novel technologies and services.

The development of new products, or novel technologies and services and the enhancement of our current CGM products (including seeking and potentially obtaining new indications for use), requires significant investment in research and development, intellectual property protection, clinical trials, regulatory approvals and third party reimbursement. The results of our product development and commercialization efforts may be affected by a range of factors, including our ability to anticipate customer needs, innovate and develop new products (whether independently or with our partners), determine a feasible or timely regulatory pathway or approach, and launch those products cost effectively into multiple markets and geographies. If we are unable to successfully anticipate customer needs, innovate, develop new products and successfully launch them, we may not be able to generate significant future revenues or profits from these efforts. Failing to timely launch our products may cause them to become obsolete and materially and adversely affect our business and financial position.

[Table of Contents](#)

The development and commercial launch timelines for our products depend a great deal on our ability to achieve clinical endpoints and satisfy regulatory requirements and to overcome technology challenges, and may be delayed due to scheduling issues with patients and investigators, requests from institutional review boards, or inquiries from regulators about our independent and collaborative product development activities, product performance and manufacturing supply constraints, among other factors. In addition,

support of these clinical trials requires significant resources from employees involved in the production of our products, including research and development, manufacturing, quality assurance, and clinical and regulatory personnel. Even if our development and clinical trial efforts appear successful to us and our regulatory submission appears satisfactory to us, the FDA may disagree and may decide not to grant marketing authorization for the products or may require additional product testing or clinical trials or other data to be developed and submitted before approving the products, which would result in product launch delays and additional expense. Even if a product receives marketing authorization from the FDA, it may not be accepted in the marketplace by physicians and people with diabetes.

In the ordinary course of our business we enter into collaborative arrangements with third parties to expand into new markets, including with insulin device manufacturers such as Eli Lilly, Insulet, Novo Nordisk, Tandem Diabetes and The Ypsomed Group to integrate our CGM technology into their insulin delivery systems. We have also entered into collaborations with several organizations that are currently using, or are developing, programs for the treatment of Type 2 diabetes that utilize our current CGM systems. As a result of these relationships, our operating results depend, to some extent, on the ability of our partners to successfully commercialize their insulin delivery systems or monitoring products. Any factors that may limit our partners' ability to achieve widespread adoption of their systems, including competitive pressures, technological breakthroughs for the treatment or prevention of diabetes, adverse regulatory or legal actions relating to insulin pump products, or changes in reimbursement rates or policies of third-party payors relating to insulin pumps or similar products, could have an adverse impact on our operating results.

Many of the companies that we collaborate with are also competitors or potential competitors who may decide to terminate our collaborative arrangement. In the event of such a termination, we may be required to devote additional resources to product development and commercialization, we may need to cancel some development programs and we may face increased competition. Additionally, collaborations may not result in the development of products that achieve commercial success and could be terminated prior to developing any products. Former collaborators may use the experience and insights they develop in the course of their collaborations with us to initiate or accelerate their development of products that compete with our products, which may create competitive disadvantages for us. Accordingly, we cannot provide assurance that any of our collaborations will result in the successful development of a commercially viable product or result in significant additional future revenues.

Our products may not achieve or maintain market acceptance.

We expect that sales of our current CGM systems will account for substantially all of our product revenue for the foreseeable future. If and when we receive FDA or other regulators' marketing authorization for, and begin commercialization of, our next-generation CGM systems, we expect most patients will migrate onto those systems. In the periods leading up to the launch of new or upgraded versions of our CGM systems, however, our customers' anticipation of the release of those products may cause them to cancel, change or delay current period purchases of our current products, which could have a material adverse effect on our business, financial condition and results of operations.

Notwithstanding our prior experience in marketing and selling our products, we might be unable to successfully expand the commercialization of our existing products or begin commercialization of our next-generation CGM systems on a wide-scale for a number of reasons, including the following:

- our G6 and G7 systems prompt the user to replace the sensor no later than the tenth day, which might make it expensive for users;
- widespread market acceptance of our products by physicians and people with diabetes will largely depend on our ability to demonstrate their relative safety, effectiveness, reliability, cost-effectiveness and ease of use;
- the limited size of our sales force;
- we may not have sufficient financial or other resources to adequately expand the commercialization efforts for our products;
- expanded coverage opportunities for our competitors' CGM devices and supplies, including coverage for adjunctive CGMs, increasing competition in the marketplace;

Table of Contents

- our FDA and other regulatory authority marketing application submissions and reviews may be delayed, or cleared or approved with limited product indications and labeling;
- we may not be able to manufacture our products in commercial quantities commensurate with demand or at an acceptable cost;
- for people with Type 2 diabetes, current reimbursement from third-party payors is generally limited to people on intensive insulin therapy;
- the uncertainties associated with establishing and qualifying new manufacturing facilities;
- people with diabetes may need to incur the costs of single-point finger stick devices, in addition to our systems;
- the relative immaturity of the CGM market internationally, and limited international reimbursement of CGM systems by third-party payors and government healthcare providers outside the United States;
- the introduction and market acceptance of competing products and technologies, which may have a lower cost or price, allow for a convenience improvement and/or allow for improved accuracy and reliability;
- the introduction and market acceptance of new drug therapies for the treatment and management of diabetes;
- greater name or brand recognition and more established medical product distribution channels by some of our competitors;
- our inability to obtain sufficient quantities of supplies timely and at appropriate quality levels from our single- or sole-source and other key suppliers;
- our inability to manufacture products that perform in accordance with expectations of consumers; and
- rapid technological change may make our technology and our products obsolete.

In addition to the risks outlined above, our G6 and G7 systems are more invasive than many other self-monitored glucose testing systems, including single-point finger stick devices, and people with diabetes may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, people with diabetes may not perceive the benefits of CGM and may be unwilling to change their current treatment regimens. Physicians may not recommend or prescribe our products unless and until (i) there is more long-term clinical evidence to convince them to alter their existing treatment methods, (ii) there are additional recommendations from prominent physicians that our products are effective in monitoring glucose levels, and (iii) reimbursement or insurance coverage is more widely available. In addition, market acceptance of our products by physicians and people with diabetes in Europe or other countries will largely depend on our ability to demonstrate their relative

safety, effectiveness, reliability, cost-effectiveness and ease of use. If we are unable to do so, we may not be able to generate product revenue from our sales efforts in Europe or other countries. We cannot predict when, if ever, healthcare professionals, including physicians, and people with diabetes may adopt more widespread use of CGM systems, including our systems. If our CGM systems do not achieve and maintain an adequate level of acceptance by people with diabetes, healthcare professionals, including physicians, and third party payors, our future revenue may be reduced and our business may be harmed.

Risks Related to Manufacturing, Commercial Operations and Commercialization

If our manufacturing capabilities are insufficient to produce an adequate supply of product at appropriate quality levels, our growth could be limited and our business could be harmed.

Our existing manufacturing facilities are designed to manufacture current and next-generation CGM systems, but may not be scaled quickly enough to permit us to manufacture one or more of our CGM systems in quantities sufficient to meet market demand. In the past, we have had difficulty scaling our manufacturing operations to provide a sufficient supply of product to support market demand and our commercialization efforts. From time to time, we have also experienced brief periods of backorder and, at times, have had to limit the efforts of our sales force to introduce our products to new customers.

We have focused significant effort on continual improvement programs in our manufacturing operations intended to improve quality, yields and throughput. We have made progress in manufacturing to enable us to supply adequate amounts of product to support our commercialization efforts; however, we cannot guarantee that supply will not be constrained in the future. We may not adequately predict the market demand for our products, in order to produce our products in the quantities we anticipate will be necessary to meet market demand. We will need to adequately predict the market demand for our products and increase our manufacturing capacity by a significant factor over the current level to meet or exceed the anticipated market demand by product. In addition, we may have

Table of Contents

to modify our manufacturing design, reliability and process for next-generation products that may hereafter be approved, cleared or otherwise authorized by the applicable regulatory body and commercialized.

There are technical challenges to increasing manufacturing capacity, including equipment design, automation, validation and installation, contractor issues and delays, licensing and permitting delays or rejections, materials procurement, manufacturing site expansion, problems with production yields and quality control and assurance. Continuing to develop commercial-scale manufacturing facilities will require the investment of substantial additional funds and the hiring and retention of additional management, quality assurance, quality control and technical personnel who have the necessary manufacturing experience. Delays in the launch of next-generation products may result in unanticipated continuing increases in demand for current-generation products (to substitute for the unavailability of the next-generation products) which, if not adequately prepared for, may result in deficits in our ability to produce adequate amounts of the prior-generation products to meet demand at appropriate prices.

The scaling of manufacturing capacity is subject to numerous risks and uncertainties, and may lead to variability in product quality or reliability, increased construction timelines, as well as resources required to design, install and maintain manufacturing equipment, among others, all of which can lead to unexpected delays in manufacturing output. In addition, any changes to our manufacturing processes may trigger the need for submissions or notifications to, and in some cases advance approval from, the FDA or other regulatory authorities because of the potential impact of changes on our previously cleared, approved and/or authorized devices. Our facilities are subject to inspections by the FDA and corresponding state agencies on an ongoing basis, and we must comply with Good Manufacturing Practices and the FDA Quality System Regulation, as well as certain state requirements. We may be unable to adequately maintain, develop and expand our manufacturing process and operations or maintain compliance with FDA and state agency requirements, and manufacturing issues could impact our cleared and approved products. If we are unable to manufacture a sufficient supply of our current products or any future products for which we may receive approval or clearance, maintain control over expenses or otherwise adapt to anticipated growth, or if we underestimate growth, we may not have the capability to satisfy market demand, contractual obligations, and our business will suffer.

Manufacturing difficulties and/or any disruption at our facilities may adversely affect our manufacturing operations and related product sales, and increase our expenses.

Our products are manufactured at certain facilities, with limited alternate facilities. If an event occurs at one of our facilities that results in damage to, restrictions on the use of, or closure of, one or more of such facilities, or if our distributions from those facilities are limited or restricted in any way, we may be unable to manufacture the relevant products at the previous levels or at all. Because of the time required to approve and lease a manufacturing facility, an alternate facility and/or a third-party may not be available on a timely basis to replace production capacity in the event manufacturing capacity is lost.

Additionally, the majority of our operations are conducted at facilities located in San Diego, California, Mesa, Arizona and, beginning in 2023, Penang Malaysia. We take precautions to safeguard our facilities, which include manufacturing protocols, insurance, health and safety protocols, and off-site storage of data. However, a natural or man-made disaster, such as fire, flood, earthquake, act of terrorism, cyber-attack or other disruptive event, such as a public health emergency, could cause substantial delays in our operations, damage, destroy or limit our manufacturing equipment, inventory, or records and cause us to incur additional expenses. Earthquakes are of particular significance since our manufacturing facilities in California are located in an earthquake-prone area. Wildfires are also increasingly more common in southern California and present risk to our manufacturing operations. Our Arizona facility may confront water supply issues resulting from the ongoing drought in the Western United States and our Malaysia facility may confront issues related to its construction on a reclaimed wetland and the political stability of the Malaysia government. In the event our existing manufacturing facilities or equipment are affected by man-made or natural disasters, we may be unable to manufacture products for sale or meet customer demands or sales projections. If our manufacturing operations were curtailed or ceased, it would seriously harm our business. The insurance we maintain against fires, floods, earthquakes and other natural disasters and similar events may not be adequate to cover our losses in any particular case.

We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our business.

We manufacture the majority of our products and procure important third-party services, such as sterilization services, at numerous facilities worldwide. We purchase many of the components, materials and services needed to manufacture these products from numerous suppliers in various countries. We have generally been able to obtain adequate supplies of such materials, components and services. However, we also rely on single and/or sole sources for certain components and materials used in manufacturing, such as for the application-specific integrated

Table of Contents

circuit that is incorporated into the transmitter and certain polymers used to synthesize the polymeric biointerface membranes for our products. In some cases, our agreements with these and other suppliers can be terminated by either party upon short notice. Our contract manufacturers may also rely on single- or sole- source suppliers to manufacture some of the components used in our products.

Although we work with our suppliers to try to ensure continuity of supply while maintaining quality, timeliness and reliability, the supply of these components, materials and services has in some cases been, and may continue to be impacted, interrupted or insufficient. Our manufacturers and suppliers may also encounter problems during manufacturing for a variety of reasons. They may fail to follow specific protocols and procedures, fail to comply with applicable regulations, or be the subject of FDA or other regulatory authority audits or inspections that result in allegations of non-compliance (for example, resulting in Form 483 Observations, Warning Letters, or other FDA enforcement actions). Our manufacturers and suppliers may also experience or be impacted by equipment malfunction, environmental factors, and public health emergencies, any of which could delay or impede their ability to meet our demand.

Further, if our sole- or single-source suppliers shift their manufacturing and assembly sites to other locations, depending on the circumstances and nature of the item supplied, in addition to quality system activities such as verification and validation, there could be a need for FDA notifications or submissions, and the new locations could be subject to regulatory inspections. If there are regulatory delays or impediments impacting our suppliers or us for any reason, we may not be able to quickly establish additional or replacement suppliers, particularly for our single-source components, in part because of the custom nature of various parts we design. Any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers and cause them to cancel orders or switch to competitive products.

Our reliance on these outside manufacturers and suppliers also subjects us to other risks that could harm our business, including:

- we may experience a reduction or interruption in supply, and may not be able to obtain adequate supply in a timely manner or on commercially reasonable terms from additional or replacement sources;
- our products are technologically complex and it is difficult to develop alternative supply sources;
- we are not a major customer of many of our suppliers, and these suppliers may therefore give other customers' needs higher priority than ours;
- our suppliers may make errors in manufacturing components that could negatively affect the quality, effectiveness or safety of our products or cause delays in shipment of our products;
- we may have difficulty locating and qualifying alternative suppliers for our single-source supplies;
- switching components may require product redesign and submission to the FDA of new applications (such as new 510(k) submissions or PMA supplements) which could significantly delay production;
- our suppliers manufacture products for a range of customers, and fluctuations in demand for the products these suppliers manufacture for others may affect their ability to deliver components to us in a timely manner or at the current pricing;
- our suppliers may discontinue the production of components that are critical to our products; and
- our suppliers may encounter financial and/or other hardships unrelated to our demand for components, including those related to changes in global economic conditions and/or disease outbreaks, which could inhibit their ability to fulfill our orders and meet our requirements.

We also outsource certain services to other parties, including inside sales, certain transaction processing, accounting, information technology, manufacturing, and other areas. Outsourcing of services to third parties could expose us to suboptimal quality of service delivery or deliverables and potentially result in repercussions such as missed deadlines or other timeliness issues, erroneous data, supply disruptions, non-compliance (including with applicable legal or regulatory requirements and industry standards) and/or reputational harm, with potential negative effects on our results.

We also require the suppliers, service providers and business partners of components or services for our products and related services to comply with law and certain of our policies regarding sourcing practices, but we do not control them or their practices. If any supplier, service provider or business partner violates laws or implements unethical practices, there could be disruptions to our supply chain, cancellation of our orders, a termination of the relationship with the partner or damage to our reputation, and the FDA or other regulators could seek to hold us responsible for such violations.

Table of Contents

If we are unable to establish and maintain adequate sales, marketing and distribution capabilities or enter into and maintain arrangements with third parties to sell, market and distribute our products, we may have difficulty achieving market awareness and selling our products in the future.

We must continue to develop and grow our sales and marketing organization and enter into partnerships or other arrangements to market and sell our products and/or collaborate with third parties, including distributors and others, to market and sell our products to maintain the commercial success of our current systems and to achieve commercial success for any of our future products. If we are unable to establish and maintain adequate sales, marketing and distribution capabilities, independently or with others, our future revenue may be reduced and our business may be harmed.

Developing and managing a direct sales organization is a difficult, expensive and time-consuming process.

To continue to develop our sales and marketing organization to successfully achieve market awareness and sell our products, we must:

- recruit and retain adequate numbers of effective and experienced sales and marketing personnel;
- effectively train our sales and marketing personnel in the benefits and risks of our products;

- establish and maintain successful sales, marketing, training and education programs that educate health care professionals, including endocrinologists, physicians and diabetes educators, so they can appropriately inform their patients about our products;
- manage geographically dispersed sales and marketing operations; and
- effectively train our sales and marketing personnel on the applicable advertising and promotion, and fraud and abuse laws that govern interactions with healthcare professionals and institutions as well as current and prospective patients and maintain active oversight and auditing measures to ensure continued compliance.

We currently employ sales and marketing personnel for the direct sale and marketing of our products in North America, Asia Pacific, Europe and the Middle East. Our direct sales and marketing team calls on healthcare providers and people with diabetes throughout the applicable country, to the extent permissible, to raise awareness and initiate sales of our products. Our sales and marketing organization competes with the experienced, larger and well-funded marketing and sales operations of our competitors. We may not be able to successfully manage our dispersed sales force or increase our product sales at acceptable rates.

We have also entered into distribution arrangements to leverage existing distributors (including wholesalers) already engaged in the distribution of drugs, devices and/or products in the diabetes marketplace. Some of our U.S distributors are focused on accessing underrepresented regions and or third-party payors that contract exclusively with distributors in the United States, while some of our international distributors call directly on healthcare providers and patients to market and sell our products. Because of the competition for their services, we may be unable to partner with or retain additional qualified distributors. Further, we may not be able to enter into agreements with distributors on commercially reasonable terms, if at all. Our distributors might not have the resources to continue to support our recent rapid growth.

Our distribution agreements with AmerisourceBergen, Byram and affiliates, Cardinal Health and affiliates (including Edgepark Medical Supplies), and McKesson, our most significant wholesalers and distributors, each generated 10% or more of our total revenue during the nine months ended September 30, 2023. We cannot guarantee that these relationships will continue or that we will be able to maintain this volume of sales from these relationships in the future. A substantial decrease or loss of these sales could have a material adverse effect on our financial results and operating performance.

We have entered into arrangements with pharmacy organizations in various countries to dispense our products directly to patients. Because of the competition for their services, we may be unable to enter into new partnerships or otherwise expand our pharmacy network on commercially reasonable terms, if at all. In addition, we cannot guarantee that our existing pharmacy relationships will continue, or that we will be able to maintain or increase sales volume from these relationships in the future.

To the extent that we enter into additional arrangements with third parties to perform sales, marketing, distribution and billing services, our product margins could be lower than if we directly marketed and sold our products. To the extent that we enter into co-promotion or other marketing and sales arrangements with other companies, any revenue received will depend on the skills and efforts of others, and we cannot predict whether these efforts will be successful.

Table of Contents

If we do not adequately predict market demand or otherwise optimize and operate our distribution channel successfully, it could result in excess or insufficient inventory or fulfillment capacity, increased costs, immediate shortages in product or component supply, or harm our business in other ways.

We operate in a highly competitive market and face competition from large, well-established companies with significant resources, and, as a result, we may not be able to compete effectively.

The market for glucose monitoring devices is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants, including enhanced software capabilities, and related data and IT platforms. Our products are based on our proprietary technology, but a number of companies and medical researchers are pursuing new technologies for the monitoring of glucose levels. FDA or other regulatory approval of a commercially viable continuous glucose monitor or sensor produced by one of our competitors could significantly reduce market acceptance of our systems. In addition, certain development efforts throughout the diabetes industry, including that of the National Institutes of Health and other supporters of diabetes research are continually seeking ways to prevent, cure or improve treatment of diabetes. Therefore, our products may be rendered obsolete by technological breakthroughs in diabetes monitoring, treatment, prevention or cure.

In selling our current CGM systems, we compete directly with the Diabetes Care division of Abbott Laboratories; Medtronic plc's Diabetes Group; Roche Diabetes Care, a division of Roche Diagnostics; privately-held LifeScan, Inc.; and Ascensia Diabetes Care, each of which manufactures and markets products for the single-point finger stick device market. Collectively, these companies currently account for the majority of the worldwide sales of self-monitored glucose testing systems.

Our competitors manufacturing adjunctive CGMs have also recognized expanded Medicare coverage of their CGM devices and supplies following CMS' December 2021 final rule expanding the classification of DME under Medicare Parts B & C to include adjunctive CGMs. These devices now directly compete with our CGM products in the Medicare market.

Several companies are developing and/or commercializing products for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin that compete directly with our products. We have competed with Abbott for several years and their Libre family of CGM products. Medtronic markets and sells one or more standalone glucose monitoring products both internationally and in the United States.

Medtronic and other third parties have developed or are developing insulin pumps integrated with CGM systems that provide, among other things, the ability to suspend insulin administration while the user's glucose levels are low and to automate basal and bolus insulin dosing.

We are also aware of companies outside the traditional medical device sector that are attempting to develop competitive products and services, including for general health and wellness, or population health.

Some of the companies developing or marketing competing devices are large and well-known publicly traded companies, and these companies may possess competitive advantages over us, including:

- greater name recognition;
- established relations with healthcare professionals, customers and third-party payors;
- established distribution networks;
- additional lines of products, and the ability to bundle products to offer higher discounts or incentives to gain a competitive advantage;

- greater experience in conducting research and development, manufacturing, clinical trials, obtaining regulatory approval for products and marketing approved products;
- duration of sensor life;
- the ability to integrate multiple products to provide additional features beyond CGM systems; and
- greater financial and human resources for product development, manufacturing, sales and marketing, and patent litigation.

As a result, we may not be able to compete effectively against these companies or their products, which may adversely impact our business.

[Table of Contents](#)

We are subject to risks associated with public health issues, including pandemics, which could have a material adverse effect on our business, financial condition and results of operations.

We are subject to risks associated with public health issues, such as the recent COVID-19 pandemic, and other events beyond our control. Public health issues and crises may adversely impact our operations, supply chain and logistics network if the locations where we operate, manufacture or distribute our products; where our raw materials or products are sourced, manufactured or distributed; or where our third-party distributors, suppliers and other service providers operate, are disrupted, temporarily closed or experience worker shortages for a sustained period of time. In addition, public health issues and crises may adversely impact our customers and/or their businesses due to lockdowns, labor shortages, lost access to private health insurance plans or modified spending priorities, all of which could cause a decline in demand for our products. These disruptions could also cause economic slowdowns or increased economic uncertainty.

While we largely navigated disruptions to our business as a result of the COVID-19 pandemic, a future public health issue, pandemic or outbreak of COVID-19 could lead to delays in the manufacturing and supply of products, which could have a material adverse effect on our business, financial condition and results of operations. Moreover, any future public health issue, such as a resurgence in COVID-19 infections, including due to new variants of the virus for which current vaccines may not be effective, could result in the imposition of new governmental restrictions, quarantine requirements or other measures to slow the spread of the virus, which could result in closures or other restrictions that significantly disrupt our operations or those of our third-party distributors, suppliers or other service providers, or otherwise adversely affect our customers or their businesses or operations, or result in economic weakness or slowdowns in one or more of our key geographies, any of which could adversely affect our business, financial condition and results of operations.

Risks Related to our International Operations

We are subject to a variety of risks due to our international operations that could adversely affect our business, our operations or profitability and operating results.

Our operations in countries outside the United States, which accounted for approximately 28% of our revenue for the nine months ended September 30, 2023, are accompanied by certain financial and other risks. In addition to our offices with manufacturing and administrative and operations in countries throughout the world, we intend to continue to pursue growth opportunities in sales outside the United States, especially in Asia and Europe. Additionally, we may increase our use of administrative and support functions from locations outside the United States. These business activities could expose us to greater risks associated with our sales and operations.

As we pursue opportunities outside the United States, we may become more exposed to these risks and our ability to scale our operations effectively may be affected. For example, we are building out a manufacturing facility in Malaysia.

Our international expansion efforts, including our new and proposed manufacturing facilities in Malaysia and Ireland, respectively, may not be successful and we may experience difficulties in scaling these functions from locations outside the United States and may not experience the expected cost efficiencies.

Our profitability and international operations are, and will continue to be, subject to a number of risks and potential costs, including:

- local product preferences and product requirements;
- longer-term receivables than are typical in the United States;
- fluctuations in foreign currency exchange rates;
- less intellectual property protection in some countries outside the United States than exists in the United States;
- trade protection measures and import and export licensing requirements;
- workforce instability;
- fluctuations in trade policy and tariff regulations; and
- political and economic instability.

Moreover, the tax laws in which we and our subsidiaries do business could change on a prospective or retroactive basis, and any such changes could adversely affect our business and financial condition. We have a significant presence in the European Union, as well as significant sales in the European Union, such that any changes in tax laws in the European Union will impact our business. The overall impact of such legislation in

[Table of Contents](#)

European Union member states is uncertain, and our business and financial condition could be adversely affected by any laws impacting our tax rate.

While it is impossible for us to predict whether these and other proposals will be implemented, or how they will ultimately impact us, they may materially impact our results of operations if, for example, our profits earned abroad are subject to U.S. income tax, or we are otherwise disallowed deductions as a result of these profits.

Changes in foreign currency exchange rates may reduce the reported value of our foreign currency denominated revenues, expenses, and cash flows. We cannot predict changes in currency exchange rates, the impact of exchange rate changes, nor the degree to which we will be able to manage the impact of currency exchange rate changes.

Following a 2016 referendum of voters in the United Kingdom, or the U.K., to exit from the European Union, or the E.U., the U.K. left the E.U. on January 31, 2020, which began a transition period that ended on December 31, 2020. In December 2020, the U.K. and E.U. agreed on a trade and cooperation agreement that was ratified by the parties in May 2021. The agreement sets out certain procedures for approval and recognition of medical products in each jurisdiction. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of the trade and cooperation agreement or otherwise, could prevent us from marketing our CGM systems in the U.K. and/or the E.U. and restrict our ability to generate revenue and achieve and sustain profitability. Under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire E.U. single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the U.K. and the E.U. Depending on the application of the terms of the trade and cooperation agreement, we could face new regulatory costs and challenges which could have a material adverse effect on our business, results of operations, or financial condition.

Laws and regulations governing the export of our products could adversely impact our business.

The U.S. Department of the Treasury's Office of Foreign Assets Control, and the Bureau of Industry and Security at the U.S. Department of Commerce, administer certain laws and regulations that restrict U.S. persons and, in some instances, non-U.S. persons, in conducting activities, and transacting business with or making investments in certain countries, governments, entities and individuals subject to U.S. economic sanctions. Due to our international operations, we are subject to such laws and regulations, which are complex, restrict our business dealings with certain countries and individuals, and are constantly changing. Further restrictions may be enacted, amended, enforced or interpreted in a manner that materially impacts our operations.

Violations of these regulations are punishable by civil penalties, including fines, denial of export privileges, injunctions, asset seizures, debarment from government contracts and revocations or restrictions of licenses, as well as criminal fines and imprisonment. We have established procedures designed to assist with our compliance with such laws and regulations. However, we have only limited experience dealing with these laws and regulations and we cannot guarantee that our procedures will effectively prevent us from violating these regulations in every transaction in which we may engage. Any such violation could adversely affect our reputation, business, financial condition and results of operations.

The failure to comply with U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws in non-U.S. jurisdictions could materially adversely affect our business and result in civil and/or criminal sanctions.

The U.S. Foreign Corrupt Practices Act, the UK Bribery Act and similar worldwide anti-bribery laws in non-U.S. jurisdictions generally prohibit companies and their intermediaries from making improper payments to non-U.S. government officials and, in some instances, other persons for the purpose of obtaining or retaining business. Because of the predominance of government-sponsored healthcare systems around the world, most of our customer relationships outside of the United States are with governmental entities and are therefore potentially subject to such anti-bribery laws. Global enforcement of anti-corruption laws has increased substantially in recent years, with more frequent voluntary self-disclosures by companies, aggressive investigations and enforcement proceedings by U.S. and foreign governmental agencies, and assessment of significant fines and penalties against companies and individuals. Our international operations create the risk of unauthorized payments or offers of payments by one of our employees, consultants, sales agents, or distributors, because these parties are not always subject to our direct oversight and control. It is our policy to implement safeguards to educate our employees and agents on these legal requirements and discourage improper practices. However, our existing safeguards and any future improvements may prove to be less than effective, and our employees, consultants, sales agents, or distributors may engage in conduct for which we might be held responsible. In addition, the government agencies may seek to hold us liable for successor liability for anti-corruption law violations committed by any companies in which we invest or that we acquire. Any alleged or actual violations of these regulations may subject us to

Table of Contents

government scrutiny, severe criminal or civil sanctions and other liabilities, including exclusion from government contracting, and could disrupt our business, and result in a material adverse effect on our business, financial condition, and results of operations.

Current uncertainty in global economic and political conditions makes it particularly difficult to predict product demand and other related matters and makes it more likely that our actual results could differ materially from expectations.

Our operations and performance depend on worldwide economic and political conditions. These conditions have been adversely impacted by continued global economic uncertainty, political instability and military hostilities in multiple geographies, including the current conflict in Ukraine, concerns over continued sovereign debt, monetary and financial uncertainties in Europe and other foreign countries, and global health pandemics. These include potential reductions in the overall stability and suitability of the Euro as a single currency, given the economic and political challenges facing individual Eurozone countries. These conditions have made and may continue to make it difficult for our customers and potential customers to afford our products, and could cause our customers to stop using our products or to use them less frequently. If that were to occur, our revenue may decrease and our performance may be negatively impacted. In addition, the pressure on consumers to absorb more of their own health care costs has resulted in some cases in higher deductibles and limits on durable medical equipment, which may cause seasonality in purchasing patterns. Furthermore, during economic uncertainty, our customers have had job losses and may continue to have issues gaining timely access to sufficient health insurance or credit, which could result in their unwillingness to purchase products or impair their ability to make timely payments to us. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect our access to capital on favorable terms or at all, our business and the value of our common stock.

We cannot predict the reoccurrence of any economic slowdown or the strength or sustainability of the economic recovery, worldwide, in the United States, or in our industry. These and other economic factors could have a material adverse effect on our business, financial condition and results of operations.

Failure to obtain any required regulatory authorization in foreign jurisdictions will prevent us from marketing our products abroad.

We conduct limited commercial and marketing efforts in certain international markets in the Asia-Pacific, North America and Europe, Middle East and Africa regions, with respect to our CGM systems and may seek to market our products in other regions in the future. Outside the United States, we can market a product only if we receive a marketing authorization and, in some cases, pricing approval, from the appropriate regulatory authorities. The marketing authorization procedures vary among countries and can involve additional testing, and the time required to obtain any required authorization or approval may differ from that required to obtain FDA marketing authorization(s). Foreign regulatory authorization or approval processes may include all of the risks associated with obtaining FDA marketing authorization(s) in addition to other risks. We may not obtain

foreign regulatory authorizations or approvals on a timely basis, if at all. Obtaining a marketing authorization from the FDA does not ensure authorization or approval by regulatory authorities in other countries will follow, and authorization or approval by one foreign regulatory authority does not ensure authorization or approval by regulatory authorities in other foreign countries or by the FDA. In addition, in order to obtain the authorization to market our products in certain foreign jurisdictions, in some cases we may need to obtain a Certificate to Foreign Government from the FDA. The FDA may refuse to issue a Certificate to Foreign Government if significant compliance-related concerns are identified. As a result, there are a range of factors that could preclude or impede our ability to file for regulatory approvals or marketing authorizations or to receive necessary approvals or authorizations to commercialize our products in any market outside the United States on a timely basis, or at all.

Risks Related to Privacy and Security

We are subject to complex and evolving U.S. and foreign laws and regulations and other requirements regarding privacy, data protection, security, and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.

We are subject to a number of foreign, federal and state laws and regulations protecting the use, disclosure, and confidentiality of certain patient health and personal information, including patient records, and restricting the use and disclosure of that protected information, including state breach notification laws, the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, the European Union's General Data Protection Regulation, or GDPR, the UK Data

Table of Contents

Protection Act and the UK GDPR, and the California Consumer Privacy Act, or CCPA, among others. As our customer base grows to include U.S. federal government agencies, Dexcom may also need comply with Federal Risk and Authorization Management Program and Cybersecurity Maturity Model Certification requirements. These frameworks, in addition to similar laws being enacted by other states and counties, impose stringent cybersecurity standards and potentially significant non-compliance penalties, involve the expenditure of significant resources, the investment of significant resources and the investment of significant time and effort to comply. As these laws and regulations continue develop in the United States and internationally, we may be required to expend significant time and resources in order to update existing processes or implement additional mechanisms as necessary to ensure compliance with such cybersecurity laws.

In addition, foreign data protection, privacy, and other laws and regulations can be more restrictive than those in the United States. For example, data localization laws in some countries generally mandate that certain types of data collected in a particular country be stored and/or processed within that country. We may be subject to inquiries, investigations and audits in Europe and around the world, particularly in the areas of consumer and data protection, which will arise in the ordinary course of business and may increase in frequency as we continue to grow and expand our operations. Legislators and regulators may make legal and regulatory changes, or interpret and apply existing laws, in ways that make our products less useful to our customers, require us to incur substantial costs, expose us to unanticipated civil or criminal liability, or cause us to change our business practices. These changes or increased costs could negatively impact our business and results of operations in material ways.

In the ordinary course of our business, we collect and store sensitive data, such as our proprietary business information and that of our clients, contractors, vendors and others as well as personally identifiable information of our customers, vendors and others, which data may include full names, social security numbers, addresses, and birth dates, in our data centers and on our networks. Our employees, contractor and vendors may also have access to and may use personal health information in the ordinary course of our business. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures and business controls, our information technology and infrastructure may be vulnerable to attacks by hackers, breaches due to employee, contractor or vendor error, or malfeasance or other disruptions or subject to the inadvertent or intentional unauthorized release of information. Any such occurrence could compromise our networks and the information stored thereon could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, and liability under laws that protect the privacy of personal information and regulatory penalties, disrupt our operations and the services we provide to our clients or damage our reputation, any of which could adversely affect our profitability, revenue and competitive position.

As we grow and expand our administrative, customer support or IT support services, we may also utilize the services of personnel and contractors located outside of the United States to perform certain functions. While we make every effort to review our applicable contracts and other payor requirements, a local, state, or federal government agency or one of our customers may find the use of offshore resources to be a violation of a legal or contractual requirement, which could result in termination of the contractual relationship, penalties, or changes in our business operations that could adversely affect our business, financial condition, and results of operations. Additionally, while we have implemented industry standard security measures for offshore access to protected health information and other personal information, unauthorized access or disclosure of such information by offshore personnel could result in legal claims or proceedings, and liability under laws that protect the privacy of personal information and regulatory penalties, disrupt our operations and the services we provide to our clients, damage to our reputation or result in the termination of contractual relationships, penalties or the loss of coverage, any of which could adversely affect our profitability, revenue and competitive position.

Security breaches and other disruptions that compromise our information and expose us to liability could cause our business and reputation to suffer and could subject us to substantial liabilities.

The Administrative Simplification Provisions of the Health Insurance Portability and Accountability Act of 1996, as amended and implemented, or HIPAA, extensively regulates the use and disclosure of certain personal information ("protected health information") and requires covered entities, including health plans and most health care providers, to implement administrative, physical and technical safeguards to protect the security of such information. Certain provisions of the security and privacy regulations apply to business associates (entities that handle protected health information on behalf of covered entities), and business associates are subject to direct liability for violation of these provisions. In addition, a covered entity may be subject to penalties as a result of a business associate violating HIPAA, if the business associate is found to be an agent of the covered entity. Dexcom is a covered entity under HIPAA and may also function in a business associate capacity to other covered entities.

Covered entities must report breaches of unsecured protected health information to affected individuals without unreasonable delay and notification must also be made to the U.S. Department of Health & Human Services, Office

Table of Contents

for Civil Rights, or OCR and, in certain situations involving large breaches, to the media. Various U.S. state laws and regulations may also require us to notify affected individuals and state agencies in the event of a data breach involving individually identifiable information.

Violations of the HIPAA privacy and security regulations may result in criminal and civil penalties. The OCR enforces the regulations and performs compliance audits. In addition to enforcement by OCR, state attorneys general are authorized to bring civil actions seeking either injunction or damages in response to violations that threaten the privacy of state residents. We follow and maintain a HIPAA compliance plan, which we believe complies with the HIPAA privacy and security regulations, but there can be no assurance that OCR or other regulators will agree. The HIPAA privacy regulations and security regulations have and will continue to impose significant costs on us in order to comply with these standards.

There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. For example, from time-to-time, the OCR issues bulletins that outline its interpretations of HIPAA as applied to specific use cases. On December 1, 2022, OCR issued a bulletin on the requirements under HIPAA for online tracking technologies (e.g., cookies, pixels) to protect the privacy and security of health information. This bulletin outlined OCR's position on the use of online tracking technology vendors, when certain information received by such vendors constitutes protected health information under HIPAA, and accordingly, when business associate agreements must be executed between covered entities, like Dexcom, and such vendors. Dexcom has assessed its responsibilities under the bulletin and undertaken a number of initiatives to support its compliance with HIPAA and other requirements relating to online tracking technologies, including updates to its cookie banners and preference center. These steps are in addition to measures Dexcom had taken previously and the company continues to evaluate its compliance with applicable laws and adjust its practices to address developments in the field over time.

We also remain subject to federal or state privacy-related laws outside of the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties. For example, the Federal Trade Commission uses its consumer protection authority to initiate enforcement actions in response to alleged privacy and data security violations. California enacted the CCPA, which came into effect January 1, 2020, was amended and expanded by the CPRA, passed on November 3, 2020, which took effect January 1, 2023. The CCPA and CPRA, among other things, create data privacy obligations for covered companies and provide privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. In addition, other states have, or may, enact similar legislation. It remains unclear what, if any, additional modifications will be made to this legislation or how it will be interpreted. The effects of the CCPA and CPRA are significant and will likely require us to modify our data processing practices, and may cause us to incur substantial costs and expenses to comply, particularly given our base of operations in California. There are also a number of other legislative proposals worldwide, including in the United States at both the federal and state level, that could impose additional and potentially conflicting obligations in areas affecting our business.

We are also subject to laws and regulations in foreign countries covering data privacy and other protection of health and employee information that may be more onerous than corresponding U.S. laws, including in particular the laws of Europe.

For instance, in the European Union, increasingly stringent data protection and privacy rules that have and will continue to have substantial impact on the use of patient data across the healthcare industry became effective in May 2018. The GDPR applies across the European Union and includes, among other things, a requirement for prompt notice of data breaches to data subjects and supervisory authorities in certain circumstances and significant fines for non-compliance. The GDPR fine framework can be up to 20 million euros, or up to 4% of the company's total global turnover of the preceding fiscal year, whichever is higher. The GDPR also requires companies processing personal data of individuals residing in the European Union to comply with EU privacy and data protection rules, even if the company itself does not have a physical presence in the European Union. Noncompliance could result in the imposition of fines, penalties, or orders to stop noncompliant activities. Due to the strong consumer protection aspects of the GDPR, companies subject to its purview are allocating substantial legal costs to the development of necessary policies and procedures and overall compliance efforts. Data transfer risk remains a potential issue as certain Data Protection Authorities continue to raise concerns about the transfer of data to the United States. Though a new framework to permit cross-border transfers - the EU-US Data Privacy Framework - came into effect in 2023, it may be challenged as well. We expect continued costs associated with maintaining compliance with GDPR into the future, and these provisions as interpreted by EU agencies, could negatively impact our business, financial condition and results of operations.

Table of Contents

In addition to the laws discussed above, we may see more stringent state and federal privacy legislation in the future. We cannot predict where new legislation might arise, the scope of such legislation, or the potential impact to our business and operations.

Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations.

There are numerous and evolving risks to our cybersecurity and privacy from cyber threat actors. These cyber threat actors, whether internal or external to the Company, are becoming more frequent, sophisticated and coordinated in their attempts to access data, including third parties with whom the Company conducts business through, without limitation, malicious software; data privacy breaches by employees, insiders or others with authorized access; cyber of phishing-attacks; ransomware; attempts to gain unauthorized access to our data and systems; and other electronic security breaches. In the ordinary course of business, we collect and store sensitive information on our network, including intellectual property, proprietary business information and personally identifiable information of individuals, such as our customers and employees. The secure maintenance of this information and technology is critical to our business operations. We have implemented and deploy multiple layers of security measures to protect the confidentiality, integrity and availability of this data and the systems and devices that store and transmit such data. We utilize current security technologies, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, threats from malicious persons and groups, new vulnerabilities and advanced new attacks against information systems create risk of cybersecurity incidents. These incidents can include, but are not limited to, gaining unauthorized access to digital systems for purposes of misappropriating assets or sensitive information, corrupting data, or causing operational disruption. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may not immediately produce signs of intrusion, we may be unable to anticipate these incidents or techniques, timely discover them, or implement adequate preventative measures.

Additionally, in response to the onset of the COVID-19 pandemic, we modified our business practices and initially implemented telework policies for certain categories of "non-essential" employees to the extent possible. We have since adopted a hybrid workplace model for our employees. Our hybrid workplace allows us to work together globally to bring our life-changing products to as many people as possible. This means we have some employees who work primarily onsite, some who work primarily offsite, and others who flex in and out of the office based on the needs of the business and the individual. We recognized the need for flexibility in our physical workplace during the COVID-19 pandemic, but also noted the potential benefits of a hybrid workplace to expand and retain our talent pool and reduce our real estate needs. The hybrid workplace does, however, introduce additional operational risk, including increased cybersecurity risk. These cyber risks include, among other risks, increased phishing, malware, and other cybersecurity attacks, vulnerability to, or disruptions of, our information technology infrastructure and systems to support remote operations, increased risk of unauthorized access, use or dissemination of confidential information, limited ability to restore the systems in the event of a systems failure or interruption, greater risk of a security breach resulting in destruction, alteration or misuse of valuable information, including proprietary business information and personally identifiable information of individuals, all of which could expose us to risks of data or financial loss, litigation and liability.

These threats can come from a variety of sources, including criminal hackers, state-sponsored intrusions, industrial espionage and employee malfeasance. Cyber threats may be generic, or they may be custom-crafted against our information systems. Over the past several years, cyberattacks have become more prevalent and much harder to detect and defend against. These threat actors may be able to penetrate our security measures, breach our information technology systems, misappropriate or compromise confidential and proprietary information of our company and our customers, cause system disruptions and shutdowns, or introduce ransomware, malware, or vulnerabilities into our products, systems, and networks or those of our customers and partners. Our network and storage applications, as well as those of our contractors, may be vulnerable to cyber-attack, malicious intrusion, malfeasance, loss of data privacy or other significant disruption and may be subject to unauthorized access by hackers, employees, consultants or other service providers. In addition, hardware, software or applications we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security or other problems that unexpectedly could interfere with the operation of our products. Unauthorized parties may also attempt to gain access to our systems or facilities through fraud, trickery or other forms of deceiving our employees, contractors and temporary staff.

Table of Contents

While we maintain cybersecurity insurance coverage there is no guarantee that it will be sufficient to cover the financial, legal, business, or reputational losses that may result from an interruption or breach of our systems. Our cybersecurity insurance includes coverage for a breach event covering expenses for notification, credit monitoring, investigation, crisis management, public relations and legal advice. Our cybersecurity insurance also provides coverage in relation to regulatory action defense including oversight, investigations and disclosure obligations as well as fines and penalties, potential payment card industry fines and penalties and costs related to cyber extortion; however, damages and claims arising from such incidents may not be covered and/or may exceed the amount of any coverage and do not cover the time and effort we incur investigating and responding to any incidents, which may be significant.

We are and may continue to be subject to cybersecurity incidents that bypass our security measures. Such incidents may impact the integrity, availability or privacy of personal health information or other data subject to privacy laws or disrupt our information systems, devices or business, including our ability to deliver services to our customers. As a result, cybersecurity, physical security and the continued development and enhancement of our controls, processes and practices designed to protect our enterprise, information systems and data from attack, damage or unauthorized access remain a priority for us. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any cybersecurity vulnerabilities. The occurrence of any of these events could result in:

- harm to customers;
- business interruptions and delays;
- the loss, misappropriation, corruption or unauthorized access of data, confidential information or intellectual property;
- litigation, including potential class action litigation, and potential liability under privacy, security and consumer protection laws or other applicable laws;
- reputational damage;
- significant remediation costs, including liability for stolen customer or employee information, repairing system damage, or providing benefit to affected customers or employees;
- increase to insurance premiums; and
- foreign, federal and state governmental inquiries, violations or sanctions, any of which could have a material, adverse effect on our financial position and results of operations.

Failure to protect our information technology infrastructure against cyberattacks, network security breaches, service interruptions, or data corruption could significantly disrupt our operations and adversely affect our business and operating results.

We rely on information technology and telephone networks and systems, including the Internet, to process and transmit sensitive electronic information and to manage or support a variety of business processes and activities, including sales, billing, customer service, procurement and supply chain, manufacturing, and distribution. We use enterprise information technology systems to record, process, and summarize financial information and results of operations for internal reporting purposes and to comply with regulatory financial reporting, legal, and tax requirements. System failures or outages, including any potential disruptions due to significantly increased global demand on certain cloud-based systems, or failures to adequately scale our data platforms and architectures support patient care could compromise our ability to perform these functions in a timely manner, which could harm our ability to conduct business or delay our financial reporting. Such failures could materially adversely affect our operating results and financial condition. Our information technology systems, some of which are managed by third parties, may be susceptible to damage, disruptions or shutdowns due to computer viruses, denial-of-service attacks, phishing attacks, ransomware or other malware, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, hardware failures, telecommunication failures, user errors or catastrophic events. Although we have developed systems and processes that are designed to protect customer information and prevent data loss and other security breaches, including systems and processes designed to reduce the impact of a security breach at a third-party vendor, such measures cannot provide absolute security. In addition, certain countries have implemented or may implement legislative and technological actions that either do or can effectively regulate access to the internet, including the ability of internet service providers to limit access to specific websites or content. Other countries have attempted or are attempting to change or limit the legal protections available to businesses that depend on the internet for the delivery of their

services. If our systems are breached or suffer severe damage, disruption or shutdown and we are unable to effectively resolve the issues in a timely manner, our business and operating results may significantly

[Table of Contents](#)

suffer and we may be subject to litigation, government enforcement actions and other actions for which we could face financial liability and other adverse consequences which may include:

- additional government oversight of our operations;
- loss of existing customers;
- difficulty in attracting new customers;
- problems in determining product cost estimates and establishing appropriate pricing;
- difficulty in preventing, detecting, and controlling fraud;
- disputes with customers, physicians, and other health care professionals;
- increases in operating expenses, incurrence of expenses, including notification and remediation costs;
- regulatory fines or penalties;
- individual actions or class actions for damages;
- loss of revenues (including through loss of coverage or reimbursement);
- product development delays;
- disruption of key business operations; and
- diversion of attention of management and key information technology resources.

Cyberattacks aimed at accessing our devices, products, and services, or related devices, products, and services, and modifying or using them in a way inconsistent with our FDA clearances and approvals could create risks to users.

Medical devices are increasingly connected to the internet, hospital networks, and other medical devices to provide features that improve healthcare and increase the ability of healthcare providers to treat patients and patients to manage their conditions. For example, we are pursuing collaborations to enable the connectivity and interoperability of our current and next-generation sensors and transmitters with third-party patient monitoring products, which may in turn be connected with the internet, hospital networks and in some cases, other medical devices. These same features may also increase cybersecurity risks and the risks of unauthorized access and use by third parties. As such, a cyberattack which intrudes, disrupts, or corrupts our devices, products, and services, or related devices, products, and services could impact the quality-of-care patients receive or the confidentiality of patient information. Additionally, modifying or using any such devices, products, or services in a way inconsistent with our FDA clearances and approvals, which may create risks to users and potential exposure to the company.

Risks Related to Non-Compliance with Laws, Regulations and Contractual Requirements and Healthcare Industry Shifts

We conduct business in a heavily regulated industry and if we fail to comply with applicable laws and government regulations, we could become subject to penalties, be excluded from participation in government programs, and/or be required to make significant changes to our operations.

The healthcare industry generally, and our business specifically, is subject to extensive foreign, federal, state and local laws and regulations, including those relating to:

- authorizations necessary for the clinical investigation and commercial marketing of products;
- the pricing of our products and services;
- the distribution of our products and services;
- the dispensing of our products;
- billing for or causing the submission of claims for our products and services;
- financial relationships with physicians and other referral sources;
- inducements and courtesies given to physicians and other health care providers and patients;
- labeling, advertising and promoting products;
- the characteristics and quality of our products and services;
- communications with payors and physicians and other healthcare stakeholders;
- confidentiality, maintenance and security issues associated with medical records and individually identifiable health and other personal information;
- medical device adverse event reporting;

[Table of Contents](#)

- prohibitions on kickbacks, including the Anti-Kickback Statute and related laws and/or regulations;
- any scheme to defraud any healthcare benefit program;

- physician and other healthcare professional payment disclosure requirements;
- use and disclosure of personal health information;
- privacy of health information and personal information;
- data protection and data localization;
- mobile communications;
- patient access and non-discrimination;
- patient consent;
- false claims; and
- licensure.

These laws and regulations are extremely complex and, in many cases, still evolving. If our operations are found to violate any of the foreign, federal, state or local laws and regulations which govern our activities, we may be subject to litigation, government enforcement actions, and applicable penalties associated with the violation, potentially including civil and criminal penalties, damages, fines, exclusion from participation in certain payor programs or curtailment of our operations. Compliance obligations under these various laws are oftentimes detailed and onerous, further contributing to the risk that we could be found to be out of compliance with particular requirements. The risk of being found in violation of these laws and regulations is further increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, particularly with respect to new and emerging technologies and remote delivery of services, and their provisions are open to a variety of interpretations.

The FDA, CMS, OIG, OCR, FTC, Department of Justice, states' attorneys general and other governmental authorities actively enforce the laws and regulations discussed above. In the United States, medical device manufacturers have been the target of numerous government prosecutions and investigations alleging violations of law, including claims asserting impermissible off-label promotion of medical devices, payments intended to influence the referral of federal or state healthcare business, and submission of false claims for government reimbursement. While we make every effort to comply with applicable laws, we cannot rule out the possibility that the government or other third parties could interpret these laws differently and challenge our practices under one or more of these laws. This likelihood of allegations of non-compliance is increased by the fact that under certain federal and state laws applicable to our business, individuals may bring an action on behalf of the government alleging violations of such laws, and potentially be awarded a share of any damages or penalties ultimately awarded to the applicable government body.

The FDA and the FTC share oversight of medical device promotion. The FDA has broad authority over device marketing (including assessment and oversight of safety and effectiveness) and over FDA-approved "promotional labeling," while the FTC has authority over "advertising" for most medical devices (i.e., non-"restricted" devices, such as ours).

Any action against us alleging a violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's time and attention from the operation of our business, and have a material effect on our business.

In addition, the laws and regulations impacting or affecting our business may change significantly in the future, which may adversely affect our business. A review of our business by courts or regulatory authorities may result in a determination that could adversely affect our operations. Also, the regulatory environment applicable to our business may change in a way that restricts or adversely impacts our operations.

If we or our suppliers or distributors fail to comply with ongoing regulatory requirements, or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market.

Any product for which we obtain marketing approval, clearance or authorization (and the activities related to its production, distribution, and promotion, sale, and marketing) will be subject to continual review and periodic inspections by the FDA and other regulatory bodies, which may include inspection of our manufacturing processes, complaint handling and adverse event reporting, post-approval clinical data and promotional activities for such product. The FDA's Medical Device Reporting, or MDR, regulations require that we report to the FDA any incident in

Table of Contents

which our product may have caused or contributed to a death or serious injury, or in which our product malfunctioned and, if the malfunction were to recur, it would likely cause or contribute to a death or serious injury.

If the FDA determines that there is a reasonable probability that a device intended for human use would cause serious, adverse health consequences or death, the agency may issue a cease distribution and notification order and a mandatory recall order. We may also decide to recall a product voluntarily if we find a material deficiency, including unacceptable risks to health, manufacturing defects, design errors, component failures, labeling defects, or other issues. Recalls of our products could divert the attention of our management and have an adverse effect on our reputation, financial condition, and operating results.

We and certain of our suppliers are also required to comply with the FDA's Quality System Regulation, or QSR, and other regulations which cover the methods and documentation of the design, testing, production, control, selection and oversight of suppliers or contractors, quality assurance, labeling, packaging, storage, complaint handling, shipping and servicing of our products. The FDA may enforce the QSR through announced (through prior notification) or unannounced inspections.

Compliance with ongoing regulatory requirements can be complex, expensive and time-consuming. Failure by us or one of our suppliers or distributors to comply with statutes and regulations administered by the FDA, competent authorities and other regulatory bodies, or failure to take adequate response to any observations, could result in, among other things, any of the following actions:

- warning letters or untitled letters that require corrective action;
- delays in approving, or refusal to approve, our CGM systems;
- fines and civil or criminal penalties;
- unanticipated expenditures;

- FDA refusal to issue certificates to foreign governments needed to export our products for sale in other countries;
- suspension or withdrawal of clearance or approval by the FDA or other regulatory bodies;
- product recall or seizure;
- administrative detention;
- interruption of production, partial suspension, or complete shutdown of production;
- interruption of the supply of components from our key component suppliers;
- operating restrictions;
- court consent decrees;
- FDA orders to repair, replace, or refund the cost of devices;
- injunctions; and
- criminal prosecution.

The potential effect of these events can in some cases be difficult to quantify. If any of these actions were to occur, it would harm our reputation and cause our product sales and profitability to suffer. In addition, we believe events that could be classified as reportable events pursuant to MDR regulations are generally underreported by physicians and users, and any underlying problems could be of a larger magnitude than suggested by the number or types of MDRs filed by us. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with applicable regulatory requirements.

Even if regulatory approval or clearance of a product is granted, the approval or clearance may be subject to limitations on the indicated uses for which the product may be marketed or contain requirements for costly post-marketing testing or surveillance to monitor the safety or effectiveness of the product. Later discovery of previously unknown problems with our products, including software bugs, unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as the QSR, MDR reporting, or other post-market requirements may result in restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls (through corrections or removals), fines, suspension of regulatory approvals, product seizures, injunctions, the imposition of civil or criminal penalties, or criminal prosecution. In addition, our distributors have rights to create marketing materials for their sales of our products, and may not adhere to contractual, legal or regulatory limitations that are imposed on their marketing efforts.

[Table of Contents](#)

Quality problems could lead to recalls or safety alerts, reputational harm, and could have a material adverse effect on our business, results of operations, financial condition and cash flows.

Quality is very important to us and our customers due to the serious and costly consequences of product failure, and our business exposes us to potential product liability risks that are inherent in the design, manufacture, and marketing of medical devices. Since the first commercial launch of our products in 2006, we have had periodic field failures related to our products and associated services, including reports of sensor errors, sensor failures, broken sensors, receiver malfunctions, audible alarms and alert failures, as well as server and transmitter failures. To comply with the FDA's medical device reporting requirements, for example, we have filed reports of applicable field failures. Although we believe we have taken and are taking appropriate action aimed at reducing and/or eliminating field failures, we may have other product failures in the future. Product or component failures, manufacturing nonconformances, design defects, off-label use, or inadequate disclosure of product-related risks or product-related information with respect to our products, if they were to occur, could result in an unsafe condition or injury to, or death of, a patient. These problems could lead to recalls, corrections or removals of, or issuance of a safety alert relating to, our products, and could result in product liability claims and lawsuits.

Additionally, the production of our products must occur in a highly controlled and clean environment to minimize particles and other yield- and quality-limiting contaminants. Weaknesses in process control or minute impurities in materials may cause a substantial percentage of defective products. If we are not able to maintain stringent quality controls, or if contamination problems arise, our clinical development and commercialization efforts could be delayed, which would harm our business and our results of operations.

If we fail to meet any applicable product quality standards and our products are the subject of recalls or safety alerts, our reputation could be damaged, we could lose customers, our reputation could be harmed and our revenue and results of operations could decline.

Potential long-term complications from our current or future products or other CGM systems under development may not be revealed by our clinical experience to date.

Based on our experience, complications from use of our products may include sensor errors, sensor failures, broken sensors, lodged sensors or skin irritation under the adhesive dressing of the sensor. Inflammation or redness, swelling, minor infection, and minor bleeding at the sensor insertion site are also possible risks with an individual's use of our products. However, if unanticipated long-term side-effects result from the use of our products or other glucose monitoring systems we have under development, we could be subject to liability and the adoption of our systems may become more limited. With respect to our G6 systems, our clinical trials have been limited to ten days of continuous use. It is possible that the data from our clinical studies and trials may not be indicative of long-term patient outcomes. We cannot assure you that repeated, long-term use would not result in unanticipated adverse effects, potentially even after the sensor is removed.

We may never receive approval, marketing authorization or clearance from the U.S. FDA and other governmental agencies to market additional CGM systems, expanded indications for use of current and future generation CGM systems, future software platforms, or any other products under development.

In March 2018, via the *de novo* process, the FDA classified the G6 and substantially equivalent devices of this generic type (i.e., "integrated continuous glucose monitoring systems" or "ICGMs") into Class II, meaning that going forward products of this generic type may utilize the 510(k) pathway. Since then we have received 510(k) clearances for modifications to the G6 and approval for G7.

Any subsequent modifications of our cleared products that could significantly affect their safety or effectiveness (for example, a significant change in design or manufacture), or that would constitute a major change in its intended use, will require us to obtain a new 510(k) clearance or could require a new *de novo* submission or a PMA.

The FDA requires each manufacturer to make this determination initially, but the FDA may review any such decision and may disagree with a manufacturer's determination. If the FDA disagrees with a manufacturer's determination, the FDA may require the manufacturer to cease marketing and/or recall the modified device until appropriate clearance or approval is obtained. Under these circumstances, the FDA may also subject a manufacturer to significant regulatory fines or other penalties.

If future product candidates are not deemed by the FDA to meet the criteria for submission under the 510(k) pathway, or for down-classification under the *de novo* process or otherwise, we would need to pursue a PMA. The PMA process requires us to prove the safety and effectiveness of our systems to the FDA's satisfaction. This process can be expensive, prolonged and uncertain, requires detailed and comprehensive scientific and human clinical data, and may never result in the FDA granting a PMA. The FDA's *de novo* classification of our G6 system under the generic name "integrated continuous glucose monitoring system," makes it a predicate device for future

[Table of Contents](#)

510(k) submissions. Complying with this classification requires ongoing compliance with the general controls required by the federal Food Drug and Cosmetic Act and the special controls specified by the FDA's G6 order as a Class II device. Any future system or expanded indications for use of current generation systems will require approval of the applicable regulatory authorities. In addition, we intend to seek either 510(k) clearances or PMA approvals for certain changes and modifications to our existing software platform, but cannot predict when, if ever, those changes and modifications will be approved.

The FDA can refuse to grant a 510(k) clearance or a *de novo* request for marketing authorization, or delay, limit or deny approval of a PMA application or supplement for many reasons, including:

- the system may not be deemed by the FDA to be substantially equivalent to appropriate predicate devices under the 510(k) pathway;
- the system may not satisfy the FDA's safety or effectiveness requirements;
- the data from pre-clinical studies and clinical trials may be insufficient to support clearance or approval;
- the manufacturing process or facilities used may not meet applicable requirements; and
- changes in FDA approval policies or adoption of new regulations may require additional data.

Even if approved or cleared by the FDA or foreign regulatory agencies, future generations of our CGM systems, expanded indications for use of current and future generation CGM systems, our software platforms or any other CGM system under development, may not be cleared or approved for the indications that are necessary or desirable for successful commercialization. We may not obtain the necessary regulatory approvals or clearances to market these CGM systems in the United States or outside of the United States. Any delay in, or failure to receive or maintain, clearance or approval for our products could prevent us from generating revenue from these products. The uncertain timing of regulatory approvals for future generations of our products could subject our current inventory to excess or obsolescence charges, which could have an adverse effect on our business, financial condition and operating results.

Our failure to comply with laws, regulations and contract requirements relating to reimbursement of health care goods and services may subject us to penalties and adversely impact our reputation, business, financial condition and cash flows.

We are subject to laws, regulations and contractual requirements regulating the provision of, and reimbursement for, health care goods and services in our capacity as a medical device manufacturer. The laws and regulations of health care goods and services that apply to us, including those described above, are subject to evolving interpretations and enforcement discretion. We have in place a compliance program, through which we seek to reduce common industry risks of noncompliance with U.S. federal and state and applicable foreign laws in areas such as sales contracts, marketing materials, referral source relationships, programmatic offerings, and billing practices (among others), monitor for compliance, and address non-compliance if identified. If a governmental authority were to conclude that we are not in compliance with applicable laws and regulations, we and our officers, directors and employees could be subject to criminal and civil penalties, as well as administrative sanctions such as exclusion from participation in federal healthcare programs, including but not limited to Medicare and Medicaid. Any failure to comply with laws, regulations or contractual requirements relating to reimbursement and health care goods and services could adversely affect our reputation, business, financial condition and cash flows.

Our products are purchased principally by individual patients, who may be eligible for insurance coverage of their devices from various third-party payors, such as governmental programs (e.g., Medicare, Medicaid, TRICARE, other federal and state health benefit plans, and comparable non-U.S. programs), private insurance plans, and managed care plans. The ability of our customers to obtain appropriate reimbursement for products and services from third-party payors is critical because it affects which products customers purchase and the prices they are willing to pay. As a result, our products are subject to regulation regarding quality and cost by the U.S. Department of Health & Human Services, including CMS, as well as comparable state and non-U.S. agencies responsible for reimbursement and regulation of health care goods and services. The principal U.S. federal laws relating to reimbursement include those that prohibit (i) the filing of false or improper claims for federal payment, known as the federal civil False Claims Act, (ii) unlawful inducements for the referral of items and services reimbursed by Federal health care programs, known as the federal Anti-Kickback Statute, and (iii) the Civil Monetary Penalties Law, including its prohibitions on Beneficiary Inducement. Many states have similar laws that apply to reimbursement by state Medicaid and other government-funded programs, as well as, in some cases, to all payors, including self-pay patients. Insurance companies can also bring a private cause of action claiming treble damages against a manufacturer for causing a false claim to be filed under the federal Racketeer Influenced and Corrupt Organizations Act, or RICO. Additionally, as a manufacturer of FDA-approved or -cleared devices reimbursable by federal healthcare programs, we are subject to the federal Physician Payments Sunshine Act, which requires us to annually

[Table of Contents](#)

report certain payments and other transfers of value we make to certain U.S.-licensed health care professionals and U.S. teaching hospitals, and under an expansion of the law to physician assistants, nurse practitioners, and other mid-level practitioners.

With respect to the federal Anti-Kickback Statute, Congress and the OIG have established a large number of statutory exceptions and regulatory safe harbors that protect financial relationships with our customers and referral sources. An arrangement that fits squarely into an exception or safe harbor will not be deemed to violate the Anti-Kickback Statute.

We train and educate employees and marketing representatives on the Anti-Kickback Statute and their obligations thereunder, and we endeavor to comply with the applicable safe harbors. However, some of our arrangements, like many other common and non-abusive arrangements, may implicate the Anti-Kickback Statute and are not covered by a safe harbor, but nevertheless we do not believe them to present a significant risk to beneficiaries or federal healthcare programs and, as such, appear unlikely to invite government scrutiny or prosecution, warrant the imposition of sanctions, or be found to violate the statute. However, we cannot offer assurance that the government or a whistleblower would agree with our position that certain arrangements fall within a safe harbor, or that arrangements that do not squarely meet an exception or safe harbor will not be found to violate the Anti-Kickback Statute. Allegations of violations of the Anti-Kickback Statute can also trigger liability under the federal Civil Monetary Penalty Law and federal civil False Claims Act, thereby increasing the penalty structure for these violations.

During the period in which we directly billed Medicare, our financial relationships with referring physicians and their immediate family members were required to comply with the federal Physician Self-Referral law, commonly referred to as the Stark Law, by meeting an applicable exception. Unlike the Anti-Kickback Statute, failure to meet an exception under the Stark Law results in a violation of the Stark Law, even if such violation is unintentional. Violations of the Stark Law create overpayment liability under the federal civil False Claims Act and can also trigger separate penalties under the Civil Monetary Penalties Law. Knowing violations of the Stark Law carry increased civil monetary penalties and would likely be classified as the knowing submission of a false claim or knowingly making a false statement to the government, triggering liability under the federal civil False Claims Act. Certain Stark Law violations can also trigger exclusion from participation in federal healthcare programs. Historical violations of the Stark Law, if any, could continue to give rise to liability during the six year statute of limitations period.

Managed care trends and consolidation in the health care industry could have an adverse effect on our revenues and results of operations.

Private third-party payors and other managed care organizations, such as pharmacy benefit managers, continue to take action to manage utilization and control costs. Consolidation among managed care organizations has increased the negotiating power of managed care organizations and other private third-party payors. Private third-party payors, as well as governments, increasingly employ formularies to control costs by taking into account discounts in connection with decisions about formulary inclusion or favorable formulary placement. Failure to obtain or maintain timely adequate pricing or favorable formulary placement for our products, or failure to obtain such formulary placement at favorable pricing, could adversely impact revenue. Private third-party payors, including self-insured employers, often implement formularies with co-payment tiers to encourage utilization of certain products and have also been raising co-payments required from beneficiaries, particularly for higher-cost products. Private third-party payors also use additional measures such as value-based pricing/contracting to improve their cost-containment efforts. Private third-party payors also are increasingly imposing utilization management tools, such as requiring prior authorization or requiring the patient to first fail on a lower-cost product before permitting access to a higher-cost product.

Many health care industry companies, including health care systems, distributors, manufacturers, providers, and insurers, are also consolidating or vertically integrating, or have formed strategic alliances. As the health care industry consolidates, competition to provide goods and services to industry participants may become more intense. This consolidation will continue to create larger enterprises with greater negotiating power, which they can try to use to negotiate price concessions or reductions for medical devices and components produced by us.

As the U.S. payor market consolidates further and we face greater pricing pressure from private third-party payors, who will continue to drive more of their patients to use lower cost alternatives, we may lose customers, our revenues may decrease and our business, financial condition, results of operations and cash flows may suffer.

Table of Contents

If we are unable to successfully complete the pre-clinical studies or clinical trials necessary to support additional PMA, de novo, or 510(k) applications or supplements, we may be unable to commercialize our CGM systems under development, which could impair our business, financial condition and operating results.

To support current and any future additional PMA, 510(k), de novo applications or supplements, we together with our partners, must successfully complete pre-clinical studies, bench-testing, and in some cases clinical trials that will demonstrate that the product is safe and effective. Product development, including pre-clinical studies and clinical trials, is a long, expensive and uncertain process and is subject to delays and failure at any stage. Furthermore, the data obtained from the studies and trials may be inadequate to support approval of an application and the FDA may request additional clinical data in support of those applications, which may result in significant additional clinical expenses and may delay product approvals. While we have in the past obtained, and may in the future obtain, an investigational device exemption, or IDE, prior to commencing clinical trials for our products, FDA approval of an IDE application permitting us to conduct testing does not mean that the FDA will consider the data gathered in the trial to be sufficient to support approval of a PMA, de novo or 510(k) application or supplement, even if the trial's intended safety and effectiveness endpoints are achieved.

Changes to the regulatory landscape may impact our ability to obtain marketing authorization for future product developments.

Development or changes to the FDA or foreign regulatory approval standards and processes, including both legal and policy changes, could also delay or prevent the approval of our products submitted for review. For example, medical device cybersecurity continues to be an area of focus for and evolving guidance from FDA.

Additionally, at the end of 2022, Congress passed the Food and Drug Omnibus Reform Act of 2022, or FDORA which (among other things), and similarly to the 2022 FDA Guidance, requires device sponsors to submit clinical trial diversity action plans outlining the goals for increasing representation of participants from racial and ethnic minority populations that have been underrepresented in clinical trials.

Any change in the laws or regulations that govern the clearance and approval processes relating to our current and future products could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market and distribute existing products. The data contained in our submissions, including data drawn from our clinical trials, may not be sufficient to support clearance or approval of our products or additional or expanded indications. Medical device company stock prices have declined significantly in certain circumstances where companies have failed to meet expectations in regards to the timing of regulatory approval. If the FDA's response causes product approval delays, or is not favorable for any of our products, our stock price (and the market price of our senior convertible notes) could decline substantially. It is uncertain how these potential changes may impact our ability to gain clearance or approval from FDA for our products in the future.

The commencement or completion of any of our clinical trials may be delayed or halted, or be inadequate to support approval of FDA marketing applications or supplements, for numerous reasons, including, but not limited to, the following:

- the FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;
- patients do not enroll in clinical trials at the rate we expect;
- patients or study site personnel who do not comply with clinical trial protocols;
- patient follow-up does not occur at the rate we expect;
- patients experience adverse side effects;
- patients die during a clinical trial, even though their death may not be related to our products;
- institutional review boards and third-party clinical investigators may delay or reject our clinical trial protocol;
- third-party clinical investigators decline to participate in a trial or do not perform a trial on our anticipated schedule or consistent with the investigator agreements, clinical trial protocol, good clinical practices or other FDA or institutional review board requirements;
- we or third-party organizations do not perform data collection, monitoring or analysis in a timely or accurate manner or consistent with the clinical trial protocol or investigational or statistical plans;
- third-party clinical investigators have significant financial interests related to us or the study that the FDA deems to make the study results unreliable, or we or clinical investigators fail to disclose such interests;

Table of Contents

- regulatory inspections of our clinical trials or manufacturing facilities may result in allegations or findings of noncompliance and, among other things, require us to undertake corrective action or suspend or terminate our clinical trials;
- changes in governmental regulations, policies or administrative actions applicable to our trial protocols;
- the interim or final results of the clinical trial are inconclusive or unfavorable as to safety or efficacy; and
- the FDA concludes that the results from our trial and/or trial design are inadequate to demonstrate safety and effectiveness of the product.

Further, health epidemics could limit or restrict our ability to initiate, conduct or continue our clinical trials. Delays and disruption in our clinical trials could result in delays for expanded FDA clearance or approval of our products.

The results of pre-clinical studies or other forms of early product testing do not necessarily predict future clinical trial results, and prior clinical trial results might not be repeated in subsequent clinical trials. Additionally, the FDA may disagree with our interpretation of the data from our pre-clinical studies, product testing, and clinical trials, or may find the clinical trial design, conduct or results inadequate to prove safety or effectiveness, and may require us to pursue the development of additional data, which could further delay the approval of our products. If we are unable to demonstrate the safety and effectiveness of our products in our clinical trials to the FDA's satisfaction, where clinical data are required, we will be unable to obtain regulatory approval to market our products in the United States. In addition, the data we collect from our current clinical trials, our pre-clinical studies and other clinical trials may not be sufficient to support FDA approval, even if our endpoints are met.

We may also conduct clinical studies to demonstrate the relative or comparative effectiveness of CGM systems for the treatment of diabetes. These types of studies, which often require substantial investment and effort, may not show adequate, or any, clinical benefit or value for the use of CGM systems.

Our CGM systems currently have regulatory marketing authorization limited to individual patient home-use, and have otherwise not received clearance or approval from the FDA or other regulators for use in hospital or other in-patient facility settings, although the FDA has advised us that it will not object to the use of our CGM systems in such settings during the COVID-19 pandemic. Our potential supply of our CGM systems for use in this environment during the COVID-19 pandemic may present risks to our business.

We have received, and may continue to receive, numerous inquiries from hospitals around the country about the use of our CGM devices to remotely monitor COVID-19 patients admitted into the hospital.

Following direct communication with the FDA regarding the potential use of our CGM devices in a hospital or other in-patient setting, the FDA notified us on April 1, 2020 that in an exercise of its enforcement discretion it will not object, in the context of the COVID-19 pandemic, to Dexcom providing CGM devices and support to users to enable real-time remote patient monitoring in hospitals and other healthcare facilities, to support COVID-19 healthcare-related efforts, so long as we provide certain FDA-specified information with respect to the unique challenges that CGM technologies can raise in the hospital environment.

As a condition of its exercise of enforcement discretion, the FDA has advised that we communicate the following information related to implementing the use of CGM systems for remote monitoring of hospitalized patients:

- Hospitals should consider whether they have the resources and expertise necessary to adequately implement CGM use and provide appropriate training to healthcare providers.
- CGM glucose results are less accurate than blood glucose results obtained using traditional testing methods (e.g., lab glucose, blood glucose meters). Users should consider all CGM glucose information (e.g., trend) along with individual glucose values, and interpret CGM results in the context of the full clinical picture.
- CGM systems are subject to interferences that may generate falsely high and falsely low glucose readings. Levels of interference depend on drug concentration; substances that may not significantly interfere in non-hospitalized patients may interfere when used in the hospital setting because of higher dose levels. Most drugs used in hospital or critical care settings have not been evaluated and their interference with CGM systems is unknown. Known interferences vary by CGM brand, and can include Acetaminophen, Ascorbic acid, Hydroxyurea, or other reducing drugs/ compounds.

- Poor peripheral blood perfusion may cause inaccurate sensor readings. CGM results should be interpreted considering accompanying patient conditions and medications. Other clinical conditions may also cause inaccurate readings.

Table of Contents

Our provision of our CGM systems to hospitals and other healthcare facilities for use during have and will continue to have the above notice.

In February 2022, we received Breakthrough Device designation for our G6 CGM system in the hospital setting. The FDA's Breakthrough Device designation is designed to expedite the development and regulatory review of medical devices that hold the potential for more effective treatment or diagnosis of life-threatening or irreversibly debilitating disease or condition.

We are not actively promoting nor do we plan to actively promote our CGM devices (and related support) for inpatient use, but if we supply them to such facilities as currently permitted by the FDA, this supply could present an increased risk of product liability claims and associated damages should an adverse event occur. Given that our CGM devices have not yet been fully evaluated or tested by either us or the FDA to the extent that would be required in standard circumstances for product development and marketing authorization, there could be unknown or unanticipated risks presented by use in this environment.

The FDA can also decide, at any time, to change its position regarding its Breakthrough Device Designation and/or enforcement discretion for our devices, and require that we seek marketing authorization for this additional intended use by submitting a 510(k) premarket notification, or that we seek and obtain Emergency Use Authorization. The COVID-19 public health emergency declared by the Department of Health and Human Services expired on May 11, 2023. While the end of the public health emergency does not by itself impact the FDA's ability to authorize devices for emergency use, and the FDA has published guidance for transition plans for medical devices that fall within enforcement policies issued during the COVID-19 pandemic. We will continue to closely monitor regulatory developments that impact our products, business, or financial results, including those relating to FDA enforcement discretion and Breakthrough Device Designation for the provision of our CGM systems in the hospital setting.

We depend on clinical investigators and clinical sites to enroll patients in our clinical trials and other third parties to manage the trials and to perform related data collection and analysis, and, as a result, we may face costs and delays that are outside of our control.

We rely on clinical investigators and clinical sites to enroll patients in our clinical trials, and other third parties to manage the trial and to perform related data collection and analysis. However, we may not be able to control the amount and timing of resources that clinical sites may devote to our clinical trials. If these clinical investigators and clinical sites fail to enroll a sufficient number of patients in our clinical trials or fail to ensure compliance by patients with clinical protocols or fail to comply with regulatory requirements, we will be unable to complete these trials, which could prevent us from obtaining regulatory approvals for our products. Our agreements with clinical investigators and clinical sites for clinical testing place substantial responsibilities on these parties and, if these parties fail to perform as expected, our trials could be delayed or terminated. If these clinical investigators, clinical sites or other third parties do not carry out their contractual duties or obligations or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, or the clinical data may be rejected by the FDA, and we may be unable to obtain regulatory approval for, or successfully commercialize, our products.

Health care policy changes, including U.S. health care reform legislation, may have a material adverse effect on our business.

In response to perceived increases in health care costs in recent years, there have been and continue to be proposals by the federal government, state governments, regulators, and third-party payors to control these costs and, more generally, to reform the U.S. health care system. Certain of these proposals could limit the prices we are able to charge for our products or the amounts of reimbursement available for our products and could limit the acceptance and availability of our products.

In November 2020, the OIG published a Special Fraud Alert addressing manufacturer Speaker Programs, signaling both a more narrow government view of AKS compliance with respect to such programs as well as the potential for increased enforcement in this space by government oversight agencies such as the OIG and DOJ. In March, 2022, the Advanced Medical Technology Association, or AdvaMed, announced revisions to its Code of Ethics on Interactions with Health Care Professionals, or Code. The revised Code, effective June, 2022, addressed concerns noted in the OIG's Special Fraud Alert, addressing things like virtual meetings, speaker programs and alcohol at events. The revised Code also addresses value-based care arrangements. We continue to assess industry responses to the Special Fraud Alert and have and may continue to make modifications to certain aspects of our speaker programs, which may have a detrimental impact on our ability to educate healthcare providers about

Table of Contents

our products and to promote use of our products, and which may in turn lead to decreased product sales and negatively impact our business, financial condition and results of operations.

Comprehensive healthcare legislation, signed into law in the United States in March 2010, titled the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, collectively, the ACA, imposes certain stringent compliance, recordkeeping, and reporting requirements on companies in various sectors of the life sciences industry, and enhanced penalties for non-compliance. Despite the ACA going into effect over a decade ago, there have been numerous legal and Congressional challenges to the law's provisions and the effect of certain provisions have made compliance costly.

We cannot predict what additional new legislation, agency priorities, and rulemaking may be on the horizon as the United States continue to reassess how it pays for healthcare. As a result, we cannot quantify or predict what impact any changes might have on our business and results of operations. However, any changes that lower reimbursement for our products could materially and adversely affect our business, financial condition and results of operations.

Other legal, regulatory and commercial policy influences are subjecting our industry to significant changes, and we cannot predict whether new regulations or policies will emerge from U.S. federal or state governments, foreign governments, or third-party payors. Government and commercial payors may, in the future, consider healthcare policies and proposals intended to curb rising healthcare costs, including those that could significantly affect reimbursement for healthcare products such as our systems. These policies have included, and may in the future include: basing reimbursement policies and rates on clinical outcomes, the comparative effectiveness, and costs, of different treatment technologies and modalities; imposing price controls and taxes on medical device providers; and other measures. Future significant changes in the healthcare systems in the

United States or elsewhere could also have a negative impact on the demand for our current and future products. These include changes that may reduce reimbursement rates for our products and changes that may be proposed or implemented by the current or future laws or regulations.

Risks Related to Intellectual Property Protection and Use

We are subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from shipping affected products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages and injunctive relief. We may also be subject to other claims or suits.

Third parties have asserted, and may assert, infringement or misappropriation claims against us with respect to our current or future products. We are aware of numerous patents issued to third parties that may relate to aspects of our business, including the design and manufacture of CGM sensors and membranes, as well as methods for continuous glucose monitoring. Whether a product infringes a patent involves complex legal and factual issues, the determination of which is often uncertain. Therefore, we cannot be certain that we have not infringed the intellectual property rights of such third parties or others. Our competitors may assert that our CGM systems or the methods we employ in the use of our systems are covered by U.S. or foreign patents held by them. We have in the past settled some such allegations and may need to do so again in the future. This risk is exacerbated by the fact that there are numerous issued patents and pending patent applications relating to self-monitored glucose testing systems in the medical technology field. Because patent applications may take years to issue, there may be applications now pending of which we are unaware that may later result in issued patents that our products infringe. There could also be existing patents of which we are unaware that one or more components of our system may inadvertently infringe. As the number of competitors in the market for CGM systems grows, the possibility of patent infringement by us or a patent infringement claim against us increases. If we are unable to successfully defend any such claims as they may arise or enter into or extend settlement and license agreements on acceptable terms or at all, our business operations may be harmed. We have been involved in various patent infringement actions in the past. For example, in July 2014, we entered into a Settlement and License Agreement with Abbott to settle all pending patent infringement legal proceedings brought by Abbott against us, which expired on March 31, 2021. Since the expiration of that agreement, we and certain Abbott entities have served complaints for patent infringement, validity, and other patent-related actions against each other in multiple jurisdictions, inside and outside the United States. We intend to vigorously pursue our claims and defenses in these cases to protect our intellectual property and to defend against Abbott's infringement allegations. See "Legal Proceedings" in Part II, Item 1 above for more information.

Any infringement or misappropriation claim could cause us to incur significant costs, place significant strain on our financial resources, divert management's attention from our business and harm our reputation. In addition, if the relevant patents are upheld as valid and enforceable and we are found to infringe such patents, we could be

Table of Contents

prohibited from selling any of our products that is found to infringe unless we could obtain licenses to use the technology covered by the patent or are able to design around the patent. We may be unable to obtain a license on terms acceptable to us, if at all, and we may not be able to redesign our products to avoid infringement. We may be unable to maintain or renew licenses on terms acceptable to us, if at all, and we may be prohibited from selling any of our products that required the technology covered by the relevant licensed patents. Even if we are able to redesign our products to avoid an infringement claim, we may not receive FDA approval for such changes in a timely manner or at all.

Any adverse determination in litigation or interference proceedings to which we are or may become a party relating to patents or other intellectual property rights could subject us to significant liabilities to third parties or require us to seek licenses from other third parties. If we are found to infringe third-party patents, a court could order us to pay damages to compensate the patent owner for the infringement, such as a reasonable royalty amount and/or profits lost by the patent owners, along with prejudgment and/or post-judgment interest. Furthermore, if we are found to willfully infringe third-party patents, we could, in addition to other penalties, be required to pay treble damages; and if the court finds the case to be exceptional, we may be required to pay attorneys' fees for the prevailing party. If we are found to infringe third-party copyrights or trademarks or misappropriate third-party trade secrets, based on the intellectual property at issue, a court could order us to pay statutory damages, actual damages, or profits, such as reasonable royalty or lost profits of the owners, unjust enrichment, disgorgement of profits, and/or a reasonable royalty, and the court could potentially award attorneys' fees or exemplary or enhanced damages. Although patent and intellectual property disputes in the medical device area have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and would likely include ongoing royalties. We may be unable to obtain necessary intellectual property licenses on satisfactory terms. If we do not obtain any such necessary licenses, we may not be able to redesign our products to avoid infringement and any redesign may not receive FDA approval or other requisite marketing authorization in a timely manner or at all. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary intellectual property licenses could prevent us from manufacturing and selling our products, which would have a significant adverse impact on our business. If litigation were to be initiated by intellectual property owners, there could be significant legal fees and costs incurred in defending litigation (which may include filing administrative actions to attack the intellectual property) as well as a potential monetary settlement payment to the owners, even if the matter is resolved before going to trial. Moreover, the owners may take an overly aggressive approach and/or include multiple allegations in a single litigation.

In addition, from time to time, we are subject to various claims, complaints and legal actions arising out of the ordinary course of business, including commercial insurance, product liability or employment-related matters. Also, from time to time, we may bring claims or initiate lawsuits against various third parties with respect to matters arising out of the ordinary course of our business, including commercial and employment-related matters. We do not believe we are party to any currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial condition or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial condition or results of operations.

Our inability to adequately protect our intellectual property could allow our competitors and others to produce products based on our technology, which could substantially impair our ability to compete.

Our success and our ability to compete depend, in part, upon our ability to maintain the proprietary nature of our technologies. We rely on a combination of patent, copyright and trademark law, and trade secrets and nondisclosure agreements to protect our intellectual property. However, such methods may not be adequate to protect us or permit us to gain or maintain a competitive advantage. Our patent applications may not issue as patents in a form that will be advantageous to us, or at all. Our issued patents, and those that may issue in the future, may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products. In addition, there are numerous recent changes to the patent laws and proposed changes to the rules of the U.S. Patent and Trademark Office, which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights.

To protect our proprietary rights, we may in the future need to assert claims of infringement against third parties. The outcome of litigation to enforce our intellectual property rights in patents, copyrights, trade secrets or trademarks is highly unpredictable, could result in substantial costs and diversion of resources, and could have a material adverse effect on our business, financial condition and results of operations regardless of the final outcome of such litigation. In the event of an adverse judgment, a court could hold that some or all of our asserted intellectual property rights are not infringed, or are invalid or unenforceable, and could award attorney fees.

[Table of Contents](#)

Despite our efforts to safeguard our unpatented and unregistered intellectual property rights, we may not succeed in doing so or the steps taken by us in this regard may not be adequate to detect or deter misappropriation of our technology or to prevent an unauthorized third party from copying or otherwise obtaining and using our products, technology or other information that we regard as proprietary. In addition, third parties may be able to design around our patents. Furthermore, the laws of foreign countries may not protect our proprietary rights to the same extent as the laws of the United States.

Litigation Risks

We face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things.

Our business exposes us to the risk of product liability claims that is inherent in the testing, manufacturing and marketing of medical devices, including those which may arise from the misuse (including system hacking or other unauthorized access by third parties to our systems) or malfunction of, or design flaws in, our products. This liability may vary based on the FDA classification associated with our devices. Notably, the classification of our G6 and G7 systems as Class II medical devices is likely to weaken our ability to rely on federal preemption of state law claims that assert liability against us for harms arising from use of those systems. We may be subject to product liability claims if our products cause, or merely appear to have caused, an injury. Claims may be made by customers, healthcare providers or others selling our products. The risk of product liability claims may increase given that G6 and G7 do not require confirmatory finger sticks when making treatment decisions or finger stick tests each day for calibration, although it does require finger stick tests when symptoms do not match readings and when readings are unavailable. The risk of claims may also increase if our products are subject to a product recall or seizure. An example of the difficulty of complying with the regulatory requirements associated with the manufacture of our products, we issued notifications to our customers regarding the audible alarms and alerts associated with our receivers.

Although we have insurance at levels that we believe is appropriate, this insurance is subject to deductibles and coverage limitations. Our current product liability insurance may not continue to be available to us on acceptable terms, if at all, and, if available, the coverage may not be adequate to protect us against any future product liability claims. Further, if additional products are approved for marketing, we may seek additional insurance coverage. If we are unable to obtain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect against potential product liability claims, we will be exposed to significant liabilities, which may harm our business. A product liability claim, recall or other claims with respect to uninsured liabilities or for amounts in excess of insured liabilities could result in significant costs and significant harm to our business.

We may be subject to claims against us even if the apparent injury is due to the actions of others or misuse of the device or a partner device. Our customers, either on their own or following the advice of their physicians, may use our products in a manner not described in the products' labeling and that differs from the manner in which it was used in clinical studies and approved by the FDA. For example, our current systems are designed to be used by an individual continuously for up to 10 days for our G6 and G7 systems, but the individual might be able to circumvent the safeguards designed into the systems and use the products for longer than 10 days. Off-label use of products by customers is common, and any such off-label use of our products could subject us to additional liability, or require design changes to limit this potential off-label use once discovered. In addition, other regulatory agencies may in the future approve similar diabetes treatment indications. We expect that such diabetes treatment indications could expose us to additional liability. These liabilities could prevent or interfere with our product commercialization efforts. Defending a suit, regardless of merit, could be costly, could divert management attention and might result in adverse publicity, which could result in the withdrawal of, or inability to recruit, clinical trial volunteers or result in reduced acceptance of our products in the market.

As a result of the recent COVID-19 pandemic, we have received and continue to receive, numerous requests from hospitals and healthcare facilities around the country regarding the use of our CGM devices to remotely monitor COVID-19 patients admitted into the hospital. As noted above, in 2020, the FDA informed us that they intend to exercise enforcement discretion and will not object to our provision of G6 CGM systems to such facilities for use in the inpatient setting during the pandemic. However, our CGM devices are currently approved only for in-home use by patients for the purpose of personal diabetes management and have not otherwise been cleared or approved by the FDA for hospital use. Given that the G6 CGM has not yet been fully evaluated or tested (by us or by the FDA) to the extent that would be required in standard circumstances for product development and marketing authorization, there could be unknown or unanticipated risks presented by use in this environment. To the extent that inpatient use of our CGM systems causes or contributes to an adverse event, we may be subjected to additional product liability lawsuits. Defending a suit, regardless of merit, could be costly, could divert management

[Table of Contents](#)

attention and might result in adverse publicity, which could result in reduced acceptance of our products in the market.

We could become the subject of governmental investigations, claims and litigation.

Healthcare companies are subject to numerous investigations and inquiries by various governmental agencies. Further, under the False Claims Act, private parties have the right to bring *qui tam*, or "whistleblower," suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Depending upon whether the underlying conduct alleged in such inquiries or investigations could be considered systemic, any resolution of any such investigations could have a material, adverse effect on our financial position and results of operations.

Governmental agencies and their agents, such as CMS Medicare Administrative Contractors and other CMS contractors, as well as the OIG, state Medicaid programs, and other state and federal agencies may conduct audits of our operations, relating to covered items and services including those furnished to beneficiaries, health care providers

and distributors. Commercial and government-funded managed care payors may conduct similar post-payment audits. Depending on the nature of the conduct found in such audits and whether the underlying conduct could be considered systemic, the resolution of these audits could have a material adverse effect on our financial position and results of operations. Our compliance program includes internal audit and monitoring functions designed to identify potential issues and facilitate remediation as appropriate.

Any future investigations of our executives, our managers or us could result in significant liabilities or penalties to us, as well as adverse publicity. Even if we are found to have complied with applicable law, the investigation or litigation may pose a considerable expense and would divert management's attention, and have a potentially negative impact on the public's perception of us, all of which could negatively impact our financial position and results of operations. Further, should we be found out of compliance with any of these laws, regulations or programs, depending on the nature of the findings, our business, our financial position and our results of operations could be negatively impacted.

We may be subject to fines, penalties and injunctions if we are determined to be promoting the use of our products for unapproved or improper off-label uses or determined to have made claims that are untruthful or misleading or not adequately substantiated.

Our marketing, promotional and educational materials and practices are subject to FDCA, Federal Trade Commission Act, and other applicable laws and regulations, as may be amended from time to time. If the FDA, FTC or other regulatory body with competent jurisdiction over us, our activities or products takes the position that our marketing, promotional or other materials or activities constitute improper promotion or marketing of an unapproved or improper use, or that they contain untruthful, misleading, or inadequately substantiated statements or claims, such regulatory body could request that we modify our materials or practices, or subject us to regulatory enforcement actions, including the issuance, depending on the regulatory body and the nature of the alleged violation, of a warning letter, injunction, seizure, civil fine and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider promotional, marketing or other materials or activities to constitute improper promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Recent court decisions have impacted the FDA's enforcement activity regarding off-label promotion in light of First Amendment considerations; however, there are still significant risks in this area in part due to the potential False Claims Act exposure and the FDA's continued focus on ensuring devices are marketed in a manner consistent with their FDA-required labeling.

We are not actively promoting nor do we plan to actively promote our G6 or G7 systems for inpatient use, but if we supply them to such facilities as currently permitted by FDA, this supply could present an increased risk of product liability claims and associated damages should an adverse event occur. Given that the G6 and G7 systems have not yet been fully evaluated or tested (by us or by the FDA) to the extent that would be required in standard circumstances for product development and marketing authorization, there could be unknown or unanticipated risks presented by use in this environment.

In some instances in our advertising and promotion, we may make claims regarding our product as compared to competing products, which may subject us to heightened regulatory scrutiny, enforcement risk, and litigation risks.

The FDA applies a heightened level of scrutiny to comparative claims when applying its statutory standards for advertising and promotion, including with regard to its requirement that promotional labeling be truthful and not

[Table of Contents](#)

misleading. There is potential for differing interpretations of whether certain communications are consistent with a product's FDA-required labeling, and FDA will evaluate communications on a fact-specific basis.

In addition, making comparative claims may draw concerns from our competitors. Where a company makes a claim in advertising or promotion that its product is superior to the product of a competitor (or that the competitor's product is inferior), this creates a risk of a lawsuit by the competitor under federal and state false advertising or unfair and deceptive trade practices law, and possibly also state libel law. Such a suit may seek injunctive relief against further advertising, a court order directing corrective advertising, and compensatory and punitive damages where permitted by law.

Direct-to-consumer marketing and social media efforts may expose us to additional regulatory scrutiny.

Our efforts to promote our products via direct-to-consumer marketing and social media initiatives may subject us to additional scrutiny of our practices of effective communication of risk information, benefits or claims, under the oversight of the FDA, FTC, HHS-OCR, or others.

Other Risks Related to Our Business and Financial Condition

We have incurred significant losses in the past and may incur losses in the future.

We have incurred significant operating losses in the past. We have financed our operations primarily through private and public offerings of equity securities and debt and the sales of our products. We have devoted substantial resources to:

- research and development relating to our continuous glucose monitoring systems;
- sales and marketing and manufacturing expenses associated with the commercialization of our CGM systems; and
- expansion of our workforce.

We expect our research and development expenses to increase in connection with our clinical trials and other development activities related to our products, including our next-generation sensors, transmitters and receivers, as well as other collaborations. We also expect that our general and administrative expenses will continue to increase due, among other things, to the additional operational and regulatory burdens applicable to public healthcare and medical device companies. As a result, it is possible that we could incur operating losses in the future. These losses, among other things, may have an adverse effect on our stockholders' equity.

Our success will depend on our ability to attract and retain our personnel and manage our human capital, while controlling labor costs.

We depend to a significant degree on our senior management, especially Kevin Sayer, our President and Chief Executive Officer. Our success will depend on our ability to retain our senior management and to attract and retain qualified personnel in the future, including salespersons, scientists, clinicians, engineers and other highly skilled personnel. Competition for senior management personnel, as well as salespersons, scientists, clinicians and engineers, is intense and we may not be able to retain our

personnel. The loss of the services of members of our senior management, scientists, clinicians or engineers could prevent the implementation and completion of our objectives, including the commercialization of our current products and the development and introduction of additional products. The loss of a member of our senior management or our professional staff would require the remaining executive officers to divert immediate and substantial attention to seeking a replacement.

Each of our officers may terminate their employment at any time without notice and without cause or good reason. Additionally, volatility or a lack of positive performance in our stock price may adversely affect our ability to retain key employees.

We expect to continue to expand our operations and grow our research and development, manufacturing, sales and marketing, product development and administrative operations. We expect this expansion to place a significant strain on our management and it will require hiring a significant number of qualified personnel. Accordingly, recruiting and retaining such personnel will be critical to our success. There is intense competition from other companies and research and academic institutions for qualified personnel in the areas of our activities. If we fail to identify, attract, retain and motivate these skilled personnel, we may be unable to continue our development and commercialization activities.

We may undertake reorganizations of our workforce, which may result in a temporary reduction in the number of employees in certain locations. We would undertake a reorganization to reduce operating expenses or achieve other business objectives, though we cannot guarantee any specific amount of long-term cost savings. Further, the

[Table of Contents](#)

turnover in our employee base could result in operational and administrative inefficiencies, which could adversely impact the results of our operations, stock price and customer relationships, and could make recruiting for future management and other positions more difficult.

[We may conduct additional financings to continue the development or commercialization of our current or future generation CGM systems.](#)

Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts on commercialization of our products, including growth of our manufacturing capacity, on research and development, and conducting clinical trials for our next-generation ambulatory CGM sensors and systems. Although we raised substantial net proceeds through the private sale of our convertible notes, we could need funds to continue the commercialization of our current products and to develop and commercialize our next-generation sensors and systems or pursue other strategic initiatives. Additional financing may not be available on a timely basis on terms acceptable to us, or at all. Any additional financing may be dilutive to stockholders or may require us to grant a lender a security interest in our assets. The amount of funding we may need will depend on many factors, including:

- the revenue generated by sales of our products and other future products;
- the costs, timing and risks of delay of additional regulatory approvals;
- the expenses we incur in manufacturing, developing, selling and marketing our products;
- our ability to scale our manufacturing operations to meet demand for our current and any future products;
- the costs to produce our continuous glucose monitoring systems;
- the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;
- the rate of progress and cost of our clinical trials and other development activities;
- the success of our research and development efforts;
- the emergence of competing or complementary technologies;
- the terms and timing of any collaborative, licensing and other arrangements that we may establish;
- the cost of ongoing compliance with legal and regulatory requirements, and third-party payors' policies;
- the cost of obtaining and maintaining regulatory or payor clearance or approval for our current or future products including those integrated with other companies' products; and
- the acquisition of business, products and technologies, although we currently have no commitments or agreements relating to any of these types of transactions.

If adequate funds are not available, we may not be able to commercialize our products at the rate we desire and/or we may have to delay the development or commercialization of our products or license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize. We also may have to reduce sales, marketing, customer support or other resources devoted to our products. Any of these factors could harm our business and financial condition.

[Uncollectible uninsured and patient due accounts could adversely affect our results of operations.](#)

The primary collection risks for our accounts receivable relate to the uninsured patient accounts and patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (exclusions, deductibles and copayments) remain outstanding. In addition, as a result of the economic slowdown, some customers have, and others may, lose access to their private health insurance plan if they lose their job. As most of our customers rely on third-party payors, including private health insurance plans, to cover the cost of our products, there has been, and may continue to be, a shift in financial responsibility to our customers for the amounts previously covered by their primary insurance carrier.

In the event that we are unsuccessful in collecting payments owed by patients, and/or experience increases in the amount, or deterioration in the collectability, of uninsured and patient due accounts receivable, this could adversely affect our cash flows and results of operations. We may also be adversely affected by the growth in patient responsibility accounts, as a result of increases in the adoption of plan structures, due to evolving health care policy and insurance landscapes that shift greater responsibility for care to individuals through greater exclusions, prior authorizations, and copayment and deductible amounts.

[Table of Contents](#)

Changes in our business strategy or restructuring of our businesses may increase our costs or otherwise affect the profitability of our businesses or the value of our assets.

As changes in our business environment occur we have adjusted, and may further, adjust our business strategies to meet these changes and we may otherwise decide to further restructure our operations or particular businesses or assets. Our new organization and strategies may not produce the anticipated benefits, such as supporting our growth strategies and enhancing shareholder value. Our new organization and strategies could be less successful than our previous organizational structure and strategies. In addition, external events including changing technology, changing consumer patterns, acceptance of our products and changes in macroeconomic conditions may impair the value of our assets. When these changes or events occur, we may incur costs to change our business strategy and may need to write-down the value of assets. For example, current economic conditions, including rising interest rates, inflation and a potential recession, as well as our business decisions, may reduce the value of some of our assets. We also make investments in existing or new businesses, including investments in the international expansion of our sales efforts and the build-out of our manufacturing facility in Malaysia as well as our proposed facility in Ireland. Additionally, we also invest in early to late-stage companies for strategic reasons and to support key business initiatives, and we may not realize a return on our equity investments. Many such companies generate net losses and the market for their products, services, or technologies may be slow to develop or never materialize. We are subject to risks associated with our equity investments including partial or complete loss of invested capital, and significant changes in the fair value of this portfolio could adversely impact our financial results. Some of these investments may have returns that are negative or low, the ultimate business prospects of the businesses related to these investments may be uncertain, and these risks may be exacerbated by current macroeconomic conditions. In any of these events, our costs may increase or returns on new investments may be lower than prior to the change in strategy or restructuring.

Risks Relating to Our Public Company Status, Tax Laws and Growth Through Acquisition

We may face risks associated with acquisitions of companies, products and technologies and our business could be harmed if we are unable to address these risks.

If we are presented with appropriate opportunities, we could acquire or make other investments in complementary companies, products or technologies. We may not realize the anticipated benefit of our acquisitions, or the realization of the anticipated benefits may require greater expenditures than anticipated by us. We will likely face risks, uncertainties and disruptions associated with the integration process, including difficulties in the integration of the operations and services of any acquired company, integration of acquired technology with our products, diversion of our management's attention from other business concerns, the potential loss of key employees or customers of the acquired businesses and impairment charges if future acquisitions are not as successful as we originally anticipated. If we fail to successfully integrate other companies, products or technologies that we acquire, our business could be harmed. Furthermore, we may have to incur debt or issue equity or equity-linked securities to pay for any future acquisitions or investments, the issuance of which could be dilutive to our existing stockholders. In addition, our operating results may suffer because of acquisition-related costs, amortization expenses or charges relating to acquired intangible assets.

Compliance with regulations relating to public company corporate governance matters and reporting may strain our resources and divert management's attention.

Many laws and regulations, notably those adopted in connection with the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, new SEC regulations and The Nasdaq Stock Market listing rules, impose obligations on public companies, such as ours, which have increased the scope, complexity and cost of corporate governance, reporting and disclosure practices. Compliance with these laws and regulations, including enhanced new disclosures, has required and will continue to require substantial management time and oversight and the incurrence of significant accounting and legal costs. The effects of new laws and regulations remain unclear and will likely require substantial management time and oversight and require us to incur significant additional accounting and legal costs. Additionally, changes to existing accounting rules or standards, such as the potential requirement that U.S. registrants prepare financial statements in accordance with International Financial Reporting Standards, may adversely impact our reported financial results and business, and may require us to incur greater accounting fees. These laws, regulations, and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to continue to invest resources to comply with evolving laws, regulations, and standards, and this investment

Table of Contents

may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.

We could be subject to changes in our tax rates, new U.S. or international tax legislation or additional tax liabilities.

We are subject to taxes in the United States and numerous foreign jurisdictions, where a number of our subsidiaries are organized. The tax laws in the United States and in other countries in which we and our subsidiaries do business could change on a prospective or retroactive basis, and any such changes could adversely affect our business and financial condition. Further, due to economic and political conditions, tax rates in various jurisdictions may be subject to change. Our effective tax rates could be affected by numerous factors, including changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, and changes in tax laws or their interpretation, both in and outside the United States.

There is growing pressure in many jurisdictions, including the United States, and from multinational organizations such as the OECD and the European Union to amend existing international tax rules in order to render them more responsive to current global business practices.

Our tax returns and other tax matters also are subject to examination by the U.S. Internal Revenue Service and other tax authorities and governmental bodies. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of our provision for taxes. We cannot guarantee the outcome of these examinations. If our effective tax rates were to increase, particularly in the United States, or in other countries implementing legislation to reform existing tax legislation, including the European Union and Germany, or if the ultimate determination of our taxes owed is for an amount in excess of amounts previously accrued, our financial condition, operating results and cash flows could be adversely affected.

Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations which could subject our business to higher tax liability.

Our ability to use our net operating losses, or NOLs, to offset future taxable income may be subject to certain limitations which could subject our business to higher tax liability. We may be limited in the portion of NOL carryforwards that we can use in the future to offset taxable income for U.S. federal and state income tax purposes, and federal tax credits to offset federal tax liabilities. Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state law provisions, limit the use of NOLs and tax credits after a cumulative change in corporate ownership of more than 50% occurs within a three-year period. The statutes place a formula limit on how much NOLs and tax credits a corporation can use in a tax year after a change in ownership. Avoiding an ownership change is generally beyond our control. Although the ownership changes we experienced in the past have not prevented us from using all NOLs and tax credits accumulated before such ownership changes, we could experience another ownership change that might limit our use of NOLs and tax credits in the future. In addition, realization of deferred tax assets, including net operating loss carryforwards, depends upon our future earnings in applicable tax jurisdictions. If we have insufficient future taxable income in the applicable tax jurisdiction for any reason, including any future corporate reorganization or restructuring activities, we may be limited in our ability to utilize some or all of our net operating losses to offset such income and reduce our tax liability in that jurisdiction. We utilized that the majority of our remaining NOLs by the end of 2021, with the exception of the NOLs limited by Section 382 of the Internal Revenue Code of 1986. See Note 8 "Income Taxes" to the consolidated financial statements for the fiscal year ended December 31, 2022 in Part II, Item 8 of our Annual Report on Form 10-K that we filed with the SEC on February 9, 2023 for additional information.

There is also a risk that due to regulatory changes or changes to federal or state law, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable either in whole or in part to offset future income tax liabilities.

Valuation of share-based payments, which we are required to perform for purposes of recording compensation expense under authoritative guidance for share-based payment, involves assumptions that are subject to change and difficult to predict.

We record compensation expense in the consolidated statements of operations for share-based payments, such as restricted stock units and employee stock purchase plan shares, using the fair value method. The requirements of the authoritative guidance for share-based payment have and will continue to have a material effect

[Table of Contents](#)

on our future financial results reported under U.S. generally accepted accounting principles, or GAAP, and make it difficult for us to accurately predict the impact on our future financial results.

For instance, estimating the fair value of share-based payments is highly dependent on assumptions regarding the future exercise behavior of our employees and changes in our stock price. If there are errors in our input assumptions for our valuations models, we may inaccurately calculate actual or estimated compensation expense for share-based payments.

The authoritative guidance for share-based payment could also adversely impact our ability to provide accurate guidance on our future financial results as assumptions that are used to estimate the fair value of share-based payments are based on estimates and judgments that may differ from period to period. We may also be unable to accurately predict the amount and timing of the recognition of tax benefits associated with share-based payments as they are highly dependent on the exercise behavior of our employees and the price of our stock relative to the exercise price of each outstanding stock option.

For those reasons, among others, the authoritative guidance for share-based payment may create variability and uncertainty in the share-based compensation expense we will record in future periods, which could adversely impact our stock price and increase our expected stock price volatility as compared to prior periods.

Risks Related to Our Common Stock

Our stock price is highly volatile and investing in our stock involves a high degree of risk, which could result in substantial losses for investors.

Historically, the market price of our common stock, like the securities of many other medical products companies, fluctuates and could continue to be volatile in the future, especially as our business continues to grow and our business plan continues to evolve. From January 1, 2023 through September 30, 2023, the closing price of our common stock on the Nasdaq Global Select Market was as high as \$137.93 per share and as low as \$86.06 per share.

The market price of our common stock is influenced by many factors that are beyond our control, including the following:

- securities analyst coverage or lack of coverage of our common stock or changes in their estimates of our financial performance;
- variations in quarterly operating results;
- future sales of our common stock by our stockholders;
- investor perception of us and our industry;
- announcements by us or our competitors of significant agreements, acquisitions, or capital commitments or product launches or discontinuations;
- changes in market valuation or earnings of our competitors;
- negative business or financial announcements regarding our partners;
- general economic conditions;
- regulatory actions;
- legislation and political conditions;
- global health pandemics, such as the recent COVID-19 pandemic; and
- other events or factors, including the, ongoing conflicts in Ukraine and Israel, recessions, rising interest rates, inflation, local and national elections, international currency fluctuations, corruption, political instability and acts of war or terrorism.

Please also refer to the factors described elsewhere in this "Risk Factors" section. In addition, the stock market in general has experienced extreme price and volume fluctuations that have often been unrelated and disproportionate to the operating performance of companies in our industry. These broad market and industry factors may materially reduce the market price of our common stock, regardless of our operating performance.

Securities class action litigation has often been brought against public companies that experience periods of volatility in the market prices of their securities. Securities class action litigation could result in substantial costs and a diversion of our management's attention and resources.

[Table of Contents](#)

The issuance of shares by us in the future or sales of shares by our stockholders may cause the market price of our common stock to drop significantly, even if our business is performing well.

This issuance of shares by us in the future, including by conversion of our senior convertible notes in certain circumstances, the issuance of shares of our common stock to partners, including up to 5,154,640 shares of our common stock that we may issue to Verily pursuant to the Restated Collaboration Agreement, or sales of shares by our stockholders may cause the market price of our common stock to decline, perhaps significantly, even if our business is performing well. The market price of our common stock could also decline if there is a perception that sales of our shares are likely to occur in the future. This might also make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Also, we may issue securities in connection with future financings and acquisitions, and those shares could dilute the holdings of other stockholders.

We do not intend to pay dividends for the foreseeable future.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the foreseeable future and the terms of our credit agreement restrict our ability to declare or pay any dividends. As a result, stockholders (including holders of our senior convertible notes who receive shares of our common stock, if any, upon conversion of their notes) may only receive a return on their investment in our common stock if the market price of our common stock increases.

Anti-takeover effects of our charter documents and Delaware law could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.

There are provisions in our certificate of incorporation and bylaws, as well as provisions in the Delaware General Corporation Law, that may discourage, delay or prevent a change of control that might otherwise be beneficial to stockholders. For example:

- our Board of Directors may, without stockholder approval, issue shares of preferred stock with special voting or economic rights;
- our stockholders do not have cumulative voting rights and, therefore, each of our directors can only be elected by holders of a majority of our outstanding common stock;
- a special meeting of stockholders may only be called by a majority of our Board of Directors, the Chairman of our Board of Directors, our Chief Executive Officer, our President or our Lead Independent Director;
- our stockholders may not take action by written consent;
- our Board of Directors is divided into three classes, only one of which is elected each year (however, over a three year period beginning with the 2022 annual meeting of stockholders the Board will be declassified and by the conclusion of this process all directors will be elected annually); and
- we require advance notice for nominations for election to the Board of Directors or for proposing matters that can be acted upon by stockholders at stockholder meetings.

Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. In September 2020, we amended and restated our restated bylaws to provide that the federal district courts of the United States will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder must be brought in federal court.

Notwithstanding the foregoing, our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.

[Table of Contents](#)

Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. The exclusive forum provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results, and financial condition.

Moreover, Section 203 of the Delaware General Corporation Law may discourage, delay, or prevent a change of control of our company. Section 203 imposes certain restrictions on mergers, business combinations, and other transactions between us and holders of 15% or more of our common stock.

Risks Related to Our Debt

Increasing our financial leverage could affect our operations and profitability.

In June 2023, we entered into the First Amendment to our Second Amended and Restated Credit Agreement, or the Amended Credit Agreement, with JPMorgan Chase and other syndicate lenders, which amended and restated the credit agreement, or the Credit Agreement, we had previously entered into in December 2018 and amended in May 2020 and October 2021, respectively. The Amended Credit Agreement is a five-year \$200.0 million revolving credit facility, or the Credit Facility. As of September 30, 2023, we had no outstanding borrowings, \$7.3 million in outstanding letters of credit, and a total available balance of \$192.7 million under the Amended Credit Agreement.

Our leverage ratio may affect the availability to us of additional capital resources as well as our operations in several ways, including:

- the terms on which credit may be available to us could be less attractive, both in the economic terms of the credit and the legal covenants;
- the possible lack of availability of additional credit;
- the potential for higher levels of interest expense to service or maintain our outstanding debt;
- the possibility of additional borrowings in the future to repay our indebtedness when it comes due; and
- the possible diversion of capital resources from other uses.

While we believe we will have the ability to service our debt and obtain additional resources in the future if and when needed, that will depend upon our results of operations and financial position at the time, the then-current state of the credit and financial markets, and other factors that may be beyond our control. Therefore, we cannot give assurances that sufficient credit will be available on terms that we consider attractive, or at all, if and when necessary or beneficial to us.

Failure to comply with covenants in the Amended Credit Agreement could result in our inability to borrow additional funds and adversely impact our business.

The Amended Credit Agreement imposes numerous financial and other restrictive covenants on our operations, including covenants relating to our general profitability and our liquidity. As of September 30, 2023, we were in compliance with the covenants imposed by the Amended Credit Agreement. If we violate these or any other covenants, any outstanding amounts under the Amended Credit Agreement could become due and payable prior to their stated maturity dates, each lender could proceed against any collateral in our operating accounts and our ability to borrow funds in the future may be restricted or eliminated. These restrictions may also limit our ability to borrow additional funds and pursue other business opportunities or strategies that we would otherwise consider to be in our best interests.

We have indebtedness in the form of convertible senior notes, which could adversely affect our financial health and our ability to respond to changes in our business.

In November 2018, we completed an offering of \$850.0 million aggregate principal amount of 0.75% senior convertible notes due 2023, or 2023 Notes, which offering we refer to as the 2018 Notes Offering. In May 2020, we completed an offering of approximately \$1.21 billion aggregate principal amount of 0.25% senior convertible notes due 2025, or 2025 Notes, which offering we refer to as the 2020 Notes Offering. In May 2023, we completed an offering of approximately \$1.25 billion aggregate principal amount of 0.375% senior convertible notes due 2028, or 2028 Notes, which offering we refer to as the 2023 Notes Offering. We refer to the 2018 Notes Offering, the 2020

Table of Contents

Notes Offering, and the 2023 Notes Offering, collectively, as the Notes Offerings, and we refer to the 2023 Notes, the 2025 Notes, and the 2028 Notes, collectively, as the Notes. As a result of the Notes Offerings, we incurred \$3.31 billion principal amount of indebtedness, the principal amount of which we may be required to pay at maturity.

Holders of the Notes will have the right to require us to repurchase their notes upon the occurrence of a fundamental change (as defined in the indenture for each of the Notes) at a purchase price equal to 100% of the principal amount of the notes to be purchased, plus accrued and unpaid interest, if any. In addition, each indenture for the Notes provides that we are required to repay amounts due under each indenture in the event that there is an event of default for the Notes that results in the principal, premium, if any, and interest, if any, becoming due prior to the maturity date for the Notes. There can be no assurance that we will be able to repay this indebtedness when due, or that we will be able to refinance this indebtedness on acceptable terms or at all.

As a result of our level of increased debt after the completion of the Notes Offerings:

- our vulnerability to adverse general economic conditions and competitive pressures will be heightened;
- we will be required to dedicate a larger portion of our cash flow from operations to interest payments, limiting the availability of cash for other purposes;
- our flexibility in planning for, or reacting to, changes in our business and industry may be more limited; and
- our ability to obtain additional financing in the future for working capital, capital expenditures, acquisitions, general corporate purposes or other purposes may be impaired.

We cannot be sure that our leverage resulting from the level of increased debt after the completion of the Notes Offerings will not materially and adversely affect our ability to finance our operations or capital needs or to engage in other business activities. In addition, we cannot be sure that additional financing will be available when required or, if available, will be on terms satisfactory to us. Further, even if we are able to obtain additional financing, we may be required to use such proceeds to repay a portion of our debt.

We may be unable to repurchase the Notes upon a fundamental change when required by the holders or repay prior to maturity any accelerated amounts due under the notes upon an event of default or redeem the Notes unless specified conditions are met under our Credit Facility, and our future debt may contain additional limitations on our ability to pay cash upon conversion, repurchase or repayment of the Notes.

Holders of the Notes will have the right to require us to repurchase their Notes upon the occurrence of a fundamental change at a purchase price equal to 100% of the principal amount of the Notes to be purchased, plus accrued and unpaid interest, if any, to, but not including, the fundamental change purchase date. In addition, each indenture for the Notes provides that we are required to repay amounts due under each indenture in the event that there is an event of default for the Notes that results in the principal, premium, if any, and interest, if any, becoming due prior to the maturity date for the Notes. In addition, upon conversion of the Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than cash in lieu of any fractional share), we will be required to make cash payments in respect of the Notes being converted.

However, we may not have enough available cash or be able to obtain financing at the time we are required to repurchase Notes surrendered upon a fundamental change or repay prior to maturity any accelerated amounts or pay cash for Notes being converted.

In addition, our ability to purchase the Notes or repay prior to maturity any accelerated amounts under the Notes upon an event of default or pay cash upon conversions of the Notes may be limited by law, by regulatory authority or by agreements governing our indebtedness outstanding at the time, including our Credit Facility. Under our Credit Facility, we are only permitted to use cash to purchase the Notes or repay prior to maturity any accelerated amounts under the Notes if we meet certain conditions that are defined under the Credit Agreement. We may not meet these conditions in the future. Our failure to repurchase Notes at a time when the repurchase is required by the respective indenture (whether upon a fundamental change or otherwise under each indenture) or pay cash payable on future conversions of the Notes as required by the indenture would constitute a default under each indenture. A default under each indenture or the fundamental change itself could also lead to a default under agreements governing our existing or future indebtedness, including our Credit Facility. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness, repurchase the Notes or make cash payments upon conversions thereof.

We may still incur substantially more debt or take other actions which would intensify the risks discussed above.

We may incur substantial additional debt in the future, subject to the restrictions contained in our debt instruments, some of which may be secured debt. We are not restricted under the terms of the indentures governing

[Table of Contents](#)

the Notes from incurring additional debt, securing existing or future debt, recapitalizing our debt, or taking a number of other actions that are not limited by the terms of the indenture governing the convertible senior notes that could have the effect of diminishing our ability to make payments on the Notes when due.

The capped call transactions we entered into in connection with the pricing of the 2028 Notes may affect the value of our 2028 Notes and common stock.

In connection with the pricing of the 2028 Notes, we entered into capped call transactions, or the 2028 Capped Calls, relating to such 2028 Notes with the option counterparties. The 2028 Capped Calls relating to the 2028 Notes cover, subject to customary adjustments, the number of shares of our common stock that initially underlie the 2028 Notes. The 2028 Capped Calls are generally expected to reduce the potential dilution to stockholders upon any conversion of the 2028 Notes, and/or offset any cash payments that we are required to make in excess of the principal amount upon any conversion of the 2028 Notes, with such reduction and/or offset subject to a cap.

The option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock in secondary market transactions following the pricing of the 2028 Notes, as applicable, and prior to the maturity of the 2028 Notes (and are likely to do so during any observation period related to a conversion of such Notes or following any repurchase of such notes by us on any fundamental change repurchase date or otherwise). This activity could also cause or avoid an increase or a decrease in the market price of our 2028 Notes or common stock, which could affect a holder's ability to convert its 2028 Notes and, to the extent the activity occurs during any observation period related to a conversion of the 2028 Notes, it could affect the amount and value of the consideration that a holder will receive upon conversion of such 2028 Notes.

The potential effect, if any, of these transactions and activities on the market price of the 2028 Notes or our common stock will depend in part on market conditions and cannot be ascertained at this time. Any of these activities could adversely affect the value of 2028 Notes or our common stock (and as a result, the amount and value of the consideration that a holder would receive upon the conversion of any 2028 Notes) and, under certain circumstances, a holder's ability to convert its notes.

We do not make any representation or prediction as to the direction or magnitude of any potential effect that the transactions described above may have on the price of the 2028 Notes or our common stock. In addition, we do not make any representation that the option counterparties or their respective affiliates will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.

The convertible note hedge and warrant transactions may affect the value of the 2023 Notes and our common stock.

In connection with the sale of the 2023 Notes, we entered into convertible note hedge, or the 2023 Note Hedge, transactions with certain financial institutions, or option counterparties. We also entered into warrant transactions with the option counterparties pursuant to which we sold warrants for the purchase of our common stock, or the 2023 Warrants. The 2023 Note Hedge transactions are expected generally to reduce the potential dilution upon any conversion of the 2023 Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted 2023 Notes. The 2023 Warrant transactions could separately have a dilutive effect to the extent that the market price per share of our common stock exceeds the exercise price of the 2023 Warrants, which is \$49.60.

The option counterparties and/or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock in secondary market transactions prior to the maturity of 2023 Notes (and are likely to do so during any observation period related to a conversion of 2023 Notes, or following any repurchase of Notes by us on any fundamental change repurchase date (as defined in the indenture for the 2023 Notes) or otherwise). This activity could also cause or avoid an increase or a decrease in the market price of our common stock or the 2023 Notes, which could affect note holders' ability to convert the 2023 Notes and, to the extent the activity occurs during any observation period related to a conversion of the 2023 Notes, it could affect the amount and value of the consideration that note holders will receive upon conversion of the 2023 Notes.

The potential effect, if any, of these transactions and activities on the market price of our common stock or the 2023 Notes will depend in part on market conditions and cannot be ascertained at this time. Any of these activities could adversely affect the value of our common stock and the value of the 2023 Notes (and as a result, the value of the consideration, the amount of cash and/or the number of shares, if any, that note holders would receive upon the conversion of the 2023 Notes) and, under certain circumstances, the ability of the note holders to convert the 2023 Notes.

[Table of Contents](#)

We do not make any representation or prediction as to the direction or magnitude of any potential effect that the transactions described above may have on the price of the 2023 Notes or our common stock. In addition, we do not make any representation that the option counterparties will engage in these transactions or that these transactions,

once commenced, will not be discontinued without notice.

We are subject to counterparty risk with respect to the 2023 Note Hedge transactions and the 2028 Capped Calls.

The option counterparties to the 2023 Note Hedge transactions and 2028 Capped Calls are financial institutions, and we will be subject to the risk that any or all of them may default under the 2023 Note Hedge transactions and 2028 Capped Calls, respectively. Our exposure to the credit risk of these counterparties is not secured by any collateral. Recent global economic conditions have resulted in the actual or perceived failure or financial difficulties of many financial institutions. If a counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings, with a claim equal to our exposure at that time under our transactions with that option counterparty. Our exposure will depend on many factors but, generally, an increase in our exposure will be correlated to an increase in the market price and in the volatility of our common stock. In addition, upon a default by an option counterparty, we may suffer adverse tax consequences and more dilution than we currently anticipate with respect to our common stock. We can provide no assurances as to the financial stability or viability of the counterparties with respect to the 2023 Note Hedge transactions and 2028 Capped Calls.

Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.

Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including the Notes, depends on our future financial condition and operating performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not continue to generate cash flow from operations in the future sufficient to satisfy our obligations under the Notes, our existing indebtedness and any future indebtedness we may incur and to make necessary capital expenditures. We may not maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on (as well as any cash due upon conversion of) our debt, including the Notes.

If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as reducing or delaying investments or capital expenditures, selling assets, refinancing or obtaining additional equity capital on terms that may be onerous or highly dilutive. These alternative measures may not be successful and may not permit us to meet our scheduled debt servicing obligations. Further, we may need to refinance all or a portion of our debt on or before maturity, and our ability to refinance the Notes, existing indebtedness or future indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities on commercially reasonable terms or at all, which could result in a default on the Notes or our current and future indebtedness.

Our Credit Facility imposes restrictions on us that may adversely affect our ability to operate our business.

Our Credit Facility contains restrictive covenants relating to our capital raising activities and other financial and operational matters which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. In addition, our Credit Facility and the agreements governing the notes each contain cross-default provisions whereby a default under one agreement would likely result in cross defaults under agreements covering other borrowings. For example, the occurrence of a default with respect to any indebtedness or any failure to repay debt when due in an amount in excess of \$25.0 million, in the case of the 2023 Notes, \$50.0 million, in the case of the 2025 Notes, and \$50.0 million, in the case of the 2028 Notes, that causes such indebtedness to become due prior to its scheduled maturity date would cause a cross-default under the indenture governing the Notes. In addition, the occurrence of a default with respect to any indebtedness or any failure to repay debt when due in an amount in excess of \$25.0 million that causes such indebtedness to become due prior to its scheduled maturity date would cause a default under our Credit Facility. The occurrence of a default under any of these borrowing arrangements would permit the holders of the Notes or the lenders under our Credit Facility to declare all amounts outstanding under those borrowing arrangements to be immediately due and payable. If the Note holders or the trustee under the indenture governing the Notes or the lenders under our Credit Facility accelerate the repayment of borrowings, we cannot assure you that we will have sufficient assets to repay those borrowings.

Table of Contents

Conversion of the Notes will, to the extent we deliver shares upon conversion of such Notes, dilute the ownership interest of existing stockholders, including holders who had previously converted their Notes, or may otherwise depress our stock price.

The conversion of some or all of the Notes will dilute the ownership interests of existing stockholders to the extent we deliver shares upon conversion of any of the Notes. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress our stock price.

The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operating results.

In the event the conditional conversion feature of the Notes is triggered, holders of the Notes will be entitled to convert the Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than cash in lieu of any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders of the Notes do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.

The accounting method for convertible debt securities that may be settled in cash, such as the Notes, may have a material effect on our reported financial results.

If the conditional conversion feature of the Notes is triggered, holders of the Notes will be entitled to convert the Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than by paying cash in lieu of delivering any fractional share), we may settle all or a portion of our conversion obligation in cash, which could adversely affect our liquidity. In addition, the consideration received upon the unwind or termination of the capped call transactions may not completely offset, and may be substantially less than, any cash payments in excess of the principal amount of the Notes we are required to make upon conversion of the Notes. Even if holders do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.

The fundamental change repurchase feature of the Notes may delay or prevent an otherwise beneficial attempt to take over Dexcom.

The terms of the Notes require us to repurchase the Notes in the event of a fundamental change. A takeover of Dexcom would trigger an option of the holders of the Notes to require us to repurchase the Notes. In addition, if a make-whole fundamental change occurs prior to the maturity date of the Notes, we will in some cases be required to

increase the conversion rate for a holder that elects to convert its Notes in connection with such make-whole fundamental change. Furthermore, each indenture for the Notes prohibits us from engaging in certain mergers or acquisitions unless, among other things, the surviving entity assumes our obligations under the notes. These and other provisions of each indenture may have the effect of delaying or preventing a takeover of Dexcom.

Risks Related to Environmental, Social and Governance Matters

Environmental, social and governance, or ESG, regulations, policies and provisions could expose us to numerous risks.

Increasingly, regulators, customers, investors, employees and other stakeholders are focusing on ESG matters and related disclosures. These changing rules, regulations and stakeholder expectations have resulted in, and are likely to continue to result in, increased general and administrative expenses and increased management time and attention spent complying with or meeting such regulations and expectations. For example, collecting, measuring and reporting ESG-related data and information is subject to evolving reporting standards, including the SEC's proposed climate-related reporting requirements, and similar proposals by other international regulatory bodies. In addition, a number of our customers who are payors or distributors have adopted, or may adopt, procurement policies that include ESG provisions that their suppliers or manufacturers must comply with, or they may seek to include such provisions in their terms and conditions. An increasing number of participants in the medical device industry are also joining voluntary ESG groups or organizations, such as the Responsible Business Alliance. These

[Table of Contents](#)

ESG provisions and initiatives are subject to change, can be unpredictable, and may be difficult and expensive for us to comply with, given the complexity of our supply chain and the outsourced manufacturing of certain components of our products. If we are unable to comply, or are unable to cause our suppliers to comply, with such policies or provisions, a customer may stop purchasing products from us, and may take legal action against us, which could harm our reputation, revenue and results of operations.

Our business could be negatively impacted by evolving expectations and challenges relating to implementing ESG initiatives, setting ESG-related goals, collecting ESG-related data, and disclosing ESG-related information.

We may communicate certain initiatives and goals regarding ESG-related matters in our SEC filings or in other public disclosures. These ESG-related initiatives and goals could be difficult and expensive to implement, the technologies needed to implement them may not be cost effective and may not advance at a sufficient pace, and we could be criticized for the accuracy, adequacy or completeness of the disclosure. Further, statements about our ESG-related initiatives and goals, and progress against those goals, may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. In addition, we could be criticized for the scope or nature of such initiatives or goals, or for any revisions to these goals. If our ESG-related data, processes and reporting are incomplete or inaccurate, or if we fail to achieve progress with respect to our ESG-related goals on a timely basis, or at all, our reputation, business, financial performance and growth could be adversely affected.

Climate change may have a long-term impact on our business.

While we seek to partner with organizations that mitigate their business risks associated with climate change, we recognize that there are inherent risks related to climate change wherever business is conducted. Access to clean water and reliable energy in the communities where we conduct our business, whether for our offices or for our vendors, is a priority. Our manufacturing sites in California, Arizona and Malaysia and our operations in the Philippines are vulnerable to climate change effects. For example, in California and Arizona, increasing intensity of droughts throughout the states and annual periods of wildfire danger increase the probability of planned and unplanned power outages in the communities where we work and live. While this danger has a low-assessed risk of disrupting normal business operations, it has the potential impact on employees' abilities to commute to work or to work from home and stay connected effectively. Climate-related events, including the increasing frequency of extreme weather events and their impact on the U.S., the Philippines, Malaysia and other major regions' critical infrastructure, have the potential to disrupt our business, our third-party suppliers, and/or the business of our customers, and may cause us to experience higher attrition, losses, and additional costs to maintain or resume operations.

We may be liable for contamination or other harm caused by materials that we handle, and changes in environmental regulations could cause us to incur additional expense.

Our research and development and clinical processes involve the handling of potentially harmful biological materials as well as hazardous materials. We are subject to international and domestic (including federal, state and local) laws, rules and regulations governing the use, handling, storage and disposal of hazardous and biological materials and we incur expenses relating to compliance with these laws and regulations. If violations of environmental, health and safety laws occur, we could be held liable for damages, penalties and costs of remedial actions. These expenses or this liability could have a significant negative impact on our financial condition. We may violate environmental, health and safety laws in the future as a result of human error, equipment failure or other causes. Environmental laws could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We are subject to potentially conflicting and changing regulatory agendas of political, business and environmental groups. Changes to or restrictions on permitting requirements or processes, hazardous or biological material storage or handling might require unplanned capital investment or relocation. Failure to comply with new or existing laws or regulations could harm our business, financial condition and results of operations.

[Table of Contents](#)

General Risk Factors

Current uncertainty in domestic and global economic and political conditions makes it particularly difficult to predict product demand and other related matters and makes it more likely that our actual results could differ materially from expectations.

Our operations and performance depend on worldwide economic and political conditions. These conditions have been adversely impacted by continued global economic uncertainty, political instability and military hostilities in multiple geographies (including the conflict between Ukraine and Russia), monetary and financial uncertainties in Europe and other foreign countries, global health pandemics, rising interest rates, and domestic and global inflationary trends. These include potential reductions in the overall stability and suitability of the Euro as a single currency, given the economic and political challenges facing individual Eurozone countries. These conditions have made and may continue to make it difficult for our customers and potential customers to afford our products, and could cause our customers to stop using our products or to use them less frequently. If that were to occur, our revenue may decrease and our performance may be negatively impacted. In addition, the pressure on consumers to absorb more of their own health care costs has resulted in some cases in higher deductibles and limits on durable medical equipment, which may cause seasonality in purchasing patterns. Furthermore, during economic uncertainty, our customers have had job losses and may continue to have issues gaining timely access to sufficient health insurance or credit, which could result in their unwillingness to purchase products or impair their ability to make timely payments to us. A recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock.

We cannot predict the reoccurrence of any economic slowdown or the strength or sustainability of the economic recovery, worldwide, in the United States, or in our industry. These and other economic factors could have a material adverse effect on our business, financial condition and results of operations.

We may be adversely affected by the effects of inflation.

Inflation has the potential to adversely affect our liquidity, business, financial condition and results of operations by increasing our overall cost structure. The existence of inflation in the economy has resulted in, and may continue to result in, higher interest rates and capital costs, supply shortages, increased costs of labor, components, manufacturing and shipping, as well as weakening exchange rates and other similar effects. As a result of inflation, we have experienced and may continue to experience cost increases. Although we may take measures to mitigate the effects of inflation, if these measures are not effective, our business, financial condition, results of operations and liquidity could be materially adversely affected. Even if such measures are effective, there could be a difference between the timing of when these beneficial actions impact our results of operations and when the cost of inflation is incurred.

If we are unable to successfully maintain effective internal control over financial reporting, investors may lose confidence in our reported financial information and our stock price and our business may be adversely impacted.

As a public company, we are required to maintain internal control over financial reporting and our management is required to evaluate the effectiveness of our internal control over financial reporting as of the end of each fiscal year. If we are not successful in maintaining effective internal control over financial reporting, there could be inaccuracies or omissions in the consolidated financial information we are required to file with the SEC. Additionally, even if there are no inaccuracies or omissions, we will be required to publicly disclose the conclusion of our management that our internal control over financial reporting or disclosure controls and procedures are not effective. These events could cause investors to lose confidence in our reported financial information, adversely impact our stock price, result in increased costs to remediate any deficiencies, attract regulatory scrutiny or lawsuits that could be costly to resolve and distract management's attention, limit our ability to access the capital markets or cause our stock to be delisted from The Nasdaq Stock Market or any other securities exchange on which it is then listed.

Changes in financial accounting standards or practices or existing taxation rules or practices may cause adverse unexpected revenue and/or expense fluctuations and affect our reported results of operations.

A change in accounting standards or practices or a change in existing taxation rules or practices can have a significant effect on our reported results and may even affect our reporting of transactions completed before the change is effective. New accounting pronouncements and taxation rules and varying interpretations of accounting pronouncements and taxation practice have occurred and may occur in the future. The method in which we market and sell our products may have an impact on the manner in which we recognize revenue. In addition, changes to

Table of Contents

existing rules or the questioning of current practices may adversely affect our reported financial results or the way we conduct our business. Additionally, changes to existing accounting rules or standards, such as the potential requirement that U.S. registrants prepare financial statements in accordance with International Financial Reporting Standards, may adversely impact our reported financial results and business, and may further require us to incur greater accounting fees.

If our financial performance fails to meet the expectations of investors and public market analysts, the market price of our common stock could decline.

Our revenues and operating results may fluctuate significantly from quarter to quarter. We believe that period-to-period comparisons of our operating results may not be meaningful and should not be relied on as an indication of our future performance. If quarterly revenues or operating results fall below the expectations of investors or public market analysts, the trading price of our common stock could decline substantially. Factors that might cause quarterly fluctuations in our operating results include:

- our inability to manufacture an adequate supply of product at appropriate quality levels and acceptable costs;
- possible delays in our research and development programs or in the completion of any clinical trials;
- a lack of acceptance of our products in the marketplace by physicians and people with diabetes;
- the inability of customers to receive reimbursements from third-party payors;
- the purchasing patterns of our customers, including as a result of seasonality;
- failures to comply with regulatory requirements, which could lead to withdrawal of products from the market;
- our failure to continue the commercialization of any of our CGM systems;
- competition;
- inadequate financial and other resources; and
- global political and economic conditions, political instability and military hostilities.

Table of Contents

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 - MINE SAFETY DISCLOSURES

None.

Table of Contents

ITEM 5 - OTHER INFORMATION

Trading Plans

During the three months ended September 30, 2023 March 31, 2024, none of our the following Section 16 officers and directors or officers informed us of the adoption or termination of adopted a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as those terms are (as defined in Item 408 of Regulation S-K Item 408, except as described in of the table below; Exchange Act) intended to satisfy the affirmative defense of Rule 10b5-1(c):

| Name | Title | Action | Action Date | Character of Trading Arrangement | | Total Aggregate Number of Shares to be Sold ⁽³⁾ | Expiration Date ⁽²⁾ |
|-------------------------------|---|----------------------------|-------------|----------------------------------|-------------------|--|--------------------------------|
| | | | | Rule 10b5-1* | Non-Rule 10b5-1** | | |
| Michael Brown Mark G. Foletta | Director | Adoption ⁽³⁾ | 3/15/2024 | 6,000 | 3/15/2025 | | |
| Bridgette P. Heller | Director | Adoption | 2/25/2024 | 3,352 | 3/21/2025 | | |
| Jacob S. Leach | Executive Vice President, Chief Legal Operating Officer | Termination ⁽²⁾ | 8/29/2023 | X | | 3,612 | 12/15/2023 |
| Michael Brown | Executive Vice President, Chief Legal Officer | Adoption ⁽²⁾ | 8/29/2023 | X | | Up to 14,463 ⁽³⁾ | 8/30/2024 |
| Nicholas Augustinos | Director | Adoption | 9/15/2023 | X | | Up to 7,648 | 9/3/15/2024 102,732 3/15/2025 |

* Intended to satisfy the affirmative defense of Rule 10b5-1(c)

** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)

⁽¹⁾ Except The actual number of shares sold may depend on the net shares vested as indicated by footnote, each a result of tax withholding obligations, the vesting of certain PSUs, the number of shares purchased under employee stock purchase plans, one or more limit orders, as applicable, and therefore, may not be determinable at this time.

⁽²⁾ Each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table.

⁽³⁾ ⁽³⁾ Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, Adopted on behalf of a written plan adopted on 12/15/2022 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), trust for which Mr. Foletta serves as then in effect, under the Exchange Act.

⁽³⁾ The number of shares of common stock sold under the Rule 10b5-1 trading arrangement will be net of shares withheld for applicable tax obligations upon the vesting of covered securities and is not yet determinable. a trustee.

Each new of the Rule 10b5-1 Plan that was adopted trading arrangements disclosed in the above table includes a representation from Messrs. Brown and Augustinos, respectively, to the broker administering the plan that he was not adopted in possession of any material nonpublic information regarding Dexcom or the securities subject to the Rule 10b5-1 Plan at the time the Rule 10b5-1 Plan was entered into. A similar representation was made to Dexcom in connection accordance with the adoption of the Rule 10b5-1 Plan under Dexcom's our insider trading policy. Those representations were Transactions made as of the Adoption Date set forth above, and speak only as of that date. In making those representations, there is no assurance with respect pursuant to any material nonpublic information of which the directors and officers was unaware, or with respect to any material nonpublic information acquired by the above directors and officers or Dexcom after the date of the representation.

Once executed, transactions under a Rule 10b5-1 Plan adopted during the period described above such trading arrangements will be disclosed publicly through Form 4 and/or Form 144 in Section 16 filings with the SEC in accordance with applicable securities laws, rules and regulations. Except as may be required by law, Dexcom does not undertake any obligation to update or report any modification, termination, or other activity under current or future Rule 10b5-1 plans that may be adopted by Messrs. Brown and Augustinos, respectively, or other

No Section 16 officers or directors adopted, modified, or terminated a "non-Rule 10b5-1 trading arrangement" (as defined in Item 408 of Dexcom, Regulation S-K of the Exchange Act) during the three months ended March 31, 2024.

[Table of Contents](#)

ITEM 6 - EXHIBITS

| Exhibit Number | Exhibit Description | Incorporated by Reference | | | | Provided Herewith |
|--|---|---------------------------|---------------------------|-----------------------------------|----------------------|-------------------|
| | | Form | File No. | Date of First Filing | Exhibit Number | |
| 10.01* 10.1* | Amendment Number Sixteen to Amended and Restated Non-Exclusive Distribution Warrant Termination Agreement dated September 1, 2023, by and between DexCom, Inc. and Byram Healthcare Centers, Inc, Bank of America, N.A., dated February 13, 2024. | 8-K | 000-51222 | February 15, 2024 | 10.1 | X |
| 10.02* | Amendment Number Thirteen to Non-Exclusive Distribution Agreement, dated September 1, 2023, by and between DexCom, Inc. and RGH Enterprises, LLC. | — | — | — | — | X |
| 31.01 | Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). | — | — | — | — | X |
| 31.02 | Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). | — | — | — | — | X |
| 32.01** | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b). | — | — | — | — | X |
| 32.02** | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b). | — | — | — | — | X |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | | | | | X |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | | | | | X |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | | | | | X |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | | | | | X |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | | | | | X |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | | | | | X |

| Exhibit Number | Exhibit Description | Incorporated by Reference | | | Exhibit Number | Provided Herewith |
|-------------------|--|---------------------------|----------|----------------------------|-------------------|----------------------|
| | | Form | File No. | Date of First Filing | | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | | | | | X |
| 104 | Cover Page Interactive Data File - the cover page from the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 March 31, 2024 is formatted in Inline XBRL | | | | | X |

* Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

** This certification is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act, of 1934, except to the extent that Dexcom specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: October 26, 2023 April 25, 2024

By:

DEXCOM, INC.
(Registrant)

Kevin R. Sayer,
Chairman of the Board of Directors,
President and Chief Executive Officer
(Principal Executive Officer)

Dated: October 26, 2023 April 25, 2024

By:

Jereme M. Sylvain,
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*****], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL.

AMENDMENT NUMBER SIXTEEN
TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT

This AMENDMENT NUMBER SIXTEEN TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT ("Amendment") is made effective as of September 1, 2023 ("Amendment Effective Date") by and between DexCom, Inc. ("DexCom") and Byram Healthcare Centers, Inc. ("Distributor"). Capitalized terms used herein but not defined shall have the meaning ascribed to them in the Agreement.

RECITALS

WHEREAS, DexCom and Distributor previously entered into that certain Amended and Restated Non-Exclusive Distribution Agreement entered into by the Parties as of February 1, 2016 (as the same has been and may be amended from time to time, the "Agreement"); and

WHEREAS, DexCom and Distributor desire to further amend the Agreement, as more fully described herein.

AGREEMENT

NOW THEREFORE, DexCom and Distributor agree as follows:

1. Section 17, General Provisions.

a. The below subsection of Section 17, General Provisions, is hereby deleted and replaced in its entirety with the following:

i. 17.1 Notice. Any notice or other communication required or permitted to be given under this Agreement shall be properly served only if it is in writing addressed as set out below or through electronic means including by e-mail to the e-mail address(es) listed below. Notice in writing may be sent by any of the following methods: (i) personal delivery; (ii) nationally recognized overnight courier service; (iii) U.S. Postal Service certified or registered mail, return receipt requested, postage prepaid; or (iv) via e-mail. Service shall be deemed to have been duly given on the date of delivery or on the date which is [*****] days from the date of deposit in the U.S. Postal Service in the manner described above. Either party may change the names, address(es), and e-mail address(es) for receipt of notice by complying with this Section 17.1.

If to DexCom: DexCom, Inc.
6340 Sequence Drive
San Diego, CA 92121
Attn: Strategic Accounts Contracting

With a copy to: DexCom, Inc.
6340 Sequence Drive
San Diego, CA 92121
Attn: Legal Department

Notice E-mail: [*****] and [*****]

If to Distributor: Byram Healthcare
120 Bloomingdale Road, Suite 301

White Plains, NJ 10605

With a copy to: Byram Healthcare
Attn: Legal Department
5302 Rancho Road
Huntington Beach, CA 92847
Notice E-mail: [*****] & [*****]

2. Schedule 1, The Products and The Prices.

a. Schedule 1 of the Agreement is hereby deleted and replaced in its entirety.

3. Exhibit 7, [*****] Rebate.

a. Exhibit 7, including Exhibit 7 (A) and Exhibit 7 (B), attached hereto is hereby appended to the Agreement and made a part hereof.

4. **No Further Modification.** Except to the extent set forth in this Amendment, all other terms and conditions of the Agreement shall remain unmodified and in full force and effect.

[Remainder of Page Intentionally Blank;
Signature Page Follows]

IN WITNESS WHEREOF, the parties have executed this Amendment effective as of the Amendment Effective Date.

DexCom, Inc.

By: /s/ Christophe Cantenot
Name: Christophe Cantenot
Title: VP, Finance and Corporate Controller
Date: 9/25/2023

Distributor

By: /s/ Neel Vadhan
Name: Neel Vadhan
Title: VP, Purchasing
Date: 9/22/2023

SCHEDULE 1

The Products and The Prices

[*****]

EXHIBIT 7 (A)

[***] Rebate**

[*****]

EXHIBIT 7 (B)

Eligible Plans

[*****]

Exhibit 10.02

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL.**

**AMENDMENT NUMBER THIRTEEN
TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT**

This AMENDMENT NUMBER THIRTEEN TO THE NON-EXCLUSIVE DISTRIBUTION AGREEMENT (“**Amendment**”) is made effective as of September 1, 2023 (“**Amendment Effective Date**”) by and between DexCom, Inc. (“**DexCom**”) and RGH Enterprises LLC. dba Edgepark Medical Supplies (“**Distributor**”). Capitalized terms used herein but not defined shall have the meaning ascribed to them in the Agreement.

RECITALS

WHEREAS, DexCom and Distributor previously entered into that certain Non-Exclusive Distribution Agreement entered into by the Parties as of April 30, 2008 (as the same has been and may be amended from time to time, the “Agreement”); and

WHEREAS, DexCom and Distributor desire to further amend the Agreement, as more fully described herein.

AGREEMENT

NOW THEREFORE, DexCom and Distributor agree as follows:

1. Section 16, General Provisions.

a. The below subsection of Section 16, General Provisions, is hereby deleted and replaced in its entirety with the following:

- i. 16.1 Notice. Any notice or other communication required or permitted to be given under this Agreement shall be properly served only if it is in writing addressed as set out below or through electronic means including by e-mail to the e-mail address(es) listed below. Notice in writing may be sent by any of the following methods: (i) personal delivery; (ii) nationally recognized overnight courier service; (iii) U.S. Postal Service certified or registered mail, return receipt requested, postage prepaid; or (iv) via e-mail. Service shall be deemed to have been duly given on the date of delivery or on the date which is [*****] days from the date of deposit in the U.S. Postal Service in the manner described above. Either party may change the names, address(es), and e-mail address(es) for receipt of notice by complying with this Section 16.1.

If to DexCom: DexCom, Inc.
6340 Sequence Drive
San Diego, CA 92121
Attn: Strategic Accounts Contracting

With a copy to: DexCom, Inc.
6340 Sequence Drive
San Diego, CA 92121
Attn: Legal Department

Notice E-mail: [*****] and [*****]

If to Distributor: RGH Enterprises, Inc.
1810 Summit Commerce Park

Twinsburg, OH 44087
Attn: Gordon Harris
With a copy to: RGH Enterprises, LLC
7000 Cardinal Place
Dublin, OH 43017
Attn: VP, Asst. General Counsel, CHAH
Notice E-mail: [*****]

2. Schedule 1, The Products and The Prices.

- a. Schedule 1 of the Agreement is hereby deleted and replaced in its entirety.

3. Exhibit 7, [***] Rebate.**

- a. Exhibit 7, including Exhibit 7 (A) and Exhibit 7 (B), attached hereto is hereby appended to the Agreement and made a part hereof.

4. Section A. Rebates of Amendment dated April 30, 2016.

- a. Paragraph 2. Rebate of Section A. Rebates of the Amendment dated April 30, 2016 is hereby amended and restated in its entirety as of the Amendment Effective Date to read as follows:
2. Rebate. DexCom shall pay Distributor, [*****], a monthly rebate equal to [*****] (the "Rebate"). The aggregate Rebate invoiced by Distributor shall be paid in full by DexCom to Distributor within [*****] days following receipt by DexCom of the invoice and reports from Distributor for such month. DexCom shall remit payments either electronically, via wire transfer or ACH, to Distributor's bank account or by check to Distributor's lock box according to instructions provided by Distributor. Should Distributor not receive payment within this time period, Distributor may deduct the amount of the Rebate from any subsequent payment owed by Distributor to DexCom.
5. **No Further Modification.** Except to the extent set forth in this Amendment, all other terms and conditions of the Agreement shall remain unmodified and in full force and effect.

[Remainder of Page Intentionally Blank;
Signature Page Follows]

IN WITNESS WHEREOF, the parties have executed this Amendment effective as of the Amendment Effective Date.

DexCom, Inc.

By: /s/ Christophe Cantenot
Name: Christophe Cantenot
Title: VP, Finance and Corporate Controller
Date: 9/13/2023

RGH Enterprises, LLC

By: /s/ Gordon Harris
Name: Gordon Harris
Title: Senior Director, Strategic Sourcing
Date: 9/12/2023

SCHEDULE 1

The Products and The Prices

EXHIBIT 7 (A)

*******] Rebate**

EXHIBIT 7 (B)

Eligible Plans

46

Exhibit 31.01

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Kevin R. Sayer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

October 26, 2023 April 25, 2024

By: /s/ KEVIN R. SAYER

Kevin R. Sayer

Chairman of the Board of Directors, President and

Chief Executive Officer

(Principal Executive Officer)

Exhibit 31.02

**CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jereme M. Sylvain, certify that:

1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

October 26, 2023 April 25, 2024

By: /s/ JEREME M. SYLVAIN

Jereme M. Sylvain

Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

Exhibit 32.01

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350

The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the "Company"), pursuant to 18 U.S.C. §1350, hereby certifies that:

(i) the quarterly Report on Form 10-Q for the period quarter ended September 30, 2023 March 31, 2024 of the Company (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 26, 2023 April 25, 2024

/s/ KEVIN R. SAYER

Kevin R. Sayer

Chairman of the Board of Directors, President and

Chief Executive Officer

(Principal Executive Officer)

Exhibit 32.02

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350

The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the "Company"), pursuant to 18 U.S.C. §1350, hereby certifies that:

(i) the quarterly Report on Form 10-Q for the period quarter ended September 30, 2023 March 31, 2024 of the Company (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 26, 2023 April 25, 2024

/s/ JEREME M. SYLVAIN

Jereme M. Sylvain

Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.